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 Alcohol dependence (AD) is a serious and common public health problem that 
contributes to great societal, medical, and legal costs. It has taken work from multiple 
disciplines, including developmental psychology, genetic epidemiology, and molecular genetics, 
to achieve our current understanding of environmental and genetic risk factors for AD as well as 
its variable developmental trajectories. Nevertheless, there is still much to be learned in order to 
improve treatment outcomes (1). One approach to augmenting our understanding of this disorder 
is through genetically informative study designs that either examine risk in aggregate or assess 
specific susceptibility variants. In this dissertation, we utilize both study designs and provide 
support for the idea that they are both important and useful approaches to continue to pursue.
1 
 
CHAPTER 1: General Introduction 
 
Significance 
 Alcohol misuse contributes to 3.8% of global deaths, 40% of traffic accidents, and $234 
billion/year in expenses due to medical/legal costs and lost productivity in the US (2,3). Chronic, 
heavy ethanol consumption is known to cause liver cirrhosis, cardiomyopathy, and pancreatitis in 
addition to several other medical and psychiatric conditions (4). Furthermore, causal 
relationships as defined by standard epidemiological criteria (i.e. consistent association and 
presence of a plausible biological process) have been supported between heavy drinking and a 
variety of other health conditions, including heart disease, stroke, neuropsychiatric disorders, and 
several types of cancers (4). Alcohol use disorders (AUDs) are common, relapsing, under-
treated, and can have a protracted course. The 2001-2002 National Epidemiologic Survey on 
Alcohol and Related Conditions (NESARC) found the prevalence of lifetime alcohol abuse (AA) 
and alcohol dependence (AD), respectively, as defined by the Diagnostic and Statistical Manual 
of Mental Disorders, edition 4 (DSM-IV), to be 17.8% and 12.5%, while the average age of 
onset for these disorders was 22.5 and 21.9, respectively (5,6). The NESARC also showed that 
the mean duration of AUDs is 4 years and that only 7.0% and 24.1% of those with lifetime AA 
and AD, respectively, ever receive treatment (5). Furthermore, for those who are treated, only 
~25% of cases remain continuously abstinent one year following treatment (1). Clearly, a better 
understanding of these serious personal and public health problems is needed to develop more 
effective prevention and intervention strategies. 
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Etiology 
 There is much to be learned about the etiology of AD, which is the more severe AUD, 
but twin, developmental, and molecular studies over the last few decades have provided some 
understanding. Twin studies have estimated the genetic contribution to  phenotypic variation, or 
heritability, for AD to be between 50% and 60% (7,8), while the heritability of alcohol 
consumption (AC) measures and problems ranges from 40%-70%, depending on the phenotype 
and the study considered (9-11). The remaining phenotypic variation is accounted for by 
common (i.e. shared by the family) and unique (i.e. limited to one member) environmental 
factors. A variety of environmental and psychological factors have been identified as correlates 
of AD, including peer culture, family-related variables, religion, education level, and other 
psychiatric conditions (5,12). The relationships between AD and its correlates are complex and 
there is support for direct causal effects as well as shared genetic and environmental liabilities. 
These two types of etiologic relationships are not mutually exclusive. For example, there is 
evidence that childhood parental loss and major depression (studied in women) are direct risk 
factors for AD and share genetic liability with AD (13-15). In this dissertation, we will explore 
the relationship between AD/ related phenotypes and several of these environmental, 
psychological, and genetic variables, including education level, alcoholic beverage preference, 
and DNA polymorphisms.  
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A maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested 
by three or more of the following seven criteria, occurring at any time in the same 12-month period:  
1. Tolerance, as defined by either of the following:  
o A need for markedly increased amounts of alcohol to achieve intoxication or desired effect. 
o Markedly diminished effect with continued use of the same amount of alcohol. 
2. Withdrawal, as defined by either of the following:  
o The characteristic withdrawal syndrome for alcohol (refer to DSM-IV for further details).  
o Alcohol is taken to relieve or avoid withdrawal symptoms.  
3. Alcohol is often taken in larger amounts or over a longer period than was intended.  
4. There is a persistent desire or there are unsuccessful efforts to cut down or control alcohol use.  
5. A great deal of time is spent in activities necessary to obtain alcohol, use alcohol or recover from its 
effects.  
6. Important social, occupational, or recreational activities are given up or reduced because of alcohol 
use.  
7. Alcohol use is continued despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the alcohol (e.g., 
continued drinking despite recognition that an ulcer was made worse by alcohol consumption).  
Phenotypes 
 The DSM-IV defines AD as follows: 
It is clear from this definition that AD is a clinically heterogeneous phenotype that 
includes a combination of physiological, cognitive, and psychosocial symptoms. Two individuals 
can be affected by the same disorder but endorse an entirely different set of symptoms. 
Furthermore, twin research has found that AD symptoms (16) as well as consumption measures 
and problems (10) comprise multiple dimensions of genetic risk, meaning that different sets of 
genes contribute to the risk for different aspects of the disorder. Therefore, while the diagnosis of 
AD continues to be used in gene identification efforts because it offers the advantage of a 
standardized measure across sites and studies (17), the diversity of symptom and problem 
combinations in a cohort of subjects can hinder the discovery of genes that contribute to 
particular sets of symptoms or types of problems. One strategy to overcome this issue is to use 
stable, heritable, disease-associated quantitative traits as outcomes in association studies (18). If 
these traits have particular characteristics, including good psychometric properties (e.g. validity 
and high test-retest reliability), they may be referred to as endophenotypes or intermediate 
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phenotypes (19). Endophenotypes offer a number of advantages over dichotomous diagnoses. 
First, they can increase power in genetic association studies because they harbor greater variation 
than a dichotomous diagnosis (20). Additionally, since some investigators hypothesize that these 
traits are influenced by a smaller number of genetic loci than diagnoses, each locus would 
theoretically have a greater effect size, meaning it would account for a greater proportion of the 
variance in the trait (21). Several candidate gene association studies that have used intermediate 
phenotypes such as alcohol craving, initial sensitivity, and maximum number of drinks in 24 
hours, have produced signals in genes that did not reach significance in analyses of AD, possibly 
due to greater effect sizes of these endophenotypes (22-25). Second, intermediate phenotypes are 
more useful in community samples, where individuals with a diagnosis represent a minority of 
the subjects (20).  Finally, some endophenotypes may be tested in model organisms, whereas AD 
cannot.  
Another approach to gene discovery that has been explored in the literature is 
consideration of other psychiatric disorders and behavioral traits that are often comorbid with 
alcohol dependence. These phenotypes are broadly classified into two groups: (1) internalizing, 
which includes neuroticism, depression, and anxiety, and (2) externalizing, which includes drug 
use disorders, conduct disorder, antisocial personality disorder, and a disinhibited personality 
(26,27). Twin studies suggest that there is strong genetic overlap between externalizing disorders 
and AD, often considered part of the externalizing spectrum, and small to modest genetic overlap 
between internalizing disorders and AD (5,15,28-30). Previous work has demonstrated the utility 
of considering broader phenotypes in gene discovery efforts. For example, Dick and colleagues 
found that CHRM2 was more strongly associated with an externalizing component score than 
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individual phenotypes that comprised the score, suggesting that this gene contributes to risk via a 
broader externalizing pathway rather than through a mechanism that is specific to AD (31).  
 
Study Design 
Research in the fields of epidemiology, psychiatric genetics, and developmental 
psychology has suggested that AD and alcohol related phenotypes (ARPs) involve (1) the main 
effects of genes and the environment; (2) interaction between these components; (3) the variable 
effect of these components across time within individuals, and (4) variable developmental 
trajectories across individuals. In order to gain a more complete understanding of these highly 
complex phenotypes, researchers must use a variety of study designs involving humans and 
model organisms, rich phenotypic, genotypic, and environmental information, and measures 
across time. In this dissertation, we focus on two approaches: genetic epidemiology (specifically 
twin studies) and gene discovery studies. The former allows us to gain a sense of aggregate 
genetic and environmental risk, while the latter enables identification of specific susceptibility 
loci (32). While some argue that twin studies are no longer needed in an age genomics, they 
remain the only way to understand risk in aggregate (33) and can be used to inform association 
studies in a number of ways. First, researchers can use them to identify phenotypes/ 
endophenotypes that are genetically correlated with diagnoses but are more easily collected and 
widely available. For example, Kendler et al. showed that AC measures assessed in a population 
sample during the heaviest year of drinking have high genetic correlations with AD, suggesting 
that these measures are good proxies for AD in gene discovery efforts (9). Second, twin studies 
can be used to construct alternative phenotypes that are potentially more genetically 
homogeneous and reduce the number of phenotypes tested. In an unpublished study by Dick and 
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colleagues, investigators showed that two latent genetic factors accounted for the genetic 
variation in seven measures of alcohol use/problems, and they constructed genetic factor scores 
from the factor loadings for use in an association study. They found several associations between 
the genetic factor scores and SNPs within DRD2/ANKK1 but none with the original phenotypes, 
suggesting that use of the scores may have indeed reduced genetic heterogeneity. Third, if twin 
models suggest that measured environmental variables moderate a trait’s effect on latent genetic 
influences (latent G x E), this is good reason to incorporate these environmental variables into 
gene discovery studies, as at least a good portion of the genes influencing that trait will be 
moderated by the environmental variable (34). Unfortunately, candidate gene studies (candidate 
G x E) of psychiatric disorders that have attempted to incorporate measured environmental 
variables have suffered from low power and many false positive findings (32,35). However, 
testing moderation of a polygenic score of GWAS findings appears more promising, as this 
approach does not rely on the selection of the proper gene/environment combination.  
While study paradigms will be discussed more extensively in subsequent chapters, they 
are briefly introduced here. The basic twin design compares the phenotypic similarity of 
monozygotic and dizygotic twins to determine the amount of phenotypic variation that can be 
attributed to additive genetic as well as common and unique environmental factors. Many 
extensions to twin studies exist that allow researchers to ask more complex questions about 
sources of variation, such as (1) Are the magnitudes of the sources of phenotypic variation 
different between the sexes? (2) What other types of variation (e.g. a special twin environment) 
contribute to the phenotype of interest? (3) Does the effect of genes alter depending on 
environment or, equivalently, does the effect of the environment change depending on genes? (4) 
How do the magnitudes of the sources of variation change throughout time? In Chapters 2 and 3, 
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we focus on answering questions (1)-(3) for several ARPs (consumption measures and AUD 
symptoms) and their correlates (education level, alcoholic beverage preference, and other 
psychiatric disorders).  
When moving from evaluation of aggregate genetic risk to specific variants, there are 
several options for study designs, including hypothesis-driven candidate gene approaches as well 
as agnostic genome-wide association studies (GWAS).  In Chapters 4 and 5, we use both 
approaches to help us identify risk variants for AD and related phenotypes. Although costs are 
now fairly reasonable for genome-wide genotyping arrays (~$300/individual), researchers 
continue to pursue both approaches because each has its own advantages and disadvantages. 
Candidate gene studies allow investigators to select particular variants of interest instead relying 
on chip manufacturer’s decisions, they do not have the same multiple testing burden as GWAS, 
and they are less prone to genotyping error. GWAS are advantageous in that researchers can 
avoid selection bias, identify candidates that were not previously selected for biological or other 
relevant reasons, more easily control for population stratification, and use their money more 
efficiently. Both approaches generally interrogate common variants, or those with minor allele 
frequencies (MAF) of greater than 5% for candidate gene and smaller genome-wide arrays, and 
greater than 1% for larger GWAS arrays (36). For GWAS, it is estimated that between 500,000 
and 1 million markers are needed to capture common variation in European populations due to 
the correlated nature of the genome, known as linkage disequilibrium, or LD. Therefore, most 
commercial genotyping arrays contain SNPs within this range.  
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GWAS  
GWAS for non-psychiatric disorders have generally been successful at identifying 
replicable variants that were not previously detected using biological or other relevant criteria. 
For example, prior to the GWAS era, there were only a handful of independent loci robustly 
associated with Type II Diabetes (T2D) and related metabolic traits, but GWAS have increased 
this number to 75 (37). Psychiatric disorders have lagged behind other complex diseases for a 
number of reasons. First, psychiatric disorders are non-ideal phenotypes for genetic inquiry. 
While many diseases have physiological or histological metrics to categorize cases (e.g. fasting 
plasma glucose >126 mg/dl in T2D), the diagnostic criteria for psychiatric disorders are 
interview-based, and thus, more subjective both on the part of the interviewer and the 
respondent. Furthermore, the DSM criteria were developed primarily for clinical purposes and 
are not well suited to gene identification efforts, since twin studies have found that they show 
multiple dimensions of genetic liability (16,38). Second, many GWAS of psychiatric disorders 
have inadequate sample sizes for the effect sizes expected (OR=1.1-1.5). However, as the sample 
sizes in GWAS of psychiatric disorders have increased, so have the number of loci discovered. 
Recent, well-powered GWAS of schizophrenia report multiple SNPs reaching the threshold for 
genome wide significance, and several discovery as well as replication samples have implicated 
the same genes, particularly the MHC region on chromosome 6 (39). GWAS of AD and ARPs 
have not reached the sample sizes, either individually or collectively, that psychiatric phenotypes 
like schizophrenia and smoking have, and this is one reason they may not have been as 
successful thus far. However, with growing numbers of GWAS of AD and related quantitative 
traits and the work of the alcohol GWAS consortium, which includes over 20,000 subjects, there 
is optimism that alcohol dependence will begin to experience similar success. Finally, some 
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GWAS of high prevalence psychiatric disorders have used unscreened controls, which reduce 
power. 
We addressed each of these issues in our association study detailed in Chapter 5. For 
phenotypes, we examined not only AD, but also two quantitative traits: AD symptom count and 
an externalizing composite phenotype. While our sample is moderately sized, as most individual 
samples are, it is part of the alcohol GWAS consortium, which is better powered to identify 
effects at the lower end of the odds ratio spectrum. For financial reasons, we used a lightly 
screened sample of blood donor as controls for a high prevalence disorder. However, there is 
evidence that non-remunerating blood donors have lower alcohol intake than the general 
population (40), and thus likely a lower prevalence of AD. Additionally, we accounted for the 
fact that the controls were only lightly screened by coding them as unknown and inputting an 
estimated prevalence of AD for blood donors in our binary analysis. 
 
Correction for Multiple Testing  
In many candidate gene and all GWA studies, the issue of multiple testing must be 
addressed to limit Type I error, or the number of false positives. In Bonferroni correction, the α 
level is adjusted through division of the target α level (usually 0.05) by the number of tests 
conducted. Because Bonferroni correction assumes all tests are independent and there are 
typically many correlated markers on genome-wide genotyping arrays, efforts have been made to 
estimate the effective number of independent tests in the genomes of several ancestry groups. 
For European populations, these estimates are 388,751 SNPs for the Affymetrix 6.0 genotyping 
array and ~1.6 million SNPs for imputation to 1000 Genomes, corresponding to p-values of 1.08 
x 10
-7
 and 3.06 x 10
-8
, respectively (41).  While many candidate gene and GWA studies use a 
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Bonferroni correction, some argue that it is too stringent and will lead to many missed findings 
(42). Bonferroni correction controls the family-wise error rate, or the probability of obtaining at 
least one false positive among all tests, while controlling the false discovery rate (FDR) limits 
the expected proportion of false positives among significant tests. Many authors suggest that in 
GWAS studies, it is desirable to allow for some false discoveries in order to maximize the 
number of true effects observed. In Chapter 5, we utilize the FDR method of Storey in which p-
values are ranked in descending order and q-values are estimated according to a formula that is 
discussed later in more detail (43). For a particular test, if the q-value is less than a pre-
determined threshold of 0.2, for example, then 20% of the tests with q-values < 0.2 are false 
discoveries.  
Prior Evidence from Association Studies of AD 
Hundreds of genes have been implicated in candidate gene and GWA studies of AD and 
ARPs. Here we review genes that show evidence across multiple studies or are suggestive/ 
genome-wide significant. The most robust evidence has come from the alcohol metabolizing 
genes. Additionally, because alcohol has widespread and diverse effects throughout the brain, a 
large number of genes encoding proteins in neurotransmitter systems have been tested and show 
good evidence of involvement in AD.  
ADH & ALDH 
Alcohol is mainly metabolized in the liver by alcohol dehydrogenase (ADH) and 
aldehyde dehydrogenase (ALDH). ADH converts alcohol into acetaldehyde, a toxic metabolite 
that causes facial flushing and nausea when it accumulates, while ALDH oxidizes acetaldehyde 
to the harmless substance acetic acid. The ADH gene family consists of seven members encoded 
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on chromosome 4q21-23. All three members of class I (ADH1A,1B, 1C) and the single member 
of class II (ADH3) encode enzymes that function in ethanol metabolism, while ADH4-AHD6 
metabolize longer-chain alcohols (44). Two class I functional variants, ADH1B*2 (His47) and 
ADH1B*3 (Cys369), are common in East Asian/certain Jewish populations and Africans/Native 
Americans, respectively, and have high enzymatic activity (45). These variants have been 
associated with lower risk for AD in both candidate gene and GWA studies in Asians and 
Europeans (46,47). It is hypothesized that these variants are protective against alcohol 
dependence because they increase the rate at which ethanol is converted to a toxin, therefore, 
decreasing the likelihood that an individual would want to ingest ethanol (48).  However, it has 
been shown that with normal functioning of the next step in the metabolism process, this variant 
does not lead to appreciable accumulation of acetaldehyde; thus, the mechanism of protection is 
still unclear (49). The remaining classes are less well studied, but ADH4 variants have been 
implicated in AD in European and African Americans (50,51). Nineteen potentially functional 
genes and 3 pseudogenes in the ALDH superfamily have been identified in humans, but only two 
(ALDH1 and ALDH2) encode isozymes that are thought to important in acetaldehyde 
metabolism. ALDH1 is expressed in the cytosol of liver cells while ALDH2 is expressed in the 
mitochondria. Individuals heterozygous for the functional ALDH2*2 (Lys487) allele, which is 
common in Asian populations, have 30%-50% enzymatic activity while homozygotes have 
completed ablated activity. This polymorphism has been associated with reduced risk of AD and 
dramatic increases of acetaldehyde in the blood (44,49,52). Therefore, it is thought that this 
variant is protective due to the large and prolonged accumulation of the unpleasant substance, 
acetaldehyde. Additionally, a recent GWAS in a Japanese population identified a highly 
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significant association between a rare nonsynonomous coding polymorphism in ALDH2 
(Lys504) and alcohol consumption (53).   
The fact that variation in the metabolizing genes is protective suggests a different model 
of disease for AD than the classic model in which mutation → dysfunction. Genes that 
efficiently metabolize ethanol were advantageous in an environment in which ethanol was only 
present in sources like fermenting fruit. In our modern environment where ethanol is much more 
widely available, these genes have become deleterious. This is a similar to the disease model of 
T2D because in ancient environments where sources of energy were scare, genes that help to 
efficiently store fat were advantageous. However, in the modern environment of excessive food 
sources, these genes contribute to the development of T2D. Thus, an additional reason to believe 
that GWAS of sufficient size will begin to produce replicated risk loci for AD is that GWAS of 
TD2 have been very successful.  
GABAergic System 
γ-aminobutyric-acid (GABA) is the brain’s main inhibitory neurotransmitter and is 
thought to mediate several responses to alcohol, including sedation, motor incoordination, 
tolerance, and dependence. Ethanol may cause these effects by altering the level of GABA and 
the firing rate of its neurons as well as changing the expression levels of GABAA receptor 
subunits. GABAA receptors are composed of five out of a possible 19 subunits, including α1–6, 
β1–3, γ1–3, δ, ε, θ, π, and ρ1–3. The most common configuration is two α, two β, and one γ subunit. 
At anesthetic concentrations, ethanol binds to the α1 subunit and causes conformational changes 
within the receptor, but this effect has not been demonstrated at physiological concentrations 
(54).  Genes encoding the α, β, and γ, subunits are GABRA1-6, GABRB1-3, and GABRG1-3, 
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respectively. There is a cluster of GABA receptor genes on chromosome 4p, including GABRA2, 
GABRA4, GABRB1, and GABRG1, and this region has been implicated in several linkage studies 
of AD and β EEG power, an endophenotype for AD (54). Multiple studies have also found 
associations with SNPs and haplotypes in GABRA2 and AD (54). There is less evidence of 
association with the chromosome 5q (GABRA1, GABRA6, GABRB2, GABRG2) and 15q 
(GABRA5, GABRB3, GABRG3) clusters, but GABRA1 was associated with AD and measures of 
drinking severity in the Collaborative Study on the Genetics of Alcoholism (COGA) (55).   
Dopaminergic System 
Multiple types of animal studies, including microinjection, microdialysis, and lesioning, 
have implicated dopamine in mediating the rewarding effects of ethanol (56). A meta-analysis 
found the commonly studied TaqIA restriction fragment length polymorphism (rs1800497) to be 
associated with AD at a modest OR of 1.31 (57) . While this SNP is located within the coding 
region of the neighboring ANKK1 gene (58), it may be tagging a polymorphism in DRD2, which 
contains several SNPs in LD (r
2≈0.7) with rs1800497. Dick et al. found weak associations 
between variants in DRD2 and AD as well as stronger associations with neighboring genes 
ANKK1, TTC2, and NRCAM1 (59). Rigorous studies of DRD1 and AD have typically found 
positive associations with modest effect sizes (60,61), while reports examining this phenotype 
and DRD3 have been negative (57). A review supports an association between the 48-bp variable 
number of tandem repeats (VNTR) in DRD4 and an intermediate phenotype termed urge for 
addictive substances, which refers to craving for substances of abuse (62). Our report in Chapter 
4 was the first to show associations between DRD5 and an ARP, an alcohol withdrawal factor 
score. 
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Other Top and/or Replicated Genes from GWAS 
 To our knowledge, there have been six GWAS of AD (46,63-67) and four of AC 
measures and symptoms (68-71). In addition to a SNP located between ADH1B and ADH1C 
(46), two intergenic SNPs in LD reached genome-wide significance in GWAS of AD in a 
German sample (63). These SNP are near the gene PECR, which is a key enzyme in fatty acid 
metabolism. One SNP in AUTS2, or autism susceptibility candidate 2 gene, was found to be 
genome-wide significant in a GWAS of alcohol consumption in Europeans (70). The function of 
this gene is unknown, but investigation by Schumann and colleagues in Drosophila showed 
evidence that AUTS2 is involved in regulating response to ethanol (70). In a GWAS of Korean 
men, several SNPs greatly surpassed the level of genome-wide significance for alcohol 
consumption, including those in the following genes: C12orf51, CCDC63, MYL2, OAS3, CUX2, 
and RPH3A (71). Some of these significant SNPs were in high LD with SNPs in ALDH2.  
Genes containing SNPs in the genome-wide suggestive range of 5 x 10
-6
 for GWAS of 
AD include: PPP2R2B, CTBP2, KRT3, TJP1, PKNOX2, CC2D2B, SH3BP5, GRM5, and BBX 
(72). Thus far, there have been some examples of replication of genes from one GWAS of AD to 
the another, including ERAP1, CPE , DNASE2B, SLC10A2, ARL6IP5, ID4, GATA4 , SYNE1, and 
ADCY3 (64,65).  For genes that have known functions, they broadly fall into the following 
categories: cell growth (PPP2R2B), transcription (CTBP2, PKNOX2, BBX, ID4, GATA4), keratin 
formation (KRT3), signaling (TJP1, SH3BP5, ADCY3, PRKCA), reception (GRM5), enzymatic 
activity (CPE), and transport (ARL6IP5, SLC10A2).  
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Overview of Current Research 
 The aim of this dissertation is to expand our understanding of the etiology of AUDs and 
related traits using genetically informative study designs. We take advantage of both the global 
perspective provided by genetic epidemiology as well as the more focused contribution of 
association studies. Part I (Chapters 2 and 3) uses the twin approach to explore the relationship 
between ARPs and education level as well as the correlates and genetic architecture of alcoholic 
beverage preference. In Part II (Chapters 4 & 5), we test for loci that contribute to risk for AD, 
AC measures, and phenotypes that are part of the externalizing spectrum. Some of the findings 
we present are currently being pursued using study designs that were not utilized in this 
dissertation (i.e. targeted and whole genome sequencing, and use of population samples and 
model organisms) to further our understanding of these complex and daunting phenotypes.  
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CHAPTER 2: Exploring the Association between Education Level & Alcohol 
Related Phenotypes Using a Genetically Informative Design 
 
 
Abstract 
Background: An extensive literature consisting of both cross-sectional and longitudinal 
studies has examined the relationship between educational attainment and a variety of alcohol 
use measures, finding both positive and negative statistical relationships. However, few studies 
have done so from a genetically informative perspective. A recent Finnish twin report assessed 
the extent to which these correlations could be explained by genetic and environmental 
influences on both phenotypes using two alcohol problem measures (73). They estimated 
modest, negative genetic correlations between educational attainment and both alcohol-related 
traits, but no environmental correlations. Additionally, they showed that education level 
significantly moderated genetic influences on alcohol problems such that higher education was 
associated with greater heritability of alcohol measures.  
Methods: We undertook a similar study in a Virginia-born sample of twins using alcohol 
dependence symptoms (ADsx) and maximum quantity in a 24 hour period as our alcohol 
measures. Descriptive statistics were generated in SAS and twin analyses were conducted in 
classic Mx. 
Results: We found modest negative phenotypic correlations in males and non-significant 
negative phenotypic correlations in females between educational qualifications and alcohol 
measures. We also estimated a significant negative genetic correlation between educational 
attainment and maximum quantity, but not ADsx, in males. Furthermore, unstandardized 
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parameters estimates showed that unique environmental variance decreased with increasing level 
of education, whereas genetic variance decreased slightly or remained stable in both sexes. To 
account for the change in unique environmental variance, when standardized, the heritabilities of 
ADsx and maximum quantity increased with increasing levels of education, reflecting the results 
in the Finnish twins. 
Conclusions: Our results have implications for the long standing debate about the 
relationship between socioeconomic status, a strong correlate of education, and mental health. 
Moreover, our work underscores the importance of considering unstandardized parameter 
estimates when interpreting the results of gene-environment interaction studies.  
 
Introduction 
Over the past two decades, several longitudinal studies in the US and abroad have found 
significant associations between (a) level of educational attainment and subsequent development 
of drinking patterns, alcohol use disorders, and alcohol related problems (74-76) as well as (b) 
alcohol misuse and subsequent educational attainment (77,78). However, the relationship is 
complex and not entirely consistent between studies; correlations vary widely in both strength 
and direction, depending on the sex, age, and country of origin of the participants as well as the 
outcome studied (e.g. drink frequency, drink quantity, alcohol abuse, etc.) (76). Generally, these 
associations remain after controlling for correlates of both educational level and alcohol 
measures; therefore, several causal explanations have been proposed. If the correlation is 
negative and the temporal ordering is such that the educational attainment occurs before the 
development of alcohol problems, one causal explanation is that lack of education, which may 
equate to unfulfilled social expectations, is stressful and individuals cope by developing 
problematic drinking that eventually leads to alcohol problems (74). Assuming the same 
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chronological order,  positive correlations may be explained by the fact that more educated 
individuals generally have more disposable income with which to purchase alcohol and may be 
exposed to work-related situations in which drinking is acceptable and encouraged (e.g. happy 
hours) (76). Finally, if the correlation is negative and the alcohol misuse occurs before the 
educational attainment, then some causal explanations include direct ethanol toxicity on cerebral 
functioning or the reduction/cessation of social bonding important for encouragement of the 
continuation of education (77).  
Another reason for the significant correlations between educational outcomes and alcohol 
measures may be that at least some of the same genes contribute to variation in both phenotypes. 
Individually, both phenotypes have been found to be moderately to strongly heritable. 
Heritability, or proportion of phenotypic variation accounted for by genes, varies based on which 
alcohol related phenotype (ARP) one is considering, but is generally on the order of 40-60% (8). 
The heritability of educational attainment has been estimated at 31%-82% (79-81). One will note 
the fairly wide range for these estimates, particularly for education, depending on the age, sex, 
and cohort being studied.  
 In a Finnish sample of twins, Latvala and colleagues examined the non-mutually 
exclusive hypotheses that (1) education and alcohol problems are genetically correlated (i.e. 
share predisposing genes) and (2) the importance of genetic and environmental influences on 
variation in alcohol problems varies depending on level of educational attainment (73). The 
authors used two measures of alcohol problems: (a) a modified version of the Rutgers Alcohol 
Problem Index (RAPI), a self-report measure that assesses alcohol problems in the previous year 
and (b) a self-reported estimate of the maximum number of alcoholic beverages consumed 
within a 24 hour period throughout one’s lifetime. Latvala and colleagues first estimated modest 
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but significant negative phenotypic correlations between their alcohol measures and education 
level in both sexes. Next, they assessed whether these phenotypic correlations could be at least 
partially explained by overlapping genetic factors. In both sexes, they estimated modest 
significant negative genetic correlations between education and both RAPI (females= -0.22; 
males= -0.12) and maximum drinks (females= -0.17; males= -0.19). These results suggest that, 
indeed, there is a common set of genes that increase the risk of both low educational attainment 
and alcohol problems. Next, the authors conducted a set of univariate twin analyses in which 
they assessed whether educational attainment moderated genetic (and environmental) influences 
on their outcomes, called gene-environment (and environment-environment) interaction (G x E, 
E x E). In other words, they asked if the influence of genetic predispositions for alcohol 
problems varied as a function of education level (or equivalently, the importance of educational 
level on the risk for alcohol problems varied as a function of genotype) (82).  Several previous 
studies have found that the heritabilities of substance related traits decrease when individuals are 
involved in marriage-like relationships (83), take part in prosocial activities (84), live in rural 
environments (85,86),  have decreased exposure to deviant peers (87,88), and experience a high 
level of parental monitoring (89,90). In both sexes, Latvala and colleagues found that education 
level moderated the unique environmental influences on RAPI and maximum drinks such that 
the unique environment had a greater influence on variation in alcohol problems in less educated 
individuals (73). Although moderation of genetic effects was not significant, in order to 
compensate for the relative change in unique environmental variation, heritability of alcohol 
problems varied such that it was higher in those with greater educational qualifications. We 
conducted a similar study in a Virginia-born sample of twins to determine if these results would 
generalize to a cohort with different cultural influences and a wider age range. 
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Methods 
Subjects 
We used data collected from the Virginia Adult Twin Study of Psychiatric and Substance 
Use Disorders (VATSPSUD), a longitudinal study of psychiatric and substance-related disorders 
in 2 samples of adult twins identified through the population-based Virginia Twin Registry born 
from 1934-1974. The subjects in the first study are comprised of female-female twin pairs, while 
the subjects in the second study include both male-male and male-female twins.  For further 
details of recruitment and subject characteristics, see Kendler and Prescott (91). We utilized data 
for the present report from the fourth wave of the female-female study (FF4) and the second 
wave of male-male and male-female study (MM/MF2). After receiving a description of the 
protocol, participants provided written consent for in-person interviews and verbal consent for 
telephone interviews. The Office of Research Subjects Protection at Virginia Commonwealth 
University approved this project.   
 
Measures 
All measures were collected by clinically trained interviewers. RAPI was not used in the 
VA twins; however, DSM-IV alcohol-related diagnoses were assessed in this sample (6). We 
elected to use ADsx because this measure has a greater range (0-7) than abuse symptoms and it 
is more often utilized in genetically informative study designs. Symptoms counts were collected 
using an adaptation of the Structured Clinical Interview for DSM-IV Disorders (92). 
Additionally, we included a measure similar to the maximum drinks variable in the Finnish 
twins; the difference was that our measure was in reference to the heaviest year of drinking, 
while the measure in the Finnish study represented a lifetime measure. Maximum quantity was 
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log transformed for use in our twin models. Educational attainment was assessed by asking the 
question, “What is the highest grade of school or year of college you completed?” Answer 
choices ranged continuously from 0 years to 20+ years. We converted education to z-scores 
(abbreviated as zEduc) for ease of interpretation in our moderation models. 
 
Descriptive Statistics & Model Fitting 
Descriptive Statistics. Descriptive statistics were obtained separately for males and 
females using raw scores in SAS 9.2 (93). To assess whether associations between our alcohol 
measures and educational attainment existed in our sample of twins, we calculated phenotypic 
correlations separately by sex using one twin randomly chosen from each twin pair.  
Classical Twin Design. The classical twin design (CTD) attempts to estimate the genetic 
and environmental contributions to twin-pair resemblance (94). By considering the phenotypic 
correlations between different types of twins in a pair, one can determine the relative importance 
of three sources of latent variation: additive genes (A or a
2
), common environment (C or c
2
), and 
individual-specific environment (E or e
2
). A refers to variation resulting from allelic effects 
across multiple genes; C reflects experiences that both twins have in common and that make 
them more similar; and E consists of both environmental experiences not shared by twins as well 
as random measurement error (95). We assume that monozygotic (MZ) twins are correlated at 1 
and dizygotic (DZ) twins at 0.5 for their genes; that is, they share 100% and 50% of their genes 
in common, respectively. Additionally, both types of twins have a correlation of 1 for their 
shared environment and no correlation for the unique environment. These correlations are 
illustrated in diagrammatic form in Figure 2.1. Using these assumptions, basic path analysis 
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provides us with the following equations for the correlations (standardized covariances) between 
MZ and DZ twin pairs: 
 
Solving these equations for A and C
 
allows for their estimation. Because the three standardized 
sources of variation by definition must sum to 1, E is estimated by subtraction of rMZ from 1: 
 
If rMZ is greater than rDZ, genetic factors likely play an important role in the phenotype, while 
if rDZ > ½ rMZ, shared environmental factors are probably influential. Finally, if rDZ < ½ rMZ 
then non-additive genetic effects (D) likely play a role in the outcome; however, both C and D 
cannot be estimated simultaneously in a sample of twins only. E is always present because this 
term includes measurement error.  
 
Figure 2.1. Path diagram of univariate model.  rMZ, correlation between MZ 
twins; rDZ, correlation between DZ twins 
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Structural Equation Modeling. While calculating A, C , and E using these equations is quick, the 
preferred approach to estimation of these parameters is structural equation modeling (SEM), 
which, among other advantages, allows for evaluation of the significance of each parameter, 
inclusion of covariates, and extension to include multiple phenotypes. In essence, a SEM is a 
linear regression model that involves two types of statistical relationships between variables: 
correlational and causal. The phenotypic relationships between twins in a pair are correlational, 
while the influences of A, C, and E on the variation of the phenotype of interest are causal (96). 
Model fitting proceeds by iteratively improving upon parameter starting values until they have 
been optimized. There are many approaches to numerical optimization, but we selected full 
information maximum likelihood because it is most commonly used in analyses with twin data 
and it provides a convenient way of handling missing data (97,98). Parameters may be 
successively dropped (i.e. set to zero) to evaluate their significance in the model. The fit of a 
model to the observed data is summarized by a statistic, -2*log likelihood, which is distributed as 
a χ2. If the ∆χ2 between two models has a significant p-value, the nested model is rejected, and 
the tested parameter is retained in the model. Model fit may also be assessed by a variety of fit 
indices, including Akaike’s information criterion (AIC), Bayesian information criterion, and root 
mean square error approximation. We chose to examine fits using the commonly applied ∆AIC, 
which equals the difference in -2 log likelihood between the models minus the difference in the 
degrees of freedom multiplied by 2, or ∆χ2-∆2df (degrees of freedom). A lower AIC suggests a 
better balance between parsimony and explanatory power (99,100), or better model fit.  
Cross-Twin Cross-Trait Correlations. Prior to formal twin modeling, we assessed cross-
twin cross-trait correlations to gain a sense of whether shared genetic factors contribute to the 
phenotypic correlations between education and our alcohol-related traits. These correlations 
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provide an estimate of the association of education level in one member of a twin pair with each 
alcohol measure in the other. They were calculated using the double-entry method in which each 
twin was entered as both Twin 1 and Twin 2, so that the variation associated with the arbitrary 
ordering of twins can be removed. Similar to assessment of correlations for univariate analyses, 
if the cross-twin cross-trait rMZ > rDZ, additive genetic factors shared between phenotypes is 
likely important. If rDZ > ½ rMZ, shared C probably contributes to the phenotypic correlation.  
Model Fitting. Thorough model fitting begins with a saturated model, which allows for 
testing of the CTD assumptions that means and variances (continuous traits) or thresholds 
(ordinal traits) are independent of birth order, zygosity, and sex. If these assumptions do not hold 
true and are not accounted for in the model, the results may be biased (97). When trait data is 
continuous, as it is in our case, we test the assumptions that there are no differences in the means 
and variances between Twin 1 and Twin 2 in each pair, MZ and DZ twin pairs, and males and 
females by comparing the fit of models in which these components are estimated separately to 
the fit of models in which they are equated. We performed all model fitting using the SEM 
program Mx (101) using four groups: female and male MZ and DZ twins. We did not include 
opposite sex twins because they add to the complexity of model fitting. In order to test the 
assumptions and to obtain good starting values for our bivariate moderation models, we began by 
fitting the data to univariate models for each trait.  
We then investigated whether education moderates the genetic and environmental 
influences on the ARPs in a series of bivariate moderation models. If gene-environment 
correlations (rGE) are present between the moderator and the trait being studied, this can inflate 
the level of moderation. rGE occurs when an environmental variable is not “pure”, but rather is 
itself influenced by genes that also influence the trait under study (102). Given that negative 
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genetic correlations were found between educational level and alcohol problems in the Finnish 
study (73), we hypothesized that this would also be the case in our data. We found negative 
genetic correlations using standard bivariate twin modeling across education and the two ARPs 
in both sexes; however, only 
the genetic correlation between 
maximum quantity and 
education in males was 
significant (data not shown). 
Purcell has developed two 
models to address G x E in the 
presence of rGE. In one model, 
the effect of the moderator is 
partialled out of the means 
model, so its effect is only 
considered on the variance 
components that are unique to 
the outcome (i.e. genetic 
influences on alcohol related traits that do not overlap with genetic influences on educational 
attainment) (103). In the other option developed by Purcell, rGE is explicitly modeled. If present, 
this allows one to distinguish between moderation of the genetic and environmental influences 
that are unique to the trait under study and those that are common to both the moderator and the 
trait, whereas the former model only allows detection of moderation on unique influences. In the 
path diagram shown in Figure 2.2 for the genetic component only, the “azEduc” path represents 
Figure 2.2. Path diagram of moderation model. Genetic 
component only is shown for Twin 1. The model has the same 
structure for the common and unique environmental variables 
as well as for Twin 2. 
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genetic influences unique to education, “ac” represents genetic influences that are shared 
between education and ARP, and the “aARP” path is unique genetic influences on the ARP. 
Moderation is modeled by the addition of the βczEduc and βARPzEduc terms to the path between 
the traits and the unique path to the ARP.  A moderating effect is indicated if any β term is 
estimated to be significantly different from zero. One advantage of using continuous traits 
(instead of ordinal ones) in moderation models is that both unstandardized and standardized 
(forced to sum to 1) parameter estimates can be considered. Unstandardized estimates provide a 
better sense of how variance is actually changing. For example, it is possible that all three 
sources of a trait’s variation (and, therefore, total variation) change in the same direction, but this 
would not be evident from a graph of standardized parameter estimates. 
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Results 
Descriptive Statistics  
 Our sample consisted of 7056 
twins, including 3039 females and 4017 
males. The mean age at interview was 
36.7 (SD=8.82), while the mean age 
during the heaviest year was 26.1 
(SD=9). The mean years of education 
was 13.8 (SD=2.5).  The distribution of 
phenotypes in our sample is shown 
separately for males and females in 
Table 2.1. There were significant 
differences in education level, ADsx, 
and maximum quantity between the 
sexes. Table 2.2 shows that, in males, 
there were moderate, significant inverse 
phenotypic correlations between the 
educational attainment and the ARPs. In 
contrast, females showed weaker, non-significant correlations between education and the ARPs.   
The cross-twin cross-trait correlations for each phenotype were again significant in males, but 
not in females (Table 2.3). While numerically lower, the MZ correlations were stronger than the 
DZ correlations in males, suggesting that overlapping genetic influences are likely present 
between educational qualifications and each alcohol measure. Due to the non-significant cross-
Table 2.1. Descriptive statistics for education and 
alcohol measures 
Variable Females 
N=3039 
Males 
N=4017 
Education Levela,  mean (SD) 14.1 (2.3) 13.5 (2.7) 
ADsxa, N (%) 
0 
1 
2 
3 
4 
5 
6 
7 
 
2424 (79.8) 
77 (2.5) 
205 (6.8) 
137 (4.5) 
104 (3.4) 
45 (1.5) 
31 (1.0) 
(0.53) 
 
2232 (55.6) 
220 (5.5) 
469 (11.7) 
380 (9.5) 
301 (7.5) 
213 (5.3) 
132 (3.3) 
70 (1.7) 
Maximum Quantitya, mean 
(SD)* 
5.6 (4.8) 12.8 (9.6) 
Notes: ADsx, alcohol dependence symptoms. aSignificant 
difference at p<0.05 as assessed by ANOVA for 
continuous variables and Pearson’s χ2 for categorical 
variables. 
 
Table 2.2. Pearson correlations between education 
and alcohol measures 
ARP Females (95% CI) 
N=3039 
Males (95% CI)   
N=4017 
ADsx -0.04 (-.09,.01) -0.13 (-.16, -.09) 
Maximum 
Quantity 
-0.04 (-.09, .01) -0.16 (-.20, -.12) 
Notes:  ADsx, alcohol dependence symptoms. Significant 
correlations in bold. Correlations calculated using one 
randomly chosen twin from each pair. Raw values for all 
variables were used. 
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twin cross-trait correlations in females, it is not clear whether genetic influences are shared 
between education and the ARPs.  
 
 
 
 
 
 
 
Table 2.3. Pearson cross-twin cross-trait correlations between educational attainment and ARPs 
 Education-ADsx 
(95% CI) 
Education-Max. Quant. 
(95% CI) 
Monozygotic females -0.01(-0.11,0.08) -0.05(-0.14,0.05) 
Dizygotic females 0.05 (-0.07,0.18) 0.10 (-0.01,0.22) 
Monozygotic males -0.15 (-0.22,-0.07) -0.22 (-0.29,-0.15) 
Dizygotic males -0.13 (-0.22,-0.05) -0.12 (-0.21,-0.04) 
Notes: ADsx, alcohol dependence symptoms. Significant correlations in bold. Correlations were calculated 
using the double entry method in which each twin is entered as both Twin 1 and Twin 2.  
 
Table 2.4. Estimates for univariate twin models 
 Females Males 
Trait A C E    
ADsx .40 (.29-.46) -- .60 (.53-.68) .45 (.43-.51) -- .55 (.49-.61) 
Maximum 
Quantity 
.58 (.52-.64) -- .42 (.36-.47) .47 (.41-.52) -- .53 (.48-.59) 
Education .44 (.29-.61) .31 (.41-.45) .25 (.22-.39) .29 (.19-.40) .49 (.39-.58) .22 (.19-.25) 
Notes: ADsx, alcohol dependence symptoms; A, additive genes; C, common environment; E, unique 
environment.  
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Twin Modeling 
 Comparing the fits of our preliminary univariate saturated and reduced models indicated 
that the means and variances for each trait could be equated by twin order and zygosity across all 
phenotypes, but not by sex (results not shown). Thus, we estimated the same means and 
variances for twin1 and 
twin2 as well as DZ and 
MZ twins in subsequent 
models. Models were run 
separately for males and 
females. Univariate 
estimates for each trait are 
shown separately by sex in 
Table 2.4. Our univariate 
parameter estimates are 
somewhat different from 
those of Latvala et al., 
which is not unusual to 
find across twin studies, 
and may be a result of 
cultural and/or age 
differences. Nevertheless, 
they are within the range 
found by previous studies 
Table 2.5. Model fitting results for moderation models in 
females 
Model 
Description 
-2LL 
 
∆χ2 
 
∆df  p-value 
 
∆AIC 
 
Education/ADsx       
1a.Full  28861.89 -- -- -- -- 
2a. Drop mod. of 
common A path 
28864.07 2.18 1 0.14 0.18 
3a. Drop mod. of 
unique A path 
28864.20 2.31 1 0.13 0.31 
 
4a. Drop mod. of 
common C path 
28863.03 1.13 1 0.29 -0.87 
5a. Drop mod. of 
unique C path 
28861.89 0.00 1 1 -2.00 
6a. Drop mod. of 
common E path 
28866.30 0.79 1 0.38 -1.21 
7a. Drop mod. of 
unique E path 
28861.93 4.41 1 0.04 2.41 
Education/Max 
Quant 
     
1a.Full  21823.99 -- -- -- -- 
2a. Drop mod. of 
common A path 
21824.05 0.07 1 0.80 -1.94 
3a. Drop mod. of 
unique A path 
21824.62 0.63 1 0.43 -1.37 
4a. Drop mod. of 
common C path 
21823.99 0.001 1 0.98 -2.00 
5a. Drop mod. of 
unique C path 
21824.19 0.20 1 0.65 -1.80 
 
6a. Drop mod. of 
common E path 
21824.16 0.17 1 0.68 -1.83 
7a. Drop mod. of 
unique E path 
21830.26 6.28 1 0.01 4.28 
Notes: LL, log likelihood; Δχ2, change in chi-square from full model; p-
value associated with change in chi-square; ∆AIC, Akaike's criterion 
from full model. All models compared against full model. 
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(8,79-81,104).Our moderation model fitting results are shown in Table 2.5 for females and Table 
2.6 for males. In females, across both alcohol related phenotypes, moderation of the common and 
unique paths of the A and C components could be dropped without deterioration in model fit.  
Also, moderation of the 
common E component 
could be dropped, but 
setting the moderation 
path for the unique E 
component was not 
statistically possible. In 
males, the same 
parameters were 
retained, except in the 
case of the unique 
moderation path on A 
for ADsx. This 
parameter was border 
line by p-value, but the 
change in AIC was 
positive, so we elected 
to retain it. The graphs 
of moderation effects 
shown in Figure 2.3 
Table 2.6. Model fitting results for moderation models in males 
Model Description -2LL 
 
∆χ2 
 
∆df  p-value 
 
∆AIC 
 
Education/ADsx       
1a.Full  28861.89 -- -- -- -- 
2a. Drop mod. of 
common A path 
28862.285 0.39 1 0.53 -1.61 
3a. Drop mod. of 
unique A path 
28866.109 3.68 1 0.06 1.68 
4a. Drop mod. of 
common C path 
28866.183 0.70 1 0.40 -1.30 
5a. Drop mod. of 
unique C path 
28866.618 1.76 1 0.19 -0.24 
6a. Drop mod. of 
common E path 
28905.888 0.23 1 0.63 -1.77 
7a. Drop mod. of 
unique E path 
28906.400 23.38 1 0.00 21.38 
Education/Max 
Quant 
     
1a.Full  21823.99 -- -- -- -- 
2a. Drop mod. of 
common A path 
21825.03 
 
1.05 
 
1 0.31 -0.95 
 
3a. Drop mod. of 
unique A path 
21824.45 0.47 
 
1 0.50 -1.54 
 
4a. Drop mod. of 
common C path 
21825.04 
 
1.05 1 0.31 
 
-0.95 
 
5a. Drop mod. of 
unique C path 
21824.67 
 
0.69 
 
1 0.41 
 
-1.32 
 
6a. Drop mod. of 
common E path 
21823.99 
 
1.20 
 
1 0.27 
 
-0.81 
 
7a. Drop mod. of 
unique E path 
21852.36 28.38 
 
1 0.00 26.38 
Notes: LL, log likelihood; Δχ2, change in chi-square from full model; p-value 
associated with change in chi-square; ∆AIC,  Akaike's information criterion 
from full model. All models compared against full model. 
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reveal that for both males and females, across the two ARPs, raw E variance decreased with 
higher levels of education; while raw A variance decreased slightly or remained stable.  To 
compensate for the change in unique environmental variance, the heritability of alcohol related 
traits was higher in more educated twins.  
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Figure 2.3. Influence of education on variance components in females and males. Unstandardized 
(a,c,e) and standardized  (A,C,E) variance components. First four panels show ADsx and maximum 
quantity for females; second four show ADsx and maximum quantity for males.  
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Discussion 
 Consistent with Latvala and colleagues as well as other studies (74,75,77,104), we found 
significant negative phenotypic correlations in males between education and ARPs.  For females, 
the correlations were negative but neither was significant, so it is difficult to draw conclusions. 
However, it is interesting to note that Heurta et al. estimated a positive, significant phenotypic 
correlation between educational qualifications and frequency of alcohol consumption after 
controlling for covariates in females but not in males (76).  These authors suggest that the 
positive correlation in females may be a result of greater engagement in traditionally male 
spheres and greater postponement of childbearing among more highly educated females. Perhaps 
a more complicated relationship is occurring in our sample of females in which there are direct 
and inverse correlations between education and the alcohol measures in different individuals that 
are non-significant when the group is viewed as a whole. Unlike the findings of Latvala and 
colleagues, the genetic correlations in females were not significant for either ARP.  
In contrast, the genetic correlation between education and maximum quantity was 
significant in males, reflecting the findings of Latvala and colleagues and providing support for 
overlapping genetic influences between ARPs and educational attainment in this gender. Johnson 
and colleagues also found a significant negative genetic correlation between education level and 
an alcohol use composite score consisting of alcohol abuse and dependence symptoms and 
maximum number of drinks (105). These overlapping genes may act to influence cognitive 
ability, which affects one’s ability to become more highly educated and to make decisions about 
substance use. Indeed, longitudinal studies have provided evidence that individuals with 
neurocognitive deficits in childhood and young adulthood show an increased risk for developing 
alcohol use problems later in life (106). Additionally, in a separate study, Latvala and co-
investigators estimated negative genetic correlations between verbal achievement scores and 
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RAPI, maximum drinks in 24 hours, and AD symptoms (104). Interestingly, other twin studies 
have demonstrated negative genetic correlations with other substance measures as well as 
psychiatric phenotypes more generally. McCaffery and co-authors found that the negative 
phenotypic correlation between smoking initiation and educational qualifications in males was 
partially explained by overlapping genetic influences (107). Tambs et al. showed that the 
negative phenotypic correlation between any anxiety disorder and education is mostly explained 
by overlapping genetic factors in a Norwegian sample (80). Taken together, these studies suggest 
that there may be a common set of genes that predispose one to lower educational level and 
psychiatric disorder(s) in general; the form that these psychiatric disorders take may depend on 
other disorder-specific genes or environmental factors. Additionally, these findings inform the 
causation debate regarding mental health and socioeconomic status (SES), which is often 
measured by educational level, occupational status, and income. The debate centers around this 
question: to what extent do psychiatric disorders lead to lower attainment (social selection) and 
to what extent does stress associated with lower SES increase propensity to psychiatric disorders 
(social causation)(80,108)?  Generally, investigators agree that both theories together account for 
the majority of the phenotypic correlation between SES and psychiatric disorders (108). 
However, the negative genetic correlation in males found in our study and the studies of Latvala 
and colleagues and Tambs and colleagues suggest that the relationship between SES and anxiety 
as well as substance use measures is partly explained by overlapping genetic factors, not just by 
direct causation in either direction. 
There was no direct moderation on additive genetic variance for maximum quantity (both 
in our study and the Finnish twins) and for RAPI in the Finnish twins, whereas there was direct 
moderation on unique environmental variance for all of these traits such the unique environment 
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was more influential on variation in ARPs in twins with lower education. Additionally, in the 
present study, the moderation of additive genetic variance was significant for ADsx, but the 
change in unique environmental variance (decrease with higher education) was far steeper. To 
compensate for the change in unique environmental variance, the heritability of the variables in 
both studies increased such that genetic influences on these traits were relatively more important 
in those with higher education. Therefore, in most of our results, and all of the results from the 
Finnish study, only the E x E interaction was significant, and this lead to a heritability x E 
interaction. It is sensible that there is increased importance of unique environmental influences 
on variation in alcohol traits in individuals with lower education in that low educational status is 
associated with stressors that are not as likely to affect those with higher education, such as job 
instability and limited income (109). It is interesting to note that in the case of ADsx in males, 
total genetic variance actually decreased slightly; however, to compensate for the much steeper 
decrease in unique environmental variance, the relative importance of genetic influences 
increased. The ADsx result in males is a good example of why, although many G x E studies 
focus on standardized estimates, several authors have pointed out that this may be misleading 
because raw variance could be changing in the opposite direction (110-113).  Higher genetic 
variance in alcohol related traits among those with less education is reasonable in light of 
previous work showing that genetic differences among individuals become more influential for 
externalizing psychopathology among those experiencing greater environmental adversity (114).   
Our study has several strengths, including that we tested moderation of genetic and 
environmental influences that are both common to education and alcohol related traits as well as 
those unique to ARPs and we considered both standardized and unstandardized variance 
components. However, we must also consider three methodological limitations. First, we were 
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not able to use all of the same measures as in the Finnish study because RAPI scores were not 
assessed in the VATSPSUD; however, these scores were correlated at 0.55 with alcohol 
dependence symptoms in a subsample of the Finnish twins (73). Second, lifetime symptoms of 
ADsx and maximum consumption during the heaviest year were based on participants’ 
retrospective recall. It is possible that our results may have been influenced by recall errors. 
Finally, it is unclear whether our sample of Virginia-born Caucasians generalizes to other 
populations, although the standardized G x E results appear similar to a Finnish population. 
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CHAPTER 3: Alcoholic Beverage Preference: An Epidemiological & Twin 
Study 
 
 
Abstract  
 
Background: Alcoholic beverage preference (ABP), defined as one’s most 
heavily/frequently consumed alcoholic beverage, has been associated with demographic and 
lifestyle characteristics, medical outcomes, and drinking habits and their consequences. The 
present study sought to replicate and extend some of these findings in a twin sample by assessing 
the risk of endorsing alcohol use disorders and related measures using ABP in both the same 
individual and the co-twin as the predictor. Additionally, this is the first study to assess the 
genetic and environmental influences on preference alone as well as those that overlap with total 
quantity/frequency. Finally, we examined the role of non-additive genetic factors and parental 
influences on ABP.  
Methods: We conducted association analyses in SAS and twin modeling in OpenMx. We 
used three twin samples, including the Virginia Adult Twin Study of Psychiatric and Substance 
Use Disorders (VATSPSUD), FinnTwin12 (FT12), and The Virginia 30,000 (VA30K). 
Symptoms and diagnoses were based on DSM-IV criteria.  
Results: The risk of endorsing AUDs or symptoms, high consumption measures, and 
other psychiatric conditions was lowest in wine drinkers, except in the case of major depression. 
Beer drinkers were the most likely to engage in high and frequent consumption, while distilled 
spirits (DS) drinkers were at the greatest risk for alcohol dependence, AUD symptoms related to 
impairment, and other psychiatric conditions, except depression. The likelihood of endorsing 
alcohol abuse and the remaining symptoms of AUDs was not different between beer and DS 
preference drinkers. Furthermore, across all three twin samples, the genetic overlap between total 
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consumption measures and preference was significant, but only small to moderate, and two out 
of the three twin samples showed that additive genetic influences on preference were greater in 
females than males. Finally, non-additive genetic factors and parental influences do not appear to 
be important sources of variation for ABP. 
Conclusions: Preference for particular alcoholic beverages is associated with differential 
risk for high/frequent consumption and the development of AUDs and other psychiatric 
conditions, suggesting that preference may be a helpful variable in defining subtypes of alcohol 
dependent individuals. Furthermore, that beer carries the same risk as spirits for AA and most 
symptoms of AUDs has implications for public health efforts. Finally, our genetic findings may 
be informative for gene finding efforts of AUDs.   
 
Introduction 
Although definitions in the extant epidemiological literature vary, alcoholic beverage 
preference (ABP) is generally defined as one’s most heavily or frequently consumed alcoholic 
beverage. Previous studies have examined the relationship between preferred alcoholic beverage 
and demographic and lifestyle characteristics, morbidity and mortality, and drinking habits and 
their consequences. Wine preference drinkers tend to eat a healthier diet, exercise more 
frequently, and have a lower incidence of several medical conditions than drinkers who prefer 
beer or distilled spirits (DS) (115-119). Wine drinkers also consume the least alcohol with the 
lowest frequency and are the least susceptible to alcohol-related problems and disorders (120-
126). In studies that find correlations between ABP and particular health outcomes, such as 
stroke, obesity, and cancer, the authors suggest the possibility that particular alcohol 
concentrations and/or beverage-specific bioactive non-ethanol substances (congeners) may 
contribute to effects on health (127-129). The average ethanol concentration in alcoholic 
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beverages varies widely across the main classes: beer ≈ 4.5%, wine ≈ 12.9%, and distilled spirits 
≈ 41.1% (130). Some studies that find beverages with higher concentrations of ethanol increase 
the risk for digestive tract cancers suggest that exposure of digestive mucosa to concentrated 
ethanol may be at play (131,132). Coder et al. proposed that spirits drinkers are the most prone to 
alcohol-related disease because they are able to drink higher amounts more quickly due to the 
decreased volume of liquid compared to other alcoholic beverages (133). Furthermore, wine, 
beer, and spirits contain varying levels of congeners and contaminants, including polyphenols, 
ethyl carbamate, and acetylaldehyde, shown to have direct effects in vitro and in vivo (134-136).  
Polyphenols, especially resveratrol in red wine, have been studied extensively for their potential 
beneficial cardiovascular and anti-carcinogenic effects. Several studies suggest that they have 
anti-coagulatory, anti-inflammatory, and anti-proliferative effects independent of ethanol (137).  
Despite the differential associations between particular forms of ethanol and lifestyle, 
demographic, and health characteristics, few epidemiological studies consider them separately or 
control for differences in analyses with aggregate consumption measures. Furthermore, to our 
knowledge, no studies have specifically examined the heritability of preference for particular 
alcoholic beverages through comparison of intake of one type of beverage to the others. 
However, two groups have assessed the genetic and environmental influences on intake 
frequency of specific alcoholic beverages. Kaprio and colleagues (138,139) found the 
heritabilities for frequency of beer (and spirits) intake in females and males, respectively, to be 
0.46 and 0.39 (0.36 and 0.38). Fabsitz and colleagues (140) presented twin correlations only, but 
if heritabilities were estimated from these correlations using Falconer’s broad sense formula 
(141), they would be as follows: 0.22 for beer, 0.15 for wine, and 0.44 for other (not beer or 
wine).  
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The first aim of our study was to replicate the associations that other investigators have 
found between ABP (assessed from data about the frequency of consumption of wine, beer, and 
spirits) and alcohol consumption (AC) measures in one of our twin samples. Second, we sought 
to examine relationships that have received less attention in the literature, including between 
ABP and AUD symptoms and diagnoses, major depression (MD), antisocial personality disorder 
(ASPD), and any symptom of illicit substance use disorders. Third, to provide a sense of the 
degree to which familial (i.e. genetic and common environmental) factors contribute to the 
associations between measures, we predicted the odds of reporting all measures in one twin 
based on the co-twin’s beverage preference. Our fourth goal was to evaluate the genetic and 
environmental underpinnings of the association between frequency of total consumption and 
ABP, as well as the unique influences on preference, in the same sample that was used in the 
previous three aims. Finally, we used two additional twin samples with continuous consumption 
measures of specific alcoholic beverages to answer the following questions: (1) Will the findings 
from the first twin sample reflect those in the second two? (2) What role do non-additive genetic 
factors and parental influences play in ABP? 
 
Methods 
VATSPSUD 
To accomplish the first four aims, we used data from the Virginia Adult Twin Study of 
Psychiatric and Substance Use Disorders (VATSPSUD), a longitudinal study of psychiatric and 
substance-related conditions in 2 samples of Caucasian adult twins identified through the 
population-based Virginia Twin Registry. One sample is comprised of female-female twin pairs, 
while the other includes both male-male and male-female twins.  For further details of 
recruitment and subject characteristics, see Kendler and Prescott (91). We utilized data for the 
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present report from the fourth wave of the female-female study (FF4) and the second wave of 
male-male and male-female twins (MM/MF2) because these were the only waves that included 
the ABP question. After receiving a description of the protocol, participants provided written 
consent for in-person interviews and verbal consent for telephone interviews. The Office of 
Research Subjects Protection at Virginia Commonwealth University approved this project. 
Zygosity was determined by a computer algorithm of standard questionnaire responses validated 
against DNA genotyping of 496 twin pairs. A total of 5,489 individual twins with non-missing 
data for the preference question were used in the regression analyses. Fewer twins (N=3,541) 
were part of the twin models because we excluded opposite sex pairs for simplicity. 
Clinically trained interviewers assessed ABP by asking “During the year when you drank 
the most, what type of alcoholic beverage did you drink most often?” The DS category included 
vodka, gin, rum, bourbon, scotch, and liqueurs. Due to the low proportion of individuals who 
endorsed malt liquor as their beverage of preference (N=15, 0.27%), we did not include this 
group of subjects in our analyses. If a subject indicated two beverages were consumed with equal 
frequency, he was categorized according to the first beverage mentioned. The interviewers also 
asked about AC measures in the heaviest year, including drink frequency, regular quantity, 
maximum quantity in 24 hours, and frequency of intoxication (drunk frequency). For the latter 
measure, we had 11 response options: 1 = Never, 2 = Once/Year, 3 = 2 Times/Year, 4 = 3 to 6 
Times/Year, 5=7 to 11 Times⁄ Year, 6 = 1 Time/Month, 7 = 2 to 3 Times/ Month, 8 = 1 to 2 
Times/Week, 9 = 3 to 4 Times/Week, 10 = 5 to 6 Times/Week, and 11 = Every Day. Due to the 
skewed distributions of the first three continuous AC measures and the unequal distribution of 
individuals in categories for drunk frequency, we divided each measure into five roughly equal 
ordinal categories. There were different cutoffs for females and males due to the differences in 
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their distributions. Respectively, the cutoffs for females and males were as follows: drink 
frequency (1, 2-3, 4-7, 8-14, 15-30; 1-3, 4-9, 10-15, 16-27, 28-30 days/mo.), regular quantity (1, 
2, 3, 4, >5; 1-2, 3, 4-5, 6-8, >9 drinks/day), maximum quantity (1, 2-3, 4, 5-6, >7; 1-5, 6-9, 10-
12, 13-20, >21 drinks/day), and, using the response options listed above, drunk frequency (1, 2, 3 
to 4, 5-7, and 8-11; 1- 2, 3- 5, 6- 7, 8, and 9-11). The twins were informed that one drink of beer 
(12oz), wine (5oz), or spirits (1.5oz) equated to a standard alcoholic “drink”. Additionally, the 
interviewers used an adaptation of the Structured Clinical Interview for DSM-IV (6,92) to 
inquire about lifetime symptoms of AUD, MD, ASPD, and illicit substance abuse and 
dependence; lifetime diagnoses were determined algorithmically using symptom data.  
 
FinnTwin12 
FinnTwin12 (FT12) is a population-based longitudinal study of twins born in Finland 
between 1983 and 1987. Because twins were ascertained through the Central Population 
Registry, which includes records of every citizen, FT12 is an unbiased sample. Twin participants 
(N=1,854 individual twins) were interviewed at different ages using the Semi-Structured 
Assessment for the Genetics of Alcoholism (142), a psychiatric interview developed for COGA. 
Additional details of study design can be found elsewhere (143). To assess quantity of intake of 
particular beverages, subjects were asked about their consumption of wine, beer, spirits in a 
typical week. Although there is also phenotypic data available for ages 12, 14, and 17, we chose 
to focus on age 22 because a stable preference is more likely to be present at this age and this age 
group would have the most access to all types of alcoholic beverages. In Finland, one must be 18 
to buy alcoholic beverages containing < 22% alcohol by volume and 20 to purchase beverages 
greater than that (144). Although prior to the 1950’s Finland’s alcohol intake was dominated by 
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the consumption of spirits, beer consumption has increased dramatically to become the most 
consumed alcoholic beverage and wine consumption has increased steadily, now accounting for 
16% of total intake (145). We believe that the availability of all three beverages is adequate to 
assume that amount consumed is reflective of preference. As in studies of coffee preference 
(146,147), we defined ABP as the ratio of a particular alcoholic beverage to the total quantity 
consumed. Due to the skewed nature of the distributions for total quantity and preference of 
wine, beer, and spirits, we polychotomized these variables into three roughly equal categories 
with separate cutoffs for females and males.  
 
VA30K 
The Virginia 30,000 (VA30K) sample contains data from 14,763 individual twins, along 
with additional relatives, ascertained from two sources, including Virginia public records and 
through response to a newsletter published by the American Association of Retired Persons 
(148). Twins participating in the study were mailed a Health and Lifestyles questionnaire (HLS) 
and were asked to supply the names and addresses of their spouses, siblings, parents, and 
children for the follow-up study of relatives of twins. Zygosity of twins was assigned based on 
responses to standard questions about similarity and the degree to which others confused them. 
For the purpose of this report, we used a question from the Drinking Habits section of the HLS: 
“Please describe your consumption of alcohol LAST WEEK.” Participants were provided with a 
chart on which they could record their consumption of beer, wine, and liquor on each day of last 
week. Although alcohol consumption in a typical week would be more informative and similar to 
the phenotype measured in FT12, unfortunately, this data is not available in the VA30K. As with 
FT12, we defined ABP as the ratio of a particular alcoholic beverage to the total quantity 
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consumed and polychotomized preference and total consumption into three roughly equal 
categories with separate cutoffs for females and males. It should be noted that there is some 
overlap between VA30K and the VATSPSUD samples.  
 
Multivariate Regression in VATSPSUD 
 To accomplish aims 1-4, we estimated the odds of endorsing the highest level of alcohol 
consumption compared to the lowest level, AUDs and their individual symptoms, and other 
psychiatric disorders using ABP as the determinant. If the within-person odds ratios (ORs) were 
significant, we also tested for associations between these variables in one twin using the 
beverage preference of the co-twin to assess for common familial influences between ABP and 
the other phenotypes. We utilized the GENMOD procedure in SAS 9.2 (93) to account for the 
correlated nature of twin data, and sex, zygosity, age at interview, age during heaviest year, years 
of education, lifetime smoking status, and current marital status as covariates. 
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Twin Resemblance & Bivariate Model Fitting in the VATSPSUD 
Because ABP does not have an underlying continuous distribution, we analyzed each 
class of beverage separately as a binary variable, categorizing individuals based on whether they 
preferred that 
beverage or not. We 
then calculated 
tetrachoric 
correlations and 95% 
confidence intervals 
for ABP in MZ and 
DZ twin pairs using 
SAS 9.2 (93). 
Because our co-twin 
regression analyses 
of AC measures in 
the VATSPSUD 
indicated some 
overlap in familial 
factors contributing 
to drink frequency and preference, we used bivariate Cholesky models (Figure 3.1) to evaluate 
(1) the extent to which genetic and environmental influences contribute to the covariation 
between total frequency/quantity and preference and (2) the contribution of these influences 
independently on preference across all three twin samples. We performed all model fitting within 
Figure 3.1. Bivariate Cholesky decomposition. A, additive genetic; 
C=shared environment; E, unique environment; a11, genetic path for total 
frequency/quantity; c11, shared environmental path for total 
frequency/quantity; e11, unique environmental path for total 
frequency/quantity; a12, genetic covariance between total 
frequency/quantity and preference; c12, shared environmental covariance 
between total frequency/quantity and preference; e12, unique environmental 
covariance between total frequency/quantity and preference; a22, genetic 
path unique to preference; c22, shared environmental path unique to 
preference; e22, unique environmental path unique to preference. 
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the SEM program OpenMx 1.1 (149) using four groups, including MZ and DZ twins of both 
sexes. We did not use opposite sex twins due to the added complexity of including them in the 
twin models. Details describing the classic twin design and the bivariate model fitting procedure 
can be found in the previous chapter.  
 
Extended Twin Family Design (ETFD)  
 By using relatives in addition to MZ and DZ twins, researchers are able to estimate 
sources of phenotypic variation beyond A, C, and E. The most extensive model involves utilizing 
information 
from twins, 
parents, 
siblings, 
spouses, and 
offspring to 
parse variation 
into two sex-
specific 
genetic 
components, 
including 
additive (A) 
and non-
additive (D), 
Figure 3.2. Cascade model for extended twin designs. Adapted from Keller et 
al., 2009 (43) 
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and four sex-specific environmental components, including common sibling (S), special twin 
(T), vertical cultural transmission (F), and unique environment (E). D refers to interactions 
between alleles within a locus (dominance) or across different loci (epistasis); dominance and 
epistasis cannot be distinguished in this model (150). S, T, and F are all components of the 
shared environment. S is the non-parental component shared between all offspring, while T 
represents an additional environmental correlation that makes twins more similar than siblings 
(97);  it is attributed to sharing the same intrauterine environment and being the same age. F 
refers to the proportion of the shared environment that is transmitted from parents to offspring 
(151). The most recent implementation of the ETFD is the Cascade model (Figure 3.2) (152), 
which we used to conduct univariate analyses of preference for wine, beer, and spirits. Again, we 
performed all model fitting with OpenMx 1.1 (149). This time we included opposite sex twins, 
allowing us to test for both qualitative (i.e. different genes and/or environments) and quantitative 
(i.e. different magnitude of effects) sex differences. We fitted the full ASETFD Cascade model, 
which may include parameter estimates that are not significantly different from zero, to avoid the 
parameter biasing that can occur when parameters are dropped from the model (153).  
 
Results  
Descriptive Statistics in the VATSPSUD 
Descriptive statistics by preference are summarized in Table 3.1. Wine preference 
drinkers were more likely to be female (83.1%), more educated (mean=14.8 years, SD=2.3), 
older during their heaviest year of drinking (mean=34.7 years, SD=10.3), and married (64.7%) 
compared to the other two classes. DS drinkers were split fairly evenly across the sexes 
(female=53.6%) and fell between the other groups in terms of age (mean=28.6 years, SD=9.8). 
They were also the least educated (mean=13.7 years, SD=2.5) of all drinking classes. Finally, 
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beer drinkers were most likely to be male (69.4%) and unmarried (42.8%) and were, on average, 
the youngest (mean=25.4 years, SD=8.4) group of preference drinkers. Our demographic 
findings were generally consistent with previous work (154-156). 
 
Multivariate Regression in the VATSPSUD   
 Using wine as the reference category, Table 3.2 shows the ORs for the highest level of 
consumption across the four AC measures compared to the first level. Those who preferred 
spirits were up to ~5 times more likely to endorse the highest levels of consumption compared to 
wine drinkers, while those who prefer beer were up to ~9 times more likely. Additionally, when 
beer drinkers were compared to DS drinkers, the risk the highest level of drink and drunk 
frequency were significantly higher for beer drinkers. Most co-twin estimates were significant, 
Table 3.1. Descriptive statistics in the VATSPSUD 
 Drinking Preference in Heaviest Year 
Variable Wine  
N= 584 
Beer  
N=3578 
Distilled Spirits  
N=1327 
Sex a, N (%) 
Female 
Male 
 
485 (83.1) 
99 (16.9) 
 
1093 (30.6) 
2485 (69.4) 
 
711 (53.6) 
616 (46.4) 
Smoking Statusa,b, N (%) 
Regular Smoker 
Never Smoked 
 
186 (50.4) 
183 (49.6) 
 
2144 (69.8) 
926 (30.2) 
 
785 (74.4) 
270 (25.6) 
Zygosity a,b, N (%) 
MZ 
DZ 
 
241 (41.3) 
343 (58.7) 
 
1348 (37.7) 
2230 (62.3) 
 
468 (35.3) 
859 (64.7) 
Heaviest year agea, mean (SD) 
 
34.7 (10.3) 25.4 (8.4) 28.6 (9.8) 
Educationa, mean (SD) 14.8 (2.3) 
 
13.9 (2.5) 
 
13.7 (2.5) 
 
Marriage Status a, N (%) 
Married 
Unmarried 
 
378 (64.7) 
206 (35.3) 
 
2046 (57.2) 
1532 (42.8) 
 
807 (60.8) 
520 (39.2)  
Notes: a Significant difference at p < 0.05 using χ2 for categorical variables and ANOVA for 
continuous variables. b Some data is missing for this variable.  
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suggesting that common familial factors contribute to the phenotypic association between AC 
measures and ABP.  
  
  
Table 3.3 shows that the odds of reporting an AUD or the majority of symptoms of these 
disorders are significantly higher in those who prefer beer or DS as compared to those who 
prefer wine. When DS drinkers were compared to beer preference drinkers, estimates were 
significantly higher for the former vs. the latter for endorsing AD and certain symptoms of 
Table 3.2. Association of ABP with AC measures in the VATSPSUD 
 ABP in Heaviest Year (Wine Reference) ABP in Heaviest Year (Beer 
Reference) 
Consumption Variable 
 
Beer  
Adjusted ORa (95% CI) 
Distilled Spirits 
Adjusted ORa (95% CI)  
Distilled Spirits 
Adjusted ORa (95% CI) 
Drink Frequency    
Female Male    
1 day/mo. 1-3 day/mo. -- -- -- 
15-30 day/mo. 28-30 day/mo. 3.18 (2.07-4.88) 1.32(0.86-2.03) 0.42(0.32-0.55) 
Co-twin -- 1.41 (0.92-2.15) -- 0.81(0.62-1.06) 
Regular Quantity    
Female Male    
1 drink/wk 1-2 drink/wk -- -- -- 
>5 drink/wk >9 drink/wk 6.40 (3.74-10.97) 4.95 (2.85-8.63) 0.78 (0.60-1.03) 
 -- 2.27 (1.42-3.62) 1.96 (1.19-3.21) -- 
Maximum Quantity    
Female Male    
1 drink/wk 1-5 drink/wk -- -- -- 
>7 drink/wk >21 drink/wk 8.99 (5.22-15.46) 4.03 (2.29-7.07) 0.46 (0.34-0.62) 
Co-twin -- 2.13 (1.32-3.45) 1.48 (0.89-2.47) 0.69 (0.50-0.96) 
Drunk Frequency    
Female  Male    
1 1-2 -- -- -- 
8-11 9-11 5.30 (2.99-9.39) 4.05 (2.23-7.36 0.78 (0.57-1.07) 
Co-twin -- 1.94 (1.23-3.06) 1.53 (0.95-2.46) -- 
Notes: Wine preference drinkers are reference group in first set of analyses and beer preference drinkers are reference 
group in second set of analyses. ABP, alcoholic beverage preference; OR, Odds Ratio; CI, Confidence Interval. aMultivariate 
logistic regression accounting for continuous (age at interview, age during heaviest year, years of education) and binary 
(sex, zygosity, lifetime smoking status, and current marital status) covariates.  
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AUDs, including withdrawal, preoccupation with obtaining, using or recovering from the effects 
of alcohol, interference with daily activities, and use despite physical/psychological problems.  
 
Table 3.3. Association of ABP with lifetime DSM-IV AUD sxs/diagnoses in the VATSPSUD 
 ABP in Heaviest Year (Wine Reference) ABP in Heaviest 
Year (Beer 
Reference) 
Lifetime DSM- IV AAsx/ADsx Beer  
OR (95% CI) 
Distilled Spirits 
OR (95% CI) 
Distilled Spirits 
OR (95% CI) 
AA 
Co-twin 
3.63 (2.36-5.59) 
1.07 (0.80-1.45) 
3.51 (2.26-5.45) 
1.06 (0.77-1.45) 
0.97 (0.83-1.14) 
-- 
Failure to fulfill major obligations 
Co-twin 
4.76 (2.39-9.48) 
1.06 (0.72-1.55) 
5.20 (2.59-10.43) 
1.18 (0.79-1.75) 
1.10 (0.90-1.33) 
Physically hazardous use 
Co-twin 
3.21 (1.79-5.75) 
1.17 (0.82-1.67) 
3.44 (1.90-6.23) 
1.17 (0.81-1.71) 
1.08 (0.90-1.30) 
-- 
Use leading to legal problems 
Co-twin 
3.18 (1.54-6.57) 
2.10 (1.20-3.69) 
2.76 (1.31-5.80) 
1.98 (1.1-3.53) 
0.88 (0.70-1.10) 
-- 
Use despite social problems 
Co-twin 
2.61 (1.64-4.16) 
1.57 (1.07-2.32) 
2.79 (1.74-4.47) 
1.67 (1.12-2.50) 
1.07 (0.89-1.28) 
-- 
AD 
Co-twin 
2.31 (1.43-3.73) 
1.28 (0.89-1.85) 
2.96 (1.82-4.81) 
1.30 (0.88-1.92) 
1.28 (1.08-1.53) 
1.03 (0.84-1.27) 
Tolerance 
Co-twin 
2.62 (1.60-4.29) 
1.09(0.77-1.55) 
2.99 (1.80-4.97) 
1.04 (0.71-1.51) 
1.14 (0.96-1.37) 
-- 
Withdrawal 
Co-twin 
2.05 (1.03-4.07) 
1.44 (0.83-2.50) 
2.76 (1.38-5.53) 
1.59 (0.89-2.82) 
1.35 (1.07-1.71) 
1.12 (0.85-1.48) 
Consumed more than intended 
Co-twin 
2.59 (1.77-3.79) 
1.17 (0.86-1.59) 
2.56 (1.73-3.78) 
1.09 (0.79-1.50) 
0.99 (0.84-1.16) 
-- 
Unsuccessful attempts to cut down  
Co-twin 
1.97 (1.30-2.98) 
1.03 (0.74-1.46) 
2.09 (1.37-3.19) 
1.08 (0.76-1.53) 
1.06 (0.89-1.27) 
-- 
Preoccupation 
Co-twin 
2.05 (1.29-3.26) 
1.21 (0.84-1.76) 
2.55 (1.60-4.07) 
1.24 (0.85-1.83) 
1.24 (1.03-1.48) 
1.04 (0.84-1.28) 
Interference 
Co-twin 
2.54 (1.03-6.27) 
1.18 (0.67-2.09) 
4.69 (1.90-11.61) 
1.14 (0.62-2.08) 
1.85 (1.44-2.39) 
0.98 (0.72-1.34) 
Use despite physical/psych.problems 
Co-twin 
1.41 (0.48-4.12) 
-- 
2.78 (0.94-8.21) 
-- 
2.00 (1.41-2.83) 
1.28 (0.86-1.91) 
Notes: Wine preference drinkers are reference group in first set of analyses and beer preference 
drinkers are reference group in second set of analyses. ABP, alcoholic beverage preference; OR= Odds 
Ratio; CI, Confidence Interval. aMultivariate logistic regression accounting for continuous (age at 
interview, age during heaviest year, years of education) and binary (sex, zygosity, lifetime smoking 
status, and current marital status) covariates. Estimates significant at p< 0.05 are bolded.  
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However, there was no difference in risk between beer and DS preference drinkers for alcohol 
abuse and the remaining symptoms of both disorders. When the likelihood for endorsement of 
AA, AD, and AUD symptoms was predicted from the beverage preference of the co-twin, only 
two estimates were significant.  
 Table 3.4 lists the likelihood of endorsing MD, ASPD, and any symptom of illicit 
substance abuse/dependence across each drinking class. Compared to those who prefer wine, 
beer drinkers were at higher risk for any symptom of substance abuse, but for no other 
symptom/diagnosis, and DS preference drinkers were at the greater risk for ASPD, and any 
symptom of illicit substance abuse or dependence, but not MD. Interestingly, wine preference 
drinkers were at a significantly higher risk for depression as compared to beer drinkers. When 
beer was used as the reference category, MD and the substance abuse and dependence estimates 
were significantly greater for DS, but ASPD was not. Only one co-twin estimate was significant. 
Due to the phenotypic associations between ABP and consumption found in this report and 
TABLE 3.4. Association of ABP with lifetime DSM-IV sxs/diagnoses in the VATSPSUD 
 ABP in Heaviest Year (Wine Reference) ABP in Heaviest Year 
(Beer Reference) 
DSM- IV Diagnosis Beer 
Adjusted ORa (95% CI) 
Distilled Spirits 
Adjusted ORa (95% CI) 
Distilled Spirits 
Adjusted ORa (95% CI) 
MD 
Co-twin 
0.71 (0.55-0.92) 
0.82 (0.61-1.09) 
1.14 (0.88-1.49) 
-- 
1.60 (1.37-1.87) 
1.23 (1.03-1.47) 
ASPD 
Co-twin 
1.74 (0.95-3.20) 
-- 
2.11 (1.12-3.96) 
1.33 (0.81-2.19) 
1.21 (0.96-1.52) 
-- 
Any DAsx 
Co-twin 
1.50 (1.01-2.21) 
1.18 (0.82-1.70) 
2.13 (1.43-3.17) 
1.27 (0.87-1.85) 
1.42 (1.20-1.69) 
1.09 (0.89-1.34) 
Any DDsx 
Co-twin 
1.08 (0.61-1.90) 
-- 
1.77 (1.00-3.14) 
1.22 (0.72-2.07) 
1.63 (1.28-2.08) 
1.13 (0.85-1.52) 
Notes: Wine preference drinkers are reference group and beer preference drinkers are reference 
group in second set of analyses. ABP=alcoholic beverage preference; OR, Odds Ratio; CI, 
Confidence Interval. aMultivariate logistic regression accounting for continuous (age at interview, 
age during heaviest year, years of education) and binary (sex, zygosity, lifetime smoking status, 
and current marital status) covariates. Estimates significant at p< 0.05 are bolded.  
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others, we also ran the multivariate logistic regression analyses shown in Table 3.3 and 3.4 using 
regular quantity as a covariate in addition to the other previously utilized covariates (data not 
shown). While the estimates declined, most remained significant. 
 
Twin Correlations & Bivariate Twin Model Fitting in VATSPSUD 
 Table 3.5 shows that, across all three beverages, the tetrachoric correlations for female 
MZ twins were greater than female DZ twins, which is consistent with a genetic influence on 
ABP in females. The difference between male MZ and DZ correlations, by contrast, is much less 
than for the females, suggesting a smaller genetic influence on preference in males. Note male 
wine estimates show higher DZ than MZ correlations, reflecting the imprecision of the estimates 
due to the low number of males preferring wine. There is no reason to expect that DZ twins 
would be more correlated that MZ twins for any trait.  
 
 
Table 3.5. Twin correlations for ABP across 3 alcoholic beverage types in the VATSPSUD 
Sex and zygosity Number of 
‘complete’ 
pairs 
Total # of 
Individuals 
Tetrachoric Twin Correlations (95% CI) 
Wine Beer DS 
Female MZ twins 292 815 .52 (.35-.68) .49 (.34-.64) .42 (.24-.58) 
Female DZ twins 179 538 .30 (.01-.58) .28 (.06-.50) .32 (.10-.54) 
Male MZ twins 456 1242 .52 (.20-.84) .46 (.32-.61) .36 (.19-.53) 
Male DZ twins 293 946 .69 (.39-.99) .42 (.23-.60) .33 (.12-.54) 
Total 1220 3541  
Notes: ABP, alcoholic beverage preference; CI, Confidence Interval. All correlations are significant.  
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The phenotypic correlations between drink frequency and the three preference measures 
varied widely across preferences and between the sexes. For wine, beer, and DS preferences, 
respectively, the correlations for females (and males) were -.28, .20, -.19 (-.32, .62, .02). Across 
the three beverages, we could equate thresholds by twin order and zygosity but not by sex. 
Therefore, we estimated thresholds separately by sex in our models.  Bivariate model fitting 
results in the VATSPSUD are shown in Table 3.6. We found that the models in which the 
parameter estimates were equated across the sexes (Model 2a-c) fit significantly worse by ∆AIC 
for all three preferences than the models in which the estimates were allowed to vary by sex 
(Model 1a-c). Therefore, we estimated all parameters separately for males and females.  
 
Table 3.6. Model fitting results for regular frequency/ABP in the VATSPSUD 
Model Model 
Comparison 
-2LL ∆χ2 ∆df p-value ∆AIC 
Regular Quantity/Wine Preference  
1a. AfCfEf ≠AmCmEm, ra, rc, re - 25157.5 - - - - 
2a. AfCfEf =AmCmEm, ra, rc, re 2a v. 1a 25177.1 19.6 9 0.02 1.6 
3a. CfEf ≠CmEm, ra, rc, re 3a v. 1a 25221.3 63.8 6 0.00 51.8 
4a. AfEf ≠AmEm, ra, rc, re 4a v. 1a 25245.7 88.2 6 0.00 76.2 
5a. AfCfEf ≠AmCmEm 5a v. 1a 25283.5 126.0 6 0.00 114.0 
Regular Quantity/Beer Preference  
1b. AfCfEf ≠AmCmEm, ra, rc, re - 28376.5 - - - - 
2b. AfCfEf =AmCmEm, ra, rc, re 2b v. 1b 28465.3 88.8 9 0.00 70.8 
3b. CfEf ≠CmEm, ra, rc, re 3b v. 1b 28441.0 64.5 6 0.00 52.5 
4b. AfEf ≠AmEm, ra, rc, re 4b v. 1b 28493.3 116.8 6 0.00 104.8 
5b. AfCfEf ≠AmCmEm 5b v. 1b 28564.3 187.8 6 0.00 175.8 
Regular Quantity/Spirits Preference  
1c. AfCfEf ≠AmCmEm, ra, rc, re - 27961.2 - - - - 
2c. AfCfEf =AmCmEm, ra, rc, re 2c v. 1c 28013.9 52.8 9 0.00 34.7 
3c. CfEf ≠CmEm, ra, rc, re 3c v. 1c 28043.0 81.8 6 0.00 69.8 
4c. AfEf ≠AmEm, ra, rc, re 4c v. 1c 27978.3 17.1 6 0.01 5.1 
5c. AfCfEf ≠AmCmEm 5c v. 1c 28007.8 46.6 6 0.00 34.6 
Notes: ABP, alcoholic beverage preference; Af/m, additive genes in females/males; Cf/m, common environment in 
females/males;  Ef/m, unique environment in females/males; LL, log likelihood; Δχ2, change in chi-square from full model; p-
value associated with change in chi-square; ∆AIC, Akaike's criterion from full model; ra, genetic correlation; rc, shared 
environmental correlation; re, unique environmental correlation. 
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When we tested the more parsimonious models AE and CE across both sexes (Models 
3a-c & 4a-c), we could drop neither A nor C for any bivariate model. We next found that the 
genetic (ra), common environmental (rc), and unique environmental (re) correlations between the 
phenotypes could not be dropped simultaneously (Model 5a-c).  
In Table 3.7, we show the amount of variance contributed to the three preference 
phenotypes by A, C, and E. We do not present parameters estimates for drink frequency 
separately because these were previously assessed in this twin sample (9). The estimates for 
preference showed a moderately heritable component in females (Awine = 47.9%, Abeer =25.7%, 
ADS = 41.1%) and a smaller heritable component in males (Awine =8.5%, Abeer = 10.1%, ADS = 
8.6%). These estimates also suggested little to modest common environmental influence in 
females (Cwine =1.0%, Cbeer = 20.2%, CDS = 2.7%) and a stronger common environmental 
influence in males (Cwine = 49.9%, Cbeer =36.1%, CDS =28.1%). With the exception of wine 
preference in males, which has the lowest heritability, the range in overlap of genetic factors 
 
TABLE 3.7. Parameter estimates for bivariate Cholesky decomposition for each ABP and liability shared with 
regular quantity in the VATSPSUD 
  Females Males 
Estimate for 
Preference 
With Regular 
Frequency 
Unique Estimate for 
Preference 
With Regular 
Frequency 
Unique 
Wine A 47.9 5 95 8.5 100 0 
C 1.0 89 11 49.9 15 85 
E 51.1 12 88 41.6 2 98 
Beer A 25.7 21 79 10.1 8 92 
C 20.2 14 86 36.1 8 92 
E 54.1 13 87 53.7 0 100 
Distilled 
Spirits 
A 41.1 30 70 8.6 4 96 
C 2.7 96 4 28.1 8 92 
E 56.3 1 99 63.4 4 96 
Notes: ABP, alcoholic beverage preference; A, proportion of variance due to additive genetic effects; C, proportion due to 
common environment; E, proportion due to unique environment. 
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between regular frequency and preference across the three drink categories was small to modest 
(4% to 30%). 
 
 
 
 
 
 
Table 3.8. Model fitting results for total quantity in a typical week/ABP in FT12 
Model Model 
Comparison 
-2LL ∆χ2 ∆df p-value ∆AIC 
Regular Quantity/Wine Preference  
1a. AfCfEf ≠AmCmEm, ra, rc, re - 2844.8 - - - - 
2a. AfCfEf =AmCmEm, ra, rc, re 2a v. 1a 2862.1 17.3 9 0.04 -0.7 
3a. CfEf ≠CmEm, ra, rc, re 3a v. 1a 2860.9 16.1 6 0.01 4.1 
4a. AfEf ≠AmEm, ra, rc, re 4a v. 1a 2852.1 7.3 6 0.29 -4.7 
5a. AfCfEf ≠AmCmEm 5a v. 4a 3942.0 1097.2 10 0.00 1081.9 
Regular Quantity/Beer Preference  
1b. AfCfEf ≠AmCmEm, ra, rc, re - 3435.8 - - - - 
2b. AfCfEf =AmCmEm, ra, rc, re 2b v. 1b 3486.6 50.8 9 0.00 32.8 
3b. CfEf ≠CmEm, ra, rc, re 3b v. 1b 3448.1 12.3 6 0.06 0.3 
4b. AfEf ≠AmEm, ra, rc, re 4b v. 1b 3438.3 2.5 6 0.87 -9.6 
5b. AfCfEf ≠AmCmEm 5b v. 4b 14850.5 11414.7 10 0.00 11404.3 
Regular Quantity/Spirits Preference  
1c. AfCfEf ≠AmCmEm, ra, rc, re - 3347.1 - - - - 
2c. AfCfEf =AmCmEm, ra, rc, re 2c v. 1c 3366.7 19.6 9 0.02 1.6 
3c. CfEf ≠CmEm, ra, rc, re 3c v. 1c 3363.3 16.2 6 0.01 4.2 
4c. AfEf ≠AmEm, ra, rc, re 4c v. 1c 3352.1 5.0 6 0.55 -7.1 
5c. AfCfEf ≠AmCmEm 5c v. 4c 5876.3 2529.1 10 0.00 2516.2 
Notes: ABP, alcoholic beverage preference; Af/m, additive genes in females/males; Cf/m, common environment in 
females/males;  Ef/m, unique environment in females/males; LL, log likelihood; Δχ2, change in chi-square from full 
model; p-value associated with change in chi-square; ∆AIC , Akaike's criterion from full model; ra, genetic correlation; 
rc, shared environmental correlation; re, unique environmental correlation. 
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Bivariate Twin Model Fitting in FT12 & VA30K 
For the FT12 bivariate models, Table 3.8 shows that the parameter estimates cannot be 
equated by sex, similar to the results in the VATSPSUD. Therefore, we again estimated all 
parameters separately for each sex. Dropping A in the three separate analyses (Models 3a-c)  
resulted in significantly worse fit by ∆AIC and p-value except in the case of beer, which was 
borderline (∆AIC=0.3; p=0.06). We found that we could set C to zero across all three models 
(Models 4a-c). Thus, in Table 3.9 we present sex-specific AE models. Next, we found that the 
additive genetic and unique environmental correlations between total quantity and each of the 
preferences could be not dropped simultaneously without a significant decrease in fit by ∆AIC 
(Models 5a-5c).  
Table 3.9 lists the estimates for A and E that are unique to preference in addition to the 
amount of variance shared with total quantity. The heritable component in females was again 
higher (Awine= 56.4%, Abeer=70.3%, ADS= 44.5%) than in males (Awine =21.3%, Abeer = 45.2%, 
ADS = 19.1%). Unlike in the VATSPSUD, the common environmental component could be 
dropped; therefore, the unique environmental estimates were lower in females (Ewine = 43.6%,  
 
Table 3.9. Parameter estimates for bivariate Cholesky decomposition for ABP and liability shared with 
total quantity in a typical week in FT12 
  Females Males 
Estimate 
for 
Preference 
With Regular  
Quantity 
Unique Estimate for 
Preference 
With Regular  
Quantity 
Unique 
Wine 
Preference 
A 56.4 2 98 21.3 4 96 
E 43.6 19 81 78.7 1 99 
Beer 
Preference 
A 70.3 28 72 45.2 0 100 
E 29.7 2 98 54.8 10 90 
Spirits 
Preference 
A 44.5 21 79 19.1 31 69 
E 55.5 14 86 80.9 7 93 
Notes: ABP, alcoholic beverage preference; A , proportion of variance due to additive genetic effects; E, 
proportion due to unique environment. 
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Ebeer =29.7%, EDS = 55.5%) than in males (Ewine =78.7%, Ebeer = 54.8%, EDS = 80.9%). As seen 
in the VATSPSUD, there was only small to modest overlap in genetic influences on alcoholic 
beverage preference and the regular consumption measure (2%-28%). 
The sex differences in parameter estimates seen in the VATSPSUD and FT12 samples 
were not maintained in the VA30K. Table 3.10 shows that models in which the parameter 
estimates were equated across the sexes (Model 2a-c) did not fit significantly worse by ∆AIC  
Table 3.10. Model fitting results for regular consumption last week/ABP in the VA30K 
Model Model 
Comparison 
-2LL ∆χ2 ∆df p-value ∆AIC 
Regular Quantity/Wine Preference  
1a. AfCfEf ≠AmCmEm, ra, rc, re - 18475.8 - - - - 
2a. AfCfEf =AmCmEm, ra, rc, re 2a v. 1a 18486.8 11.0 9 0.27 -7.0 
3a. CfEf ≠CmEm, ra, rc, re 3a v. 2a 18494.6 7.8 3 0.05 1.8 
4a. AfEf ≠AmEm, ra, rc, re 4a v. 2a 18499.4 12.6 3 0.01 6.6 
5a. AfCfEf ≠AmCmEm 5a v. 2a 18576.2 89.4 3 0.00 83.4 
Regular Quantity/Beer Preference  
1b. AfCfEf ≠AmCmEm, ra, rc, re - 19044.4 - - - - 
2b. AfCfEf =AmCmEm, ra, rc, re 2b v. 1b 19072.3 27.9 9 0.00 9.9 
3b. CfEf ≠CmEm, ra, rc, re 3b v. 2b 19091.2 18.9 3 0.00 12.9 
4b. AfEf ≠AmEm, ra, rc, re 4b v. 2b 19081.6 9.3 3 0.03 3.3 
5b. AfCfEf ≠AmCmEm 5b v. 2b 19151.5 79.1 3 0.00 73.2 
Regular Quantity/Spirits Preference  
1c. AfCfEf ≠AmCmEm, ra, rc, re - 19438.0 - - - - 
2c. AfCfEf =AmCmEm, ra, rc, re 2c v. 1c 19444.6 6.6 9 0.68 -11.4 
3c. CfEf ≠CmEm, ra, rc, re 3c v. 2c 19462.2 17.6 3 0.00 11.6 
4c. AfEf ≠AmEm, ra, rc, re 4c v. 2c 19448.5 3.9 3 0.27 -2.1 
5c. AfCfEf ≠AmCmEm 5c v. 2c 19494.5 50.0 3 0.00 44.0 
Notes: ABP, alcoholic beverage preference; Af/m, additive genes in females/males; Cf/m, common environment in 
females/males;  Ef/m, unique environment in females/males; LL, log likelihood; Δχ2, change in chi-square from full 
model; p-value associated with change in chi-square; ∆AIC, Akaike's criterion from full model; ra, genetic correlation; 
rc, shared environmental correlation; re, unique environmental correlation. 
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and p-value than models in which the parameters were estimated separately (Model 1a-c). 
Therefore, we proceeded with model fitting using sex-equated parameters.  
We found that A (Models 3a-c) and C components (Models 4a-c) could not be dropped for any 
preference, except for the C components in distilled spirits (4c). For comparison purposes across 
the preferences, we present the estimates for the full models (Table 3.11). The genetic and 
environmental correlations between last week’s total quantity and the preference phenotypes 
could not be dropped simultaneously (Model 5a-c) across all three preferences. Again, as seen in 
Table 3.11 and in the two samples, the overlap of genetic factors between the regular 
consumption measure and preference was small to modest (wine=36%, beer=5%, and DS=1%). 
 
Extended Twin Modeling in VA30K 
 We found that there were no qualitative or quantitative sex differences when we fitted the 
full Cascade model to the ordinal preference data. As listed in Table 3.12, across wine, beer, and 
Table 3.11. Parameter estimates for bivariate Cholesky decomposition for 
ABP and liability shared with regular quantity last week in the VA30K 
 
  Both Sexes 
Estimate for 
Preference 
With Last Wk  
Quantity 
Unique 
Wine 
Preference 
A 12.1 36 64 
C 33.6 1 99 
E 54.3 3 97 
Beer 
Preference 
A 39.3 5 95 
C 24.7 6 94 
E 36.0 1 99 
Spirits 
Preference 
A 42.5 1 99 
C 6.1 2 98 
E 51.4 4 96 
Notes: A, proportion of variance due to additive genetic effects; C, proportion due 
to common environment; E, proportion due to unique environment 
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DS preferences, there was a modest additive genetic component (Awine=21%, Abeer=15%, 
ADS=19%) and little to no non-additive genetic variance (Dwine=0%, Dbeer=3%, DDS=0%). We 
found no evidence for cultural transmission for any preference and the sibling environment 
ranged from none to small (Swine=11%,  Sbeer=7%, SDS=0%). The special twin environment was 
also small to modest (Twine=2%, Tbeer=18%, TDS=14%), while the unique environment 
represented the greatest source of variance (Ewine=65%, Ebeer=57%, EDS=67%). Spousal 
correlations were modest to moderate across all three preferences (wine= 0.32; beer=0.21; 
spirits=0.29).  
 
Discussion 
In the first part of this study, we sought to examine the relationship between endorsing 
certain levels of consumption, AUD symptoms and diagnoses, as well as other psychiatric 
conditions, using ABP in the heaviest year as the determinant. All of the studies discussed below, 
including our own, controlled for several socio-demographic factors shown to be correlated with 
preference. Our finding that wine preference drinking is associated with the lowest likelihood of 
AUDs is in agreement with findings of Flensborg-Madsen and colleagues (120). We also found 
that beer preference drinkers had the greatest odds of high levels and frequency of consumption, 
which is consistent with previous work examining frequency of drinking and drunkenness (123), 
 
Table 3.12. Parameter estimates for univariate extended twin analysis for each ABP in the VA30K 
 A D F S T E 
Wine 
Preference 
0.21 0.00 0.00 0.11 0.02 0.65 
Beer 
Preference 
0.15 0.03 0.00 0.07 0.18 0.57 
Spirits 
Preference 
0.19 0.00 0.00 0.00 0.14 0.67 
Notes: A, additive genetic variance; D, non-additive genetic variance; S, common sibling environmental 
variance; F, cultural transmission; T, twin environmental variance; E, unique environmental variance. 
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heavy and excessive drinking (122), as well as problem drinking and level of intoxication (125). 
Further support for our findings comes from research that found that beer accounts for the 
majority of hazardous alcoholic beverage consumption in the US (81%) (157) and that binge 
drinkers show a high level of preference for beer (158). Our findings are also reasonable in light 
of work indicating that beer drinkers are more likely than any other type of drinker to be arrested 
for drunk driving and involved in alcohol-related accidents (125,159-161). It should be 
emphasized that while some individuals have the perception that beer is a social drink (123), less 
harmful than spirits due to its lower alcohol content (123,162), and even safe during pregnancy 
(163), our results suggest that the risk for AA and most symptoms of AUDs is the same for beer 
and DS preference drinkers. This, combined with the additional correlates of beer drinking seen 
in other studies, is reason for reconsideration of beverage-specific public policies in the US, such 
as lower taxes for beer than DS (162), and for better education regarding the effects of all forms 
of ethanol.  
We also found that DS preference drinkers were at the greatest risk for AD, the most 
severe form of AUD, and certain symptoms of AUDs that may be considered particularly 
impairing, including withdrawal, preoccupation, interference with daily activities, and use 
despite physical/psychological problems. These finding are in line with work by Baltieri and 
colleagues, who reported that spirit drinkers had a higher severity of AD and craving for alcohol 
than beer drinkers (164). The only previous study we know of examining depression in relation 
to ABP found that beer and spirits preference drinkers did not score differently on the Hamilton 
Depression Rating Scale (164), while our data showed that DS preference drinkers were at 
greater risk for MD. Compared to beer drinkers, we also found that wine drinkers are at greater 
risk for MD, which was the only variable we tested that showed this pattern. We are unaware of 
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any previous work relating ASPD specifically to beverage preference. However, in line with our 
work, previous research has found that engagement in delinquent behavior in adolescence (126) 
and assault and homicide rates in adulthood (165) were correlated with spirit and beer drinking 
but not wine drinking. Our findings on substance use disorders are supported by work indicating 
that adolescents in Finland who preferred beer or spirits had more exposure to illicit substances 
than wine or cider preference drinkers (123) and underage youth in the US who preferred these 
beverages showed greater marijuana use than wine cooler and malt liquor preference drinkers 
(161). Additionally, beer drinkers had a higher prevalence of illicit drug use than wine drinkers 
in a Danish adult sample (166). 
Along with the results from others studies, the findings from the first part of our report 
suggest that beverage preference may help define meaningful subtypes of alcohol dependent 
individuals. A number of typologies currently exist, categorizing dependent individuals using 
such measures as age at onset, alcohol consumption, comorbidity, and alcohol-related problems 
(167). Our work suggests that DS preference drinkers are more likely to fall into a chronic/severe 
subtype, consisting of early onset, severe AD with a high probability of comorbidity, including 
MD, ASPD, and polysubstance use, while beer preference drinkers are more likely to belong to a 
subtype with high levels of drinking/drunkenness and legal consequences, but less probability of 
comorbidity. If wine drinkers develop an AUD, they would likely belong to a later onset subtype, 
supported by our demographic data of age during the heaviest year, with lower consumption and 
fewer alcohol-related problems but greater probability of comorbid MD than beer preference 
drinkers (168). These typologies have implications for treatment efforts, such as that spirits 
preference drinkers may require more intense intervention and/or a combination of different 
intervention strategies, while wine and beer preference drinkers may be more responsive to 
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treatment. Interestingly, Baltieri and co-authors compared the adherence to treatment 
(topiramate, naltrexone, and placebo) of beer and distilled spirits preference drinkers and found 
that spirit drinkers were indeed less adherent to drug therapies (164).  
There are several plausible explanations for the phenotypic associations between ABP 
and our outcome variables, including overlapping genetic and environmental liability factors and 
direct causal effects. The significant co-twin findings for AC measures and ABP indicate that 
common familial factors account, at least partially, for the correlations. Further evidence for this 
explanation was provided by the bivariate twin analyses across the VATSPSUD, FT12, and 
VA30K, which generally showed significant genetic and common environmental correlations 
between AC measures and preference. Setting is one environmental factor that has been shown 
to influence alcohol consumption measures as a well as what one chooses to drink. Wine tends to 
be consumed at home, with meals, and during religious occasions, which provide social 
constraints on intake, whereas beer and spirits are drunk more frequently at bars, sports games, 
and parties, where high consumption is tolerated and even preferable (169). A few previous 
studies have implicated genes that appear to influence both consumption measures and ABP. 
Ishibashi et al. (170) found that individuals expressing the ALDH2*2 variant in the alcohol 
dehydrogenase gene preferred beverages with lower concentrations of ethanol, and this variant is 
well known to effect consumption measures (171) as well as for risk for AD (44). Additionally, 
taste sensitivity to the synthetic compound PROP differs based on genetic variability in the bitter 
taste receptor genes (172), and PROP sensitivity is a good predictor of alcoholic beverage 
preference (173). Two bitter taste receptor genes, TAS2R38 and TASR16, have been associated 
with level of alcohol consumption and AD (25,172,174). The majority of co-twin findings for 
AUDs/symptoms and other psychiatric disorders were not significant, providing less evidence of 
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common familial influences on these measures and ABP, but there may still be common unique 
environmental influences.  
An additional/alternative explanation for the associations, which is not mutually 
exclusive from the first, is a causal relationship. As discussed in the introduction, studies suggest 
that both the concentration and congener differences in specific alcohol beverages may be 
partially causal for non-psychiatric health outcomes, such as obesity, cancer, and cardiovascular 
disease (117,119,127). However, there have been few studies on concentration and congeners in 
terms of their effects on the development of neuropsychiatric outcomes. In a review of 
experimental studies on the behavioral effects of different types of alcohol, mostly from the 
1970’s or earlier, Smart (125) notes that subjects generally showed greater psychomotor and 
intellectual impairment after consumption of spirits than beer. Smart suggested some of these 
effects may be due to the more rapid rise in blood alcohol concentration after consumption of 
spirits. A more recent study found that craving, known to be an important factor in relapse, was 
associated with beer consumption, but not wine or spirits consumption, in males inpatients on a 
detoxification unit (175). The authors posited that since beer has the highest volume of liquid of 
the alcoholic beverages, it may alter hormone levels that influence withdrawal craving more than 
the other beverages. Furthermore, wine and spirits have been shown to increase homocysteine 
levels, while beer has no effect or perhaps a negative effect (176); increased homocysteine is 
associated with craving and withdrawal seizures (177). Wilhem et al. also suggest that the 
hippocampal volume loss that they found to be associated with wine and spirits drinking, but not 
beer drinking, was due to homocysteine level changes directly caused by these beverages (178). 
Another study found a significantly increased risk of dementia in beer drinkers and decreased 
risk in wine drinkers with no effect in DS drinkers (179). Thus, certain alcoholic beverages may 
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confer neurotoxic effects that result in neuropsychiatric outcomes. Finally, while the main effect 
of alcohol on hangover appears to be from ethanol, additional effects on hangover severity have 
been demonstrated depending on congener content of various alcoholic beverages (180,181).  
Causal explanations are only logical if the temporal ordering is such that the effect occurs 
subsequent to the cause. Because we have cross-sectional data, we cannot be certain of the 
chronological order in which preference and the variables that we treated as outcomes developed. 
It is possible that individuals establish/change their preference after they develop drinking 
patterns, AUDs/symptoms, and other psychiatric conditions. However, we believe our assumed 
temporal ordering is reasonable because longitudinal studies have shown that individuals who 
prefer wine are less likely to develop into excessive drinkers (122) or become alcohol dependent 
(120). Additionally, prior literature suggests that preference develops during the teenage years 
for many individuals (123,161). Other work indicates that preference is relatively stable in 
several populations (182).  In our twin data, both the average age of individuals during the year 
when AC measures were assessed (27.2 years old, SD=9.44) and the average age at onset of the 
occurrence of two or more symptoms in the same year (22.1 years old, SD= 5.79) were past the 
teenage years.  
A final explanation for the associations is residual or uncontrolled confounding. We 
controlled for several demographic variables that we found to be associated with preference and 
to which we had access; however, our covariates may not have been adequate. For example, 
socioeconomic status is known to be a strong correlate of ABP (183), and while we attempted to 
control for this variable with education level, there may still be residual confounding.  
Additionally, there are other variables to which we did not have access that the extant literature 
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has shown to be correlates of preference and drinking patterns/AUDs/other psychiatric 
conditions, including personality characteristics (155) and coping styles (184). 
We are unaware of any studies that have assessed the association between ABP and 
particular outcomes in the context of a twin study. When a twin’s preference was used to assess 
the odds of reporting particular levels of AC measures, most ORs were significant, suggesting 
that the association between ABP and consumption levels is at least partly influenced by familial 
factors. To further explore this relationship, we examined the genetic and environmental 
influences on regular frequency of consumption and ABP in bivariate twin models in the 
VATSPSUD and these influences on regular quantity of consumption and ABP in the VA30K 
and FT12. Generally, we found that total AC measures index genetic liability to the three 
preferences only modestly. Given that beverage preference may help define certain subtypes of 
alcohol dependent individuals and examining subtypes are a potential way to reduce genetic 
heterogeneity, it may be more informative to retain particular beverages as separate measures in 
association studies instead of combining them into one measure. Genes that influence preference 
for particular alcoholic beverages may act as modifiers of AUD characteristics (185). For 
example, being more tolerant of bitter tastes may lead to a preference for spirits, earlier onset of 
regular drinking, and higher levels of alcohol consumption. Additionally, genes associated with 
preference may influence the metabolism of particular congeners. Knowing these genes could 
aid in prediction of individuals at higher risk for negative effects from certain alcoholic 
beverages, such as red wine headaches (186), and those who are most likely to benefit from 
positive effects.   
In males, the parameter estimates for ABP in the VATSPSUD and FT12 suggest that 
preference is more influenced by environmental factors. However, in females, we found that 
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additive genetic factors had a stronger influence. Sex differences in alcohol-related phenotypes 
are not unusual in the twin literature. In the same twin sample used for the present study, our 
group found differences between the genders in the heritability for AC measures (9) as well as 
variability in the sources of genetic and environmental factors contributing to AD (187). Other 
groups have seen significant sex differences in the heritability of alcohol misuse (188) and AD 
symptoms (189). Furthermore, a number of studies examining preference for a variety of food 
items also showed sex differences (146,190,191).  
There are several possible explanations for the higher environmental influences on 
beverage preference in males. Prior research suggests that, in comparison to females, males are 
more motivated to drink to fulfill conformity motives (fitting in with a peer group) and more 
influenced by peers in the amount of alcohol they consume because they regard confederate 
drinking as a challenge (184,192). It may follow that they are more influenced by peers in the 
type of alcohol that they consume. Landrine and colleagues (193) found that undergraduate 
subjects attributed beer drinking significantly more often to males, indicating that drinking this 
beverage is part of gender expectations for men. Work by Corcoran et al. supports this finding 
(194). The researchers divided males and females into two groups based on their scores on The 
Fear of Negative Evaluation (FNE) scale, which measures level of apprehension over potential 
negative social evaluation. The participants sampled four beverages (pineapple juice, diet cola, 
tonic water, and beer) and were then presented with a series of questions about their preferences. 
High-FNE males were more likely to select beer than low-FNE men or either group of women. 
Furthermore, certain sets of genes that affect beverage preference, such as those that encode the 
bitter taste receptors, may be differentially expressed in the sexes. Interestingly, a higher number 
of females are classified as supertasters (highest level of bitterness and irritation/astringency) 
67 
 
(195,196), suggesting that females may be more influenced by taste, and thus genetic factors, 
when selecting their preferred alcoholic beverage.  
We are not certain why the VA30K data did not show the same gender discrepancy in 
parameter estimates as the VATSPSUD and the FT12 samples, but there are several possible 
explanations. The latter two studies assessed consumption measures and preference over a longer 
period of time, whereas the VA30K collected information about “last week,” which may be more 
variable, and thus less powerful, as well an atypical week for some individuals. The range of 
birth years is greater for the VA30K (1915-1971) (148) as compared to the VATSPSUD (1934-
1970) (91) and FT12 (1983-1987) (143). A cohort effect on ABP has been seen, which could 
affect parameter estimates (197). Additionally, participants in the latter two samples were 
interviewed by clinically trained interviews, whereas subjects in the third sample filled out 
questionnaires on their own.  
In terms of our full Cascade model estimates, we saw less evidence for additive genetic 
influences on all three preferences than the bivariate models in the VA30K and no evidence for 
cultural transmission. It is not uncommon to see variable parameter estimates based on the 
number of relatives and little to no evidence of cultural transmission in traits that have been 
previously assessed in the literature (153,198). The other common environmental estimates 
indicate that shared environmental variance in preference is more due to special twin 
environment (beer and spirits) or sibling environment (wine). These influences could be from 
peers, financial factors, and/or country specific-trends. For example, European countries can be 
divided into “alcohol belts,” based on their production and consumption of wine (Portugal, 
Spain, Greece, Italy, and France), beer (Germany, Belgium, Denmark, and the United Kingdom) 
and distilled spirits (the Czech Republic, Russia, Norway, Finland, Sweden,  and Poland).  
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The results of our work must be considered in the context of several limitations. First, we 
did not ask the subjects directly about their ABP, but rather assumed that their most frequently 
consumed beverage (VATSPSUD) or the quantity with they consumed particular beverages 
(FT12 and VA30K) would reflect their preferences. Alcoholic beverage choice may not always 
reflect preference; however, Straus and Bacon (199) showed that the two traits are highly 
correlated in college students. While some authors have also utilized “most frequently used 
beverage” synonymously with ABP (155), others have based preference on a quantity measure. 
Quantity-based definitions are variable in the literature, including defining preference as the 
“most consumed beverage” (200), the type of alcohol usually consumed during the past 30 days 
(161),  >35% of alcohol consumed (120), and > 50% of total alcohol used (115,122,123,201-
203), > 2/3 of total consumption (164,204) . It is reassuring to note that definitions based on 
quantity may not be very different than those based on frequency. Using continuous measures of 
the quantity and frequency of intake of specific beverages from three datasets to which we have 
access, including FT12, VA30K, and an AD sample, the correlations between quantity and 
frequency for wine, beer, and spirits were high, ranging from 0.66-0.86. However, it still would 
be helpful to have a standard definition of preference throughout the alcohol literature, so that 
studies using this trait could be more directly comparable.  
Second, we did not have specific information on the form of spirits (straight or mixed) or 
types of beverages within main classes (e.g. red vs. white wine or fortified vs. regular wine). We 
also did not have access to data on additional alcoholic beverages beyond the three main classes, 
such as alcopops, cider, and caffeinated alcoholic beverages, which have been shown to have 
differential associations as compared to wine, beer, and spirits (123,205).  Third, it would have 
been interesting to test for significant differences in the magnitude of genetic and environmental 
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influences on quantity of consumption of particular alcoholic beverages using multivariate 
modeling approaches, as has been done with different forms of caffeine, cannabis, and cocaine 
(146,206). However, this is more challenging with forms of alcoholic beverages in that 
individuals tend to drink multiple classes of beverages, and so they are more dependent on each 
other than other forms of drugs of abuse. Finally, it is unclear whether our samples of Virginia- 
and Finnish-born Caucasians generalizes to other populations. Nevertheless, in the first part of 
the study in which we attempted to replicate and extend others’ work on beverage preference 
correlates, our findings are broadly similar to the results of studies using Finnish, Danish, 
Brazilian, and American samples.  
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CHAPTER 4: Limited Associations of Dopamine System Genes with Alcohol 
Dependence and Related Traits in the Irish Affected Sib Pair Study of Alcohol 
Dependence 
 
Adapted from: Hack LM, Kalsi G, Aliev F, Kuo P-H, Prescott CA, Patterson DG, Walsh D, Dick 
DM, Riley BP, Kendler, KS. Limited Associations of Dopamine System Genes with Alcohol 
Dependence and Related Traits in the Irish Affected Sib Pair Study of Alcohol Dependence 
(IASPSAD). Alcohol: Clinical & Experimental Research. 2011, 35(2): 376-385. 
 
 
Abstract 
 
Background: Over 50 years of evidence from research has established that the central 
dopaminergic reward pathway is likely involved in alcohol dependence (AD). Additional 
evidence supports a role for dopamine (DA) in other disinhibitory psychopathology, which is 
often comorbid with AD. Family and twin studies demonstrate that a common genetic 
component accounts for most of the genetic variance in these traits. Thus, DA related genes 
represent putative candidates for the genetic risk that underlies not only AD, but also behavioral 
disinhibition. Many linkage and association studies have examined these relationships with 
inconsistent results, possibly due to low power, poor marker coverage, and/or an inappropriate 
correction for multiple testing. 
Methods: We conducted an association study on 10 DA related genes (DRD1-D5, 
SLC18A2, SLC6A3, DDC, TH, COMT) using a large, ethnically homogeneous sample with 
severe AD (N=545) and screened controls (N= 509). We collected genotypes from linkage 
disequilibrium (LD) tagging SNPs and employed a gene-based method of correction. A total of 
135 SNPs were genotyped using the Illumina GoldenGate and Taqman Assays-on-Demand 
protocols. We tested for association with AD diagnosis in cases and controls and with a variety 
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of alcohol-related traits (including age-at-onset, initial sensitivity, tolerance, maximum daily 
drinks, and a withdrawal factor score), disinhibitory symptoms, and a disinhibitory factor score 
in cases only. We also sought to replicate association results from the Study of Addiction: 
Genetics and Environment (SAGE) sample between specific DA SNPs and the phenotype 
sensation seeking (207).  
Results: Of the 101 SNPs entered into standard analysis, 6 independent SNPs from 5 
dopamine genes were associated with AD or a quantitative alcohol-related phenotype (ARP). 2 
SNPs across 2 genes were associated with a disinhibitory symptom count, while 1 SNP in DRD5 
was positive for association with the general disinhibitory factor score. We did not replicate the 
findings from the SAGE sample in our Irish sample. 
Conclusions: Our study provides evidence of modest associations between a small 
number DA related genes and AD as well as a range of ARPs and measures of behavioral 
disinhibition. While we did conduct gene-based correction for multiple testing, we did not 
correct for multiple traits because the traits are correlated and there is a priori evidence of 
association with each trait. However, false positive findings remain possible, so our results must 
be interpreted with caution. 
 
Introduction 
Owing to its involvement in a broad range of functions, alteration in dopamine (DA) 
activity appears to play a central role in the etiology and/or treatment of many psychiatric 
disorders. DA’s posited role in alcohol dependence (AD) stems from its involvement in the 
mesocorticolimbic reward pathway, which spans from the ventral tegmental area to the nucleus 
accumbens and prefrontal cortex (208). DA was first implicated in mediating the effects of 
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reward in Olds’ and Milner’s (209) classic experiments. Subsequent behavioral studies have 
generated considerable additional evidence to show that dopaminergic transmission in the 
mesocorticolimbic pathway is essential to reinforcing reward (210).  
Of all addictive substances, alcohol has created one of the greatest societal burdens (3). 
AD is a clinically and etiologically heterogeneous condition that is 50%-60% heritable (7,8). 
Due to its etiological heterogeneity, considering subtypes of individuals with AD may increase 
power to detect underlying susceptibility variants. A recent latent class analysis of our sample 
found that cases could be divided into three classes based on comorbidities: a severe (S) class 
with the highest probabilities of all comorbidities and high novelty seeking; a depressed (D) class 
with the highest probability of neuroticism and high probability of depression; and a mild (M) 
class with the lowest probabilities of all comorbidities (211). These classes are consistent with 
the idea that at least two independent pathways to the development of AD exist, including 
negative affect regulation, in which alcohol consumption is a means of relieving negative mood 
states, and behavioral disinhibition, in which high consumption is part of an overall tendency to 
behave impulsively and to seek excitement (212). The etiologically independent nature of these 
pathways is supported by evidence that one common factor is largely responsible for the genetic 
susceptibility to internalizing disorders, while another common genetic factor explains most of 
the genetic variation in externalizing disorders, and there is only a small correlation between the 
two factors (28). These common genetic liabilities may help explain why internalizing 
phenotypes, such as depression and anxiety/neuroticism, and disinhibitory phenotypes, including 
drug dependence (DD), antisocial behavior, and attention deficit/hyperactivity disorder (ADHD) 
are highly comorbid in many samples, including our Irish sample (5,29). 
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Since the mescorticolimbic pathway may be involved in the rewarding aspects of 
externalizing behavior, DA genes are reasonable candidates for susceptibility to AD as well as 
other disinhibitory psychopathology. We considered AD, ADHD, antisocial personality disorder 
(ASPD), conduct disorder (CD), DD, and novelty seeking (NS) to be part of the externalizing 
spectrum. Several studies suggest that a disinhibitory personality style, including NS, shares a 
common genetic influence with disorders in the externalizing spectrum (30,213,214). 
Childhood/early adolescent studies suggest ADHD share genetic liability with CD (215-220). 
Additionally, a recent twin study reported shared genetic influences between adolescent ADHD 
and adult AD beyond those shared with CD (110). 
 We examined ten DA related genes, including the following: the five receptors, DRD1-
D5; two transporters, solute carrier family 18 member A2 (SLC18A2 or vesicular monoamine 
transporter type 2, VMAT2) and solute carrier family 6, member 3 (SLC6A3 or dopamine active 
transporter, DAT or DAT1); and three enzymes, tyrosine hydroxylase (TH), dopa decarboxylase 
(DDC), and catechol-O-methyltransferase (COMT).  If no studies of association between a 
particular gene and trait are discussed below, we are unaware of any reports (either positive or 
negative) with rigorous methodology that have examined these associations.  
 
DRD2 
DRD2 (11q22-q23) has been examined most thoroughly in relation to AD and 
disinhibitory phenotypes. The majority of human studies have focused on the TaqIA restriction 
fragment length polymorphism (rs1800497), which a meta-analysis estimated to be associated 
with AD at a modest odds ratio (OR) of 1.31 (57). In 2004, Neville et al. (58)found this SNP to 
be within the coding region of the neighboring ankyrin repeat and kinase domain containing 1 
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(ANKK1) gene; therefore, the most parsimonious explanation is that phenotypic associations are 
due to this nonsynonymous coding change in ANKK1. However, this SNP could be tagging a 
polymorphism in DRD2, which contains several SNPs in modest LD (r
2≈0.6) with rs1800497. 
Furthermore, Dick et al. (59) found weak associations between variants in DRD2 and AD. 
Studies examining association with DRD2 and aspects of heroin dependence have generally been 
positive (57). The meta-analysis of Gizer and colleagues (221) identified no association of DRD2 
with ADHD.  
 
Other DA receptors 
Rigorous studies of DRD1 (5q35.1) and AD have typically estimated positive 
associations with modest effect sizes (60,61), while reports examining this phenotype and DRD3 
(3q13.3) have been negative (57). A recent review supports an association between the 48-bp 
variable number of tandem repeats (VNTR) in DRD4 (11p15.5) and an intermediate phenotype 
termed urge for addictive substances, which refers to craving for substances of abuse (62). We 
know of no rigorous reports investigating associations between DRD5 (4p16.1) and AD or 
related traits.   
Le Foll and colleagues’ 2009 (57) review notes that certain variants in DRD3-D5 confer 
an increased risk of heroin dependence, while research on psychostimulant dependence has 
either been negative or inconclusive. A recent meta-analysis examining ADHD reported 
significant associations with variants in both DRD4 and DRD5, whereas there was no association 
with DRD3 (221). Additionally, Kim and colleagues (61) identified variants in DRD1 that 
increase scores for the disinhibitory personality trait novelty seeking (NS) in alcohol dependent 
subjects. Of all DA genes, DRD4 has been the best studied for its role in NS. Munafò et al.’s 
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2008 (222) meta-analyses identified association with C521T (rs1800955) but not with DRD4’s 
48-bp VNTR.  
 
Transporters 
SLC18A2 shuttles cytosolic monoamines into synaptic vesicles. Schwab et al. (223) 
reported an association with variation in SLC18A2 (10q25) and AD, but we are unaware of any 
reports of association with other disinhibitory psychopathology. SLC6A3 terminates DA 
signaling by removing this neurotransmitter from synaptic clefts. Some research has indicated 
that striatal SLC6A3 density and availability is reduced in alcohol dependent subjects (224). Van 
der Zwaluw’s 2009 (225) review notes that many investigators have identified association 
between SLC6A3’s (5p15.3) best studied 40-bp VNTR and alcohol-withdrawal symptoms but 
typically not with AD. Generally, association studies of other drug use phenotypes and SLC6A3 
have been negative (226,227), although Guindalini and colleagues (228) did find that alleles in a 
30-bp VNTR increased risk of cocaine abuse. Additionally, there have been mixed results of 
association with SLC6A3’s functional 40-bp VNTR in relation to antisocial behavior in 
adolescence (229-233). The meta-analysis of Gizer and coauthors (221) found association of 
variants in SLC6A3 with ADHD. 
 
Enzymes 
TH is the rate limiting enzyme in DA synthesis. Dahmen et al. (234) showed an increased 
frequency of the Val allele (Val81Met polymorphism) of TH (11p15) in patients with early onset 
AD. Association studies of ADHD have been negative (235), and no rigorous reports have 
examined any of the other disinhibitory traits. The final enzyme in the synthesis pathway, DDC, 
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converts L-DOPA to DA. No published studies have reported an association with DDC (7p12.2) 
and AD or any disinhibitory phenotypes that we studied, including ASPD, ADHD, CD, DD, or 
NS. 
COMT is a degradatory enzyme for catecholamines. The most well-researched 
polymorphism in COMT (22q11.21) is the common G>A transition (rs4680), which results in a 
valine to methionine substitution (Val158Met) and a decrease in enzyme activity by 3- to 4-fold 
(236). Many studies have investigated the association between the low activity allele (Met) and 
AD with inconsistent results (237). Investigators have reported associations between this SNP 
and methamphetamine abuse (226) and NS (238,239), while Cheuk et al.’s (240) meta-analysis 
estimated no association with ADHD.  
 
Study Goals 
 The primary goal of the present study was to test for association between AD and several 
ARPs, such as initial sensitivity, and SNPs in 10 DA genes in a large, homogeneous sample. Because 
twin studies have found that a single genetic factor is largely responsible for the genetic susceptibility 
to AD and several other disinhibitory phenotypes and traits, a second goal of the study was to test for 
association of these SNPs with relevant symptoms of disinhibitory disorders as well as a disinhibitory 
factor score. Our final goal was to attempt replication of work by Derringer and colleagues in which 
the authors tested for association of 273 LD-tagging SNPs across 8 DA genes with the phenotype 
sensation seeking (207). Their sample included 635 participants from the SAGE sample of which 
65.2% met criteria for lifetime AD using DSM-IV criteria (6).  The authors found 12 of these SNPs 
to be individually associated with sensation seeking. Furthermore, they showed that a linear 
regression model that included the SNPs fit better and explained 3.9% more of the variance in 
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sensation seeking than one in which covariates alone were included. While we did not measure 
sensation seeking in our subjects, previous work has found a moderate and significant correlation 
between this phenotype and one of our phenotypes, novelty seeking (241). Therefore, we assessed 
association between NS and specific DA SNPs both individually and in aggregate in our replication 
attempt. To our knowledge, we are the first group to report results on an association analysis of both 
quantitative ARPs and symptoms of disinhibitory disorders within alcohol dependent cases for a large 
group of DA related genes. 
 
Methods 
Subjects and phenotype measurement 
Participants in the Irish Affected Sibpair Study of Alcohol Dependence (IASPSAD) were 
recruited in Ireland and Northern Ireland between 1998 and 2002. Further details of the study design, 
sample ascertainment, and clinical characteristics of this sample are described elsewhere (242). In 
brief, ascertainment of probands was mainly conducted in community alcoholism treatment facilities 
and public and private hospitals. Probands were eligible for study inclusion if they met the current 
DSM-IV criteria for AD and if all four grandparents had been born in Ireland, Northern Ireland, 
Scotland, Wales, or England. After a prospective family was identified through probands, parents and 
potentially affected siblings whom the probands provided permission to contact were recruited. 
Probands, siblings, and parents were interviewed by clinically-trained research interviewers, 
most of whom had extensive clinical experience with alcoholism. The assessment included 
demographic characteristics, lifetime history of AD and other comorbid conditions, ARPs, 
personality features, and clinical records. All participants provided informed consent. Controls were 
recruited in Northern Ireland from volunteers donating at the Northern Ireland Blood Transfusion 
Service and in the Republic from the Garda Siochana (the national police force) and the Forsa 
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Cosanta Aituil (the army reserve). Controls were screened and their samples excluded if they reported 
a history of heavy drinking or problem alcohol use. In the present case-control study design, we 
included 545 independent AD cases and 509 controls with an ample yield of high quality DNA for 
genotyping. The selection of cases was random with respect to AD severity and comorbid 
phenotypes.  
In addition to the binary diagnosis of AD, we chose to examine several quantitative ARPs 
because examining such traits may provide more power than analysis of dichotomous phenotypes 
(20); prior research in this sample detected  linkage and association signals with some of these traits 
but not with AD (e.g.(243)). We assessed age-at-onset of AD (ONSET), subjective response to 
ethanol, maximum drinks in 24 hours (MAX24), and a factor score of withdrawal symptoms 
(WDSFS). ONSET was defined as the age at which the first criterion for DSM-IV AD was satisfied. 
Subjective response to ethanol was assessed using the self-rating of the effects of ethanol (SRE,(244) 
to form two scores, initial sensitivity (ISENS) and tolerance/maximum drinking (TOLMX). The SRE 
inquires about how many drinks were needed for a subject to experience effects from alcohol 
consumption at different stages of use. ISENS is based on “the first 5 times you ever drank” and 
items contributing to TOLMX concern the “period when you drank the most”. The score of each 
measure was computed by summing the number of drinks required to produce an effect and dividing 
by the number of effects endorsed. The SRE has been shown to have good internal consistency and 
test–retest reliability, to successfully identify people who had low response to alcohol in a laboratory 
challenge test, and to be associated with AD diagnosis in several populations. Due to non-normal 
distributions of the regression residuals, we log transformed values for ISENS and TOLMX. MAX24 
refers to the largest number of drinks an individual reported ever having consumed in 24 hours. The 
withdrawal severity factor score was based on ten symptoms in the Semi-Structured Assessment of 
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the Genetics of Alcoholism (SSAGA, version 11, (142)) interview (such as hands trembling, feeling 
anxious following cessation or reduction of drinking). To account for the possible non-equal 
contribution of each symptom to withdrawal severity, a factor analysis was conducted (for details see 
(243)). A factor score of withdrawal severity for each individual was derived based on the item 
loadings on one major factor, which accounted for 70% of the variance in these symptoms based on 
the entire IASPSAD sample.  
We also tested the DA genes for association with scores for disinhibitory disorders. Symptom 
counts for lifetime DSM-IV alcohol dependence (ADsx, range 3-7) were assessed using the SSAGA, 
modified to reduce assessment time. Counts for number of illicit drugs fulfilling criteria for substance 
dependence (DDsx, range 0-7), conduct disorder symptoms (CDsx, range 0-14), and antisocial 
personality disorder symptoms (ASPDsx, range 0-9) were collected using adapted versions of the 
Structured Clinical Interview for DSM-IV Disorders (SCID, (92)). Drugs assessed as part of illicit 
substance use included cannabis, sedatives, stimulants, cocaine, opiates, hallucinogens, and other 
drugs (e.g. steroids, nitrous oxide). All drugs were considered illicit in this context because the 
subjects were asked only about nonmedical use (e.g. use without a prescription, use in greater 
amounts/more often than was prescribed, or use not in the intended manner). Other measures include 
retrospective reports of childhood attention deficit/hyperactivity disorder symptoms (ADHDsx) using 
items from Wender’s Childhood Problem Behavior Checklist (245) and novelty seeking scores (NS) 
using the 18-item version from Cloninger’s Tridimensional Personality Questionnaire (246). Scores 
for ADHDsx and NS were rescaled such that their range is 0-1. Finally, we tested for association with 
a factor score based on the item loadings on one major factor for all disinhibitory phenotypes. We 
modeled this analysis off association analyses previously conducted in the Collaborative Study on the 
Genetics of Alcoholism and the Virginia Adult Twin Study for Psychiatric and Behavioral Genetics 
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(31,247). Due to non-normal distributions, we log transformed ADsx, ASPDsx, CDsx, and DDsx for 
the factor score analysis. 
 
Tag SNP selection and genotyping 
The majority of genotyping was conducted in Dr. David Goldman’s lab at NIAAA on the 
Addiction Array (248) using the Ilumina GoldenGate method. For details of study design, see 
reference (248).  In instances where additional SNPs had to be genotyped in order to complete 
tagging in our sample, we selected LD-tagging SNPs (tSNPs) with Tagger (249) as implemented in 
Haploview 3.2 (250) using the default criteria of r
2
 ≥ 0.8 and minor allele frequency (MAF) ≥ 0.2.  
Because SNPs genotyped using the Ilumina GoldenGate platform were chosen based on being 
African haplotype tagging, some SNPs have a MAF< 0.2 in our Caucasian sample. However, no SNP 
has an MAF< 0.01, which was our threshold for eliminating SNPs in the overall sample.  For genes 
displaying several isoforms, the longest isoform was chosen for tag selection but in order to limit 
genotyping load and cost, 5’ and 3’ regions of the genes and ESTs were not directly tagged.     
tSNPs were genotyped in-house as monoplex reactions using Taqman Assays-on-Demand 
(Applied Biosystems, Foster City, CA). To ensure uniformity and accuracy, all reaction steps were 
performed using the Eppendorf 5075 automated liquid handling platform. Stringent evaluation of 
initial data is important to avoid artifactual effects of genotyping errors; therefore, all genotypes were 
independently assessed by two raters. Ambiguous calls were discussed and in cases of non-resolution, 
genotypes were dropped from the analyses. Individual DNA samples with 20% or more missing 
genotypes across the entire study were also excluded. Individual SNPs were excluded if they showed 
deviation from Hardy-Weinberg equilibrium (p > 0.001) in the overall sample and controls alone, 
had an MAF<0.01 or had a low genotyping call rate (<80%). The present study reports on the results 
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from genes included in the DA functional domain (248), including DRD1-5, SLC18A2, SLC6A3, 
DDC, TH, and COMT. Several coding SNPs were genotyped, such as rs155417 and rs5326 in DRD1, 
rs6279 in DRD2, rs6347 in SLC6A3, rs11575542 and rs11575377 in DDC, and the well studied 
nonsynonymous SNP rs4680 in COMT. The well known TaqIA polymorphism in DRD2 was not 
included because, as noted above, it is actually located in a different gene.  
 
Statistical methods 
Single marker analyses were implemented in PLINK 1.07 (251) using logistic regression 
for the binary trait of AD and linear regression for the quantitative traits in cases only to 
calculate effect size (either odds ratio or regression coefficient) and significance level. We used 
sex as a covariate in the logistic regressions and both age and sex as covariates in the linear 
regressions. To address the possibility of type I error due to multiple testing of several SNPs 
within individual genes, we permuted each p-value 10,000 times using the gene-based set test in 
PLINK and only reported the empirical P-value here if it was significant after this correction. We 
reasoned that gene-based correction was sufficiently conservative because all selected genes 
have a priori evidence of association with AD and/or related phenotypes. We used the set-based 
test in PLINK for multiple test correction because this method allows for identification of 
independent SNPs determined by a selected threshold. We changed the default threshold for LD 
from r
2
=0.5 to r
2
=0.8 because our LD-tagging SNPs were selected based on r
2
> 0.8. 
Additionally, we did not correct for multiple phenotypes because (1) they reflect reasonable a 
priori hypotheses, and (2) they are, in some cases, substantially inter-correlated, making it 
difficult to implement any simple multiple test correction.  
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The goal of principal component analysis is to reduce the number of observed correlated 
variables in a data set by uncovering latent dimensions (principal components, factors). We used 
the FACTOR procedure in SAS version 9.2 (93) to determine the structure of our phenotypes: 
ADsx, ASPDsx, ADHDsx, CDsx, DDsx, and NS. This procedure offers a number of methods for 
extracting factors, including principal component and principal factor analysis. The former 
method decomposes the total variance, or both the variance shared between variables and that 
which is unique to individual variables, while the latter decomposes only the variance shared 
between the variables. We chose principal component analysis for this study. Several options for 
rotation of factors are available to produce more interpretable results; we chose an orthogonal 
rotation procedure called VARIMAX (variance maximizing) in which the components are forced 
to be uncorrelated and each variable is associated with only one component. We then calculated 
component scores for each individual with nonmissing data for all disinhibitory phenotypes and 
tested for association with these scores.   
We utilized the statistical program R (252) to assess the fits of two linear regression 
models for predicting variation in novelty seeking. In the first (restricted) model, we included the 
covariates age and sex only. In the second (unrestricted) model, we added the effects of 5 DA 
SNPs that were identical or proxies for those in the SAGE study to the base model. These SNPs 
are located in DDC and COMT. We then compared the amount of variance in novelty seeking 
explained and the fit of each model using an F test and its associated p-value.  
Power estimates for this study were calculated using QUANTO 1.2.4 
(http://hydra.usc.edu/gxe) for the dichotomous AD outcome (Table 4.1) and the continuous traits 
(Table 4.2) using a two-sided t-test with a significance level of 0.05 and a range of MAF from 
0.05-0.4. We assumed an additive mode of inheritance. Effect sizes are listed as OR from 1.1 to  
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1.5 for AD and 
variation in the traits 
from 1% to 5% for 
continuous outcomes. 
The power for the 
dichotomous outcome 
was based on a 
lifetime population 
risk for AD of 12.5% 
(5) 
  
        
                          
Results 
Missingness 
Genotyping was 
completed for 135 SNPs in the DA related genes, but 10 SNPs were excluded due to a low 
genotyping rate (<80%) and 24 due to a MAF<0.01. The average genotyping call rate for the 
remaining 101 SNPs was 98.7% (90.6%-100%). All remaining SNPs were in Hardy Weinberg 
equilibrium (regular cut off p-value of 0.001). Genotyping error rate was estimated using 
duplicates at 0.6%. Among the 1054 genotyped individuals, 26 (8 cases and 18 controls) were 
excluded due to >20% missing genotypes, leaving a total of 1028 individuals. 592 individuals 
were missing no genotypes, 374 were missing 1-5, 40 were missing 6-10, 15 were missing 11-
15, and 7 were missing 16-20. After QC measures were completed, the following number of 
Table 4.1. Power for 
dichotomous AD outcome 
 Table 4.2. Power for  
continuous outcomes 
MAF OR Power  MAF Variance Power 
 0.05 1.1 0.0765  0.05 0.01 0.6418 
1.2 0.1526   0.02 0.9089 
1.3 0.2711   0.03 0.9814 
1.4 0.4163   0.04 0.9968 
1.5 0.5663   0.05 0.9995 
0.1 1.1 0.1006  0.1 0.01 0.6418 
1.2 0.2459   0.02 0.9089 
1.3 0.4552   0.03 0.9814 
1.4 0.6665   0.04 0.9968 
1.5 0.8271   0.05 0.9995 
0.2 1.1 0.1406  0.2 0.01 0.6418 
1.2 0.3908   0.02 0.9089 
1.3 0.6836   0.03 0.9814 
1.4 0.8819   0.04 0.9968 
1.5 0.9676   0.05 0.9995 
0.3 1.1 0.1690  0.3 0.01 0.6418 
1.2 0.4817   0.02 0.9089 
1.3 0.7895   0.03 0.9814 
1.4 0.9447   0.04 0.9968 
1.5 0.9902   0.05 0.9995 
0.4 1.1 0.1855  0.4 0.01 0.6418 
1.2 0.5288   0.02 0.9089 
1.3 0.8331   0.03 0.9814 
1.4 0.9635   0.04 0.9968 
1.5 0.9948   0.05 0.9995 
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SNPs from each gene were entered in standard analysis: 4 SNPs in DRD1, 15 in DRD2, 13 in 
DRD3, 4 in DRD4, 7 in DRD5, 11 in SLC18A2, 12 in SLC6A3, 22 in DDC, 3 in TH, and 10 in 
COMT.  
 
Principal Component Analysis  
Table 4.3 lists the means and standard deviations for the disinhibitory symptom counts as 
well as the Pearson correlations among counts included in the factor analysis. To determine the 
number of factors to retain, one can use several guidelines, including the Kaiser (eigenvalue) 
criterion and 
visual inspection 
of the data using 
a scree plot. 
Eigenvalues 
provide the 
proportion of 
variance in the 
total sample 
accounted for by 
each component when divided by the number of variables entered into the analysis. In the first 
method, one chooses to retain components with eigenvalues greater than 1.0.  A scree plot is a 
graph of the components on the x-axis and their corresponding eigenvalues on the y-axis. One 
finds the place in the plot where the smooth decrease levels off and retains factors to the left of 
this point. While the Kaiser criterion may sometimes over-extract factors and visual inspection 
Table 4.3. Means and standard deviations for disinhibitory symptom counts and 
Pearson correlations between counts 
 ADsx 
(6.39, 1.03)  
ADHDsx 
(0.50, 0.20) 
ASPDsx 
(2.02, 2.75) 
CDsx 
(2.86, 2.99) 
DDsx 
(.82, 1.4) 
NS 
(.58,0.22) 
ADsx 1.00      
ADHDsx 0.18  1.00     
ASPDsx 0.20  0.36 1.00    
CDsx 0.22  0.45 0.78 1.00   
DDsx 0.13 0.19 0.34 0.38 1.00  
NS 0.18 0.31 0.18 0.22 0.19 1.00 
Notes: ADsx, alcohol dependence symptoms; ASPDsx, antisocial personality disorder 
symptoms; ADHDsx, attention deficit/hyperactivity symptoms; CDsx, conduct disorder 
symptoms; DDsx, drug dependence symptoms; NS, novelty seeking scores. Means and 
standard deviations are listed in parentheses. ADHDsx and NS scores were rescaled such 
that their range is 0-1.  
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using the scree plot may retain too few, both perform relatively well in situations like ours where 
there are few factors and many subjects (253).  
By both a traditional eigenvalue criterion and a scree plot, only one factor was evident 
with an eigenvalue of 2.55 that accounted for 42.5% of the variance. The eigenvalue difference 
between the first and second factors was 1.56 and all other factors comprised less than 17% of 
the variance. The component loadings for each of the symptom counts were as follows: ADsx, 
0.41; ADHDsx, 0.65; ASPDsx, 0.82; CDsx, 0.87, DDsx, 0.56, and novelty seeking scores, 0.47. 
These loadings represent the correlation coefficients between the factor and each variable and 
can be squared to determine the amount of variance in the dependent variables explained by the 
factor. The comparatively low factor loading for ADsx may be explained by the restricted range 
of alcohol dependence symptoms. Subjects could only have within the range of 3 to 7 symptoms 
and over 80% had > 6 symptoms.  
 
Single marker association 
In Table 4.4, marker information, empirical P-values, and effect sizes are provided for 
SNPs (1 in DRD4 and 2 in SLC6A3) were associated with AD, 2 SNPs (in DRD5 and TH) with 
WDSFS, and 1 in DRD3 with ISENS. Table 4.5 presents the marker information, empirical P-
values, and effect sizes only for SNPs that were significant after permutation with the 
disinhibitory symptoms and the disinhibitory factor score. See Table A.2, which contains 
nominal p-values, for a complete listing of all SNPs that underwent analysis for disinhibitory 
phenotypes. 2 independent SNPs across 2 genes were associated with one or more disinhibitory 
symptom counts after permutation testing, including 1 SNP in SLC6A3 with ADsx and 1 in DDC 
with DDsx.  Additionally, 1 SNP in DRD5 was significantly associated with for the factor score. 
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Table 4.4. Marker information, empirical P-values, and effect sizes for SNPs significantly associated with AD or ARPs 
after permutation testing 
GENE & 
CHR 
SNP BP LOCATION 
CALL 
RATE 
MAF 
AD 
(N=1028) 
ONSET 
(N=436) 
ISENS 
(N=428) 
TOLMX 
(N=427) 
MAX24 
(N=436) 
WDSFS 
(N=436) 
DRD3 rs2654754 115338486 intron 5 99.8 .025 -- -- 0.026 -- -- --- 
(Chr 3) 
       
(0.24) 
   
DRD4 rs12280580 616220 5' near gene 92.7 .354 0.035 -- -- -- -- -- 
(Chr 11) 
     
(1.28) 
     
DRD5 rs7655090 9374973 3' near gene 98.1 .049 -- -- -- -- -- 0.0037 
(Chr 4) 
          
(-0.37) 
SLC6A3 rs27048 1465645 intron 8 97.1 .451 0.025 
     
(Chr 5) 
     
(0.68) -- -- -- -- -- 
 
rs10052016 1481111 intron 4 93.9 .412 0.025 
     
      
(1.33) 
     
TH rs11564717 2143465 intron 12 99.9 .408 
     
0.025 
(Chr 11) 
     
-- -- -- -- - (0.59) 
            Notes: AD, alcohol dependence; ONSET, age-at-onset of AD; ISENS, initial sensitivity; TOLMX, tolerance/maximum drinking; 
MAX24, maximum drinks in 24 hours; WDSFS, withdrawal severity factor score. Empirical P-values are in bold. Effect sizes are listed 
in parentheses as odds ratios for AD and as regression coefficients for quantitative traits. An odds ratio >1 or a positive regression 
coefficient indicates that the minor allele increases risk of the phenotype. ISENS and TOLMX were log transformed. 
 
 
Table 4.5. Marker information, empirical P-values, and effects sizes for SNPs significantly associated with disinhibitory 
symptom counts after permutation testing  
GENE & 
CHR 
SNP bp LOCATION 
CALL 
RATE 
MAF 
ADsx 
(N=436) 
ADHDsx 
(N=426) 
ASPDsx 
(N=436) 
CDsx 
(N=436) 
DDsx 
(N=432) 
NS 
(N=429) 
Factor 
Score 
(N=426) 
DRD5 rs7655090 9374973 
3' near 
gene 
98.1 .049 -- -- -- -- -- -- 0.033 
 (Chr 4)                       (-0.34) 
SLC6A3 rs6350 1496199 exon 2 99.9 .076 0.012 -- -- -- -- -- -- 
(Chr 5)           (-0.36)             
DDC rs11575542 50305196 exon 14 99.7 .015 -- -- -- -- 0.014 -- -- 
(Chr 7)                   (0.30)   
 
Notes: ADsx, alcohol dependence symptoms; ASPDsx, antisocial personality disorder symptoms; ADHDsx, attention 
deficit/hyperactivity symptoms; CDsx, conduct disorder symptoms; DDsx, drug dependence symptoms; NS, novelty seeking scores. 
Empirical P-values are in bold. Effect sizes are listed in parentheses as regression coefficients. A positive regression coefficient 
indicates that the minor allele increases risk of the phenotype.  
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Table 4.6 shows the marker information, nominal p-values, and effect sizes for SNPs that 
were part of our replication effort. None of these SNPs were individually significant. Table 4.7 
shows the characteristics and comparison of model fit for the two models fitted to the data. The 
unrestricted model did not fit significantly better (F=0.181, p-value=0.97) than the restricted one 
and the additional variance explained by the SNPs was only 0.2%, indicating that these SNPs 
have no explanatory power for variation in novelty seeking in our Irish sample. 
 
 
Discussion 
For greater than a half century, dopaminergic dysregulation has been implicated in AD 
and other disinhibitory psychopathology. Molecular genetics studies over the past 20 years have 
attempted to demonstrate associations with DA genes and disinhibitory phenotypes, producing 
Table 4.6. Marker information, nominal p-values, and effect sizes for replication attempt  
GENE & CHR SNP BP LOCATION CALL RATE EFFECT SIZE (β) p 
DDC 
(Chr 7) 
rs11575542 50305196 exon 14 99.7 0.01 0.86 
DDC 
(Chr 7) 
rs921451 50397494 intron 1 94.2 0.00 0.83 
DDC 
(Chr 7) 
rs6969081 50398714 intron 1 99.7 0.00 0.83 
DDC 
(Chr 7) 
rs3829897 50403973 intron 1 99.7 0.00 0.93 
COMT 
(Chr 22) 
rs933271 18305961 intron 1 99.6 0.01 0.69 
Notes: Effect sizes are regression coefficients. A positive regression coefficient indicates that the minor 
allele increases risk of the phenotype.  
Table 4.7. Comparison of models predicting variation in novelty seeking 
MODEL # of SNPs R2 F ∆df p 
Covariates alone 0 8.6% -- -- -- 
Covariates plus 
SNPs 
5 8.8% 0.181 5 0.97 
Notes: R2, amount of variance explained by the model; F, F-statistic;  df, degrees of freedom. 
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an inconsistent and controversial literature. Meta-analyses, reviews, and reports with rigorous 
methodology suggest that variation in DA genes does contribute to susceptibility to disinhibitory 
traits, although not to the extent and effect size originally hypothesized.  
We attempted to address some of the problems that have riddled candidate gene studies 
by using a relatively large, ethnically homogeneous sample with severe AD. We genotyped a 
sufficient number of tSNPs to cover most of the variation within 10 DA related genes, including 
DRD1-D5, SLC18A2, SLC6A3, DDC, TH, and COMT. Our study not only tested for association 
with the categorical diagnosis of AD, but also with quantitative ARPs, which give more power 
than dichotomous traits and provide additional clinical information beyond a binary phenotype. 
Within alcohol dependent cases only, we tested for association with disinhibitory 
psychopathology, including symptoms for alcohol dependence, antisocial personality disorder, 
attention deficit/hyperactivity disorder, conduct disorder, drug dependence, and scores for 
novelty seeking. Additionally, we assessed for association with a disinhibitory factor score. 
Finally, we only reported findings that were significant after set-based permutation, which limits 
the possibility that any of our results are false positives.  
Overall, we found evidence for association with modest effect sizes between a small 
number of DA related genes and alcohol dependence, ARPs, and disinhibitory phenotypes. The 
minor allele frequencies for several of the positive SNPs are low. The limited number of positive 
signals suggests that these 10 DA related genes play a minor role in susceptibility to alcohol 
dependence and related disinhibitory psychopathology, which is consistent with previous meta-
analyses, reviews, and reports with rigorous methodology. Furthermore, we did not find evidence 
that the DA SNPs associated with sensation seeking in the Derringer et al. study (207) were 
significantly associated with novelty seeking either individually or in aggregate in our sample. In 
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addition to the associations in the first study being false positives or ours being false negatives, 
there are several other possible explanations for the lack of agreement. One explanation is that 
while the sensation seeking and novelty seeking are phenotypically correlated, they are not the 
same phenotype; therefore, it is reasonable to hypothesize that some SNPs that explain variation 
in one phenotype would not explain variation in the other. Second, SAGE consists of individuals 
from the US, whereas our sample comes from Ireland; there may be different polymorphisms 
that contribute to variation in sensation/novelty seeking in each of these ethnicities. Finally, 
65.2% of the cases in the Derringer paper were alcohol dependent, whereas all of our subjects 
were. The lack of replication may be explained by the differing proportion of cases in the two 
samples.          
 
Receptors 
In agreement with reports from several other groups (254-256), we did not find 
significant association after permutation between the well-studied DRD3 BaII polymorphism 
(rs6280) and AD. However, we did show that another SNP (rs2654754, p=0.026, β=0.24) in 
DRD3 is associated with the quantitative trait of initial sensitivity. Perhaps we obtained these 
findings when other researchers did not because our sample size is larger, we captured most of 
the variation in DRD3 with our 11 tSNPs, and we assessed quantitative ARPs in addition to the 
dichotomous phenotype. However, the chance that this is a false positive is greater in light of the 
fact that the MAF=2.3%.  
Moreover, we identified an association with 1 SNP in DRD4 (rs12280580, p=0.011, 
OR=1.28) and AD. While no other groups have reported associations with this particular SNP 
and AD or disinhibitory psychopathology, several meta-analyses have noted associations with 
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variants in DRD4 and urge for addictive substances (62), ADHD (221), and NS (222). 
Furthermore, we identified associations with the same SNP in DRD5 and two phenotypes, 
including withdrawal (rs7655090, p=0.0037, β=-0.37) and the factor score (rs7655090, 
p=0.0033, β=-0.34). The fact that DRD5 is associated with an alcohol-related trait and the factor 
score suggests it may contribute to AD through the broader disinhibitory spectrum. However, 
since only one SNP is associated with the factor score and this polymorphism has a low MAF 
(4.9%), this finding might represent is a false positive.  
Perhaps we did not identify strong evidence for association of DA genes with the general 
disinhibitory factor because our design assessed disinhibitory phenotypes in subjects with 
alcohol dependence. Another explanation is that variation in dopamine genes may contribute 
more to risk for specific disorders than the liability to a general disinhibitory spectrum of 
disorders.  
 
Transporters 
Two SNPs in SLC6A3 (rs27048, p=0.025, β=0.68; rs10052016, p=0.25, β=1.33) were 
associated with the dichotomous phenotype of alcohol dependence. Within the same gene, we 
also identified an association between the common allele of another SNP (rs6350, p=0.012, β=-
0.36) and alcohol dependence symptoms. Lind and colleagues (224) found association of the 
same allele in rs6350 with problem drinking in a Finnish population.  
 
Enzymes 
We identified association of one SNP in TH (rs11564717) with the withdrawal factor 
score (p=0.025, β=0.59). However, we must note that this SNP has a MAF of only 1.5%. We did 
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not show association of the Val81Met (rs6356) variant with any ARPs, although Dahmen and 
colleagues (234) identified association of this polymorphism with early onset AD. 
Furthermore, we did not detect any signal with COMT’s well-studied functional 
polymorphism rs4680, which has been associated with a number of disinhibitory phenotypes, 
including AD (237), methamphetamine abuse (226), and NS (238,239). One explanation for this 
may be that none of the potential risk alleles were found in our population.  It is noteworthy that 
the SNP in DDC (rs11575542, p=0.014, β=0.30) that we identified as associated with drug 
dependence symptoms is a missense coding polymorphism that results in a substitution from Arg 
to Gln; however, the MAF of this SNP in our sample is only 2.5%, which increases the 
likelihood that it is a false positive.  
Although, in many ways, we improved the design of previous candidate gene studies, our 
report still has limitations. First, as noted previously, a proper correction for multiple testing has 
been problematic in these studies. Using too liberal an approach will maximize power but is 
likely to lead to false positives. A correction method that is too conservative will decrease power 
to detect true results. We attempted to strike a balance between the two approaches by using 
gene-based correction. However, we did not correct for testing multiple phenotypes because 
there is a priori evidence of association of at least some of the 10 DA related genes with each of 
the phenotypes examined. Furthermore, many of these phenotypes are highly inter-correlated, 
making an appropriate correction problematic. It can be argued that our approach is still too 
liberal. The possibility that some proportion of our findings represents false positives is 
plausible. Therefore, our findings should be considered tentative pending the outcome of 
attempted replications. Second, quantitative ARPs and disinhibitory symptoms were measured 
only among cases but not controls, so the values for these traits are not representative of the full 
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variation in the population. Thus, the most meaningful replication of our study would be in 
population sample. Third, although the LD patterns of the DA genes are compatible with the 
Hapmap CEPH population data, it remains possible that we lack complete coverage of common 
variation in our Irish sample. Additionally, the impact of rare functional polymorphisms was not 
assessed. Finally, we did not include all genes that affect dopaminergic tone, such DBH 
(dopamine beta hydroxylase) and the MAO (monoamine oxidase) gene.  
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CHAPTER 5: Preliminary Genome-wide Association Studies of Alcohol 
Dependence, Symptom Count, and Externalizing Phenotype in an Irish 
Family Sample 
Note: These results are based on preliminary analyses and will likely be updated in the final, 
published manuscripts.  
 
Abstract  
Background: The powerful, systematic, and unbiased GWAS has been successful in 
identifying replicated susceptibility variants for numerous complex diseases. Compared to 
several other psychiatric disorders, such as schizophrenia and autism, the total sample size for 
genome-wide studies of alcohol dependence (AD) is more modest with individual samples in the 
range of 500-2500 individuals. We report here results from a comparably sized sample (total 
N=2465) consisting of related cases and unrelated, population controls.   
Methods: The related cases are from the Irish Affected Sib Pair Study of Alcohol 
Dependence (IASPSAD) and were diagnosed using lifetime DSM-IV criteria. Genotyping was 
conducted using the Affymetrix v6.0 array by three separate genotyping core facilities. Because 
artifacts are a known issue when combining samples genotyped at multiple sites, genotypes were 
called using the algorithm BEAGLECALL, which considers both allele signal intensities and LD 
information. After quality control filtering, the sample contained 710 cases, 1755 controls, and 
676,736 SNPs for analysis. The within-site and cross-site duplicate error rates were 0.0043% and 
0.0054%, respectively. After imputation using the March 2012 1000 Genomes data and post-
imputation filtering, we had a total of 8.2 million SNPs. We analyzed AD, AD symptom count, 
and an externalizing component score. The binary trait analysis was conducted using MQLS 
(modified quasi-likelihood score test), while the quantitative trait analyses were run in 
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ProbABEL; both programs use relationship matrices to correct for the non-independence of 
siblings. We attempted replication of the binary diagnosis in the European American sample 
(N=1399) from COGA, which we also imputed to the latest 1000 Genomes panel.  
Results: For AD, there were 12 non-independent genome-wide significant signals in the 
novel risk gene, COL6A3. Other top signals fell within additional novel candidate genes, 
including those involved in neurodevelopmental disorders and cancer. There was little evidence 
for replication with the COGA sample, but a joint meta-analysis produced additional novel 
candidates. Likely due to the limited variation of ADsx in our severely affected sample, results 
from this trait yielded a deflated QQ plot, but there was one intergenic genome-wide significant 
signal. Finally, we present preliminary results from the externalizing component score analysis.  
Conclusions: We have identified some potentially interesting loci associated with AD, 
AD symptom count, and a composite externalizing phenotype that should be followed-up in 
functional studies. Ongoing work includes replication of ADsx and the externalizing component 
score analyses in COGA as well as replication of all three traits in a clinically ascertained 
German sample. 
 
Introduction 
Alcohol dependence (AD), as defined by the Diagnostic and Statistical Manual of Mental 
Disorders, edition 4 (DSM-IV), is common, relapsing, and under-treated (5,6). Some progress 
has been made in clarifying the etiology of this serious personal and public health problem, but a 
more complete understanding is needed to develop more effective prevention and intervention 
strategies. One approach to improving our understanding of the etiology of AD is identification 
of susceptibility variants. The powerful, systematic, and unbiased genome wide association study 
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has been successful in identifying replicated risk variants for several common, complex 
disorders. Over the last several years, multiple GWAS of AD, AD symptomatology, and 
consumption measures in both clinical and community samples have been published (46,63-
66,68,69). However, there have been fewer genome-wide significant findings and less robust 
replication of top results than in other psychiatric disorders, such as schizophrenia and nicotine 
dependence (39,257). One reason is likely that sample sizes for AD studies individually have not 
reached the level of other psychiatric disorders. Another reason may be that even though most 
studies define cases using lifetime DSM-IV criteria, individual samples may still be 
phenotypically diverse, and thus potentially genetically diverse. Previous GWAS of AD have 
tried to address the latter issue by conducting more limited analyses with males only and subjects 
with early onset AD (63,64). Here we present a GWAS of AD, AD symptomatology, and a 
composite externalizing phenotype using an ethnically homogeneous, severely affected sample.  
In order to increase power, we elected to genotype all siblings from our original linkage sample 
that met criteria for AD instead of selecting one independent case from each family. Including 
affected siblings from multiply afflicted families may reduce locus heterogeneity. 
 
Methods 
Cases & Controls 
Participants in the Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) were 
recruited in Ireland and Northern Ireland between 1998 and 2002. Further details of the study design, 
sample ascertainment, and clinical characteristics of this sample are described elsewhere (242). In 
brief, ascertainment of probands was mainly conducted in community alcoholism treatment facilities 
and public and private hospitals. Probands were eligible for study inclusion if they met the current 
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DSM-IV criteria for AD and if all four grandparents had been born in Ireland, Northern Ireland, 
Scotland, Wales, or England. After a prospective family was identified through probands, parents and 
potentially affected siblings whom the probands provided permission to contact were recruited. 
Probands, siblings, and parents were interviewed by clinically-trained research interviewers, most of 
whom had extensive clinical experience with alcoholism. The assessment included demographic 
characteristics, lifetime history of AD and other comorbid conditions, alcohol-related traits, 
personality features, and clinical records. All participants provided informed consent. We used a 
subset of the linkage sample for the current study, including 710 probands and affected siblings after 
filtering. The DSM-IV AD diagnosis was assessed in probands and siblings using a modified SSAGA 
(semi-structured assessment of the genetics of alcoholism) interview (version II,(142)). Items entered 
into our component score included ADsx, conduct disorder (CDsx), antisocial personality disorder 
(ASPDsx), drug dependence (DDsx) and novelty seeking scores (NS). Further details on these 
phenotypes can be found in Chapter 4 of this dissertation. We did not include ADHDsx in this 
principal component analysis, as we did in Chapter 4, because while there is evidence of genetic 
overlap between adolescent ADHD and adults AD (110), it is not as strong as for the other traits we 
used and AD.    
1755 DNA samples from healthy, unpaid volunteers donating blood at the Irish Blood 
Transfusion Service from The Trinity College Dublin (TCD) were used as controls. These TCD 
Biobank controls were asked if they had any problems with alcohol and excluded if they endorsed 
this. These individuals were previously genotyped on Affymetrix v6.0 arrays (Santa Clara, CA) by 
the Wellcome Trust Case Control Consortium and the Broad Institute Center for Genotyping and 
Analysis as part of a GWAS of schizophrenia (258,259). Information about age and sex was available 
for these subjects.  
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Replication sample 
Our replication sample consists of subjects from the European American (EA) portion of 
the COGA sample (64). Researchers ascertained cases (N=847 EA and N=345 AA) at alcohol 
treatment programs in 7 centers throughout the US (64), and lifetime AD diagnoses were made 
using DSM-IV criteria with information collected from the SSAGA (142). Controls (N=552 EA 
and N=140 AA) were recruited by the same centers from driver’s license registries and dental 
clinics and were nondependent.  Genotyping was conducted using Illumina HumanHap 1M 
BeadChips (Illumina, San Diego, CA). For more details about the sample and analyses, see 
Bierut et al. (65). We constructed an externalizing factor score in cases only using phenotypes 
that were mostly overlapping with the IASPSAD; however, the illicit drug variable (range=0-45) 
differed in that COGA used a sum of DSM-III dependence symptoms for the 5 drug classes 
available. Additionally, we chose not to include novelty seeking in our factor analysis because 
there was a high degree of missingness in the COGA data. Thus, 4 phenotypes from the COGA 
data were entered into a factor analysis, including ADsx, CDsx, ASPDsx, and DDsx.   
 
Genotyping & Pre-calling QC 
Genomic DNA from whole blood was required to pass rigorous quality standards prior to 
plating. Genotyping plates included probands and affected siblings, 11 sets of parents to check 
for Mendelian errors,  duplicates, as well as a subset of TCD Biobank controls (N=102) to check 
for concordance with the other sites. Samples were individually genotyped at Vanderbilt’s core 
facility on Affymetrix v6.0 SNP arrays. After obtaining allele signal intensities in the form of 
CEL files from Vanderbilt, we generated quality control (QC) metrics using both the apt-geno-qc 
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program within Affymetrix Power Tools (260) and Birdseed v2 (261). The apt-geno-qc program 
assesses one array at a time and only uses a small subset of SNPs, whereas Birdseed v2 provides 
QC metrics for arrays in aggregate. One of these metrics is Contrast QC (CQC), which assesses 
the ability of an experiment to categorize SNP signals into three genotype clusters. There are also 
separate CQC measures for both restriction enzymes, Nsp and Sty. All arrays with CQC < 0.04 
and/or CQC Nsp/Sty < 0 were excluded. Additionally, apt-geno-qc and Birdseed v2 provide four 
different measures of sex, which had to be known and equivalent in order for the array to be 
included.  
 
BEAGLECALL  
After calling arrays using the Birdseed v2 algorithm and recognizing a site effect, the 
calling algorithm BEAGLECALL (BC) was implemented at Golden Helix, as this program has 
been successful in correcting batch effects in other data sets (Matt Keller, pers. comm.). BC 
takes not only allele signal intensity information into consideration, but also information about 
the genotypes of neighboring markers (262). The algorithm uses genotypic probabilities obtained 
from another program as a starting point. Since we performed initial QC in Birdseed v2, we used 
probabilities generated from this program as input. All CEL files from the three sites (Vanderbilt 
University, the Affymetrix Contract Facility, and the Broad Institute) were quantile normalized 
together using the Golden Helix SVS algorithm and called together. This includes case arrays 
from a separate GWAS for schizophrenia; the total set of arrays is referred to as the full array set. 
No sex chromosomes were entered into the analysis because BC is not able to call the Y-
chromosome or X-chromosome in males. A total of 890,920 autosomal SNPs were entered into 
the BC algorithm. SNPs that did not conform to Hardy Weinberg equilibrium were removed at 
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each of the three iterations with increasingly stringent filters as follows: p < 1 x 10
-10
,  p < 1 x 
10
7
,  p < 1 x 10
-6
. Genotypes were received from Golden Helix as probabilities and were 
converted into hard calls using a threshold of 98% probability of a specified genotype; otherwise, 
they were set to missing.  
 
Post –BC SNP & Sample QC 
We performed all QC checks in PLINK version 1.7 (251). Since the X-chromosome was 
not called using BC, we used Birdseed v2 calls to remove samples in which the phenotypic sex 
did not match the genotypic sex. The remaining QC steps were conducted using BC calls. We 
ran IBD estimation on a pruned subset of SNPs and generated pi-hats for each individual. Using 
the IBD estimates, we ran multi-dimensional scaling with HapMap3 samples, and samples that 
did not cluster tightly with each other toward the European HapMap3 samples were removed. 
Additionally, if either controls or case-control pairs were cryptically related (pi-hat > 0.05), one 
control from each pair was excluded. In order to maintain power, we did not remove two families 
with minimally elevated pair-wise pi-hats in the range of 0.07 to 0.11. Family members whose 
pi-hats did not match the pedigree file were re-coded according to the genotypic information and 
mean pi-hat outliers, representing DNA samples that were contaminated or poor quality, were 
excluded. Heterozygosity outliers, which may also represent poor quality samples and were 
highly overlapping with mean pi-hat outliers, were also removed. Graphs depicting the cutoffs 
for mean pi-hat and heterozygosity outliers are shown in Figure 5.1. Furthermore, for each 
duplicate pair, the sample with the higher call rate was carried forward. All samples had calls 
rates > 98%; therefore, none needed to be excluded based on this criteria. SNPs with > 1 Mendel 
or duplicate error were removed. Additionally, we excluded SNPs with a low minor allele 
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frequency (<1%) and/or a high level of missingness (>2%) using the full array set. SNPs with 
significant differences (p < 7.37 x10
-8
) in missingness between cases and controls within the 
alcohol subset were also removed.  
 
Imputation 
 To increase coverage and comparability between the discovery and replication samples, 
we imputed the IASPSAD and COGA case control arrays (European American and African 
American samples) using IMPUTE version 2.2 (263) and the 1000 Genomes Project integrated 
variant reference panel from March 2012. This panel contains whole genome sequence from 
1,092 individuals of African, American, Asian, or European Ancestry. Using samples from 
multiple ethnicities in the reference panel increases imputation accuracy (264). The panel 
Figure 5.1. Histograms showing mean pi-hat and heterozygosity outliers.  
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contains 36.5 million SNPs and 1.5 million structural variants and insertion/deletions, the 
majority of which are invariant in the Irish population. We filtered both the IASPSAD and 
COGA data sets post-imputation by excluding non-SNPs and SNPs with MAF < 1% and 
information criterion (an estimated correlation between imputed and true allele counts) < 0.3, 
leaving 8.2 million and 8.5 million SNPs, respectively.  
 
Statistical Methods 
AD: Single Marker Analysis. We performed association tests on 710 cases and 1755 
population controls using the Liming and Abecasis version of MQLS, which accounts for 
relatedness between subjects by using a kinship matrix calculated from pedigree data (265). We 
increased power and took advantage of additional phenotypic information from the full linkage 
sample by including relatives with phenotypic, but not genotypic, information in the analysis. 
MQLS takes these relatives into consideration by assigning individual weights based on the 
familial burden of disease. Controls were coded as having unknown phenotypes, as they did not 
undergo formal screening for AD. We used a sex weighted prevalence estimate of AD in our 
controls based on the National Epidemiological Study of Alcohol and Related Conditions report 
and data on alcohol consumption in non-remunerating blood donors from Holland (5,40). While 
no published studies have examined the prevalence of AD in this demographic, we were able to 
adjust the prevalence for the proportional difference in heavy drinking between blood donors and 
the general population, leaving us with an estimate of  8.9%. MQLS was run using allelic dosage 
data. IMPUTE2 outputs 3 posterior genotypic probabilities for each SNP, which can be 
converted to MACH style dosages using a command within the R program GenABEL (266). In 
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dosage format, each SNP is represented by a single number ranging from 0-2. MQLS does not 
allow for incorporation of covariates.  
AD: Gene-based Analysis. We conducted gene-based analysis for both traits in the 
program Versatile Gene-based Association Study (VEGAS), which can be used with related 
individuals (267). All p-values were entered into the program and an empirical gene-wide p-
value was generated based on SNPs lying within +/- 50 kb of a gene’s 5’ and 3’ UTRs. The 
program converts all association p-values for SNPs in each gene region into chi-squared test 
statistics and sums them to obtain a gene-based test statistic. An empirical gene-based p-value is 
then derived via a simulation procedure in which the LD structure of the SNPs entered into the 
analysis are considered. The software uses the HapMap2 Caucasians as a reference population 
for determination of LD structure. Since we used 1000 Genomes for imputation, our haplotypic 
resolution was not as fine as it would have been if genotypes from this panel were used by 
VEGAS. Gene-based tests can provide different information than SNP-based association because 
a gene may be enriched for signal but no individual signals in this gene surpass a pre-defined 
threshold. One disadvantage of this method is that it devalues larger genes due to the large 
number of SNPs considered. We used two approaches to select markers and genes that we report 
here. First, we utilized a genome-wide significance threshold of p < 3.06 x 10
-8
, which controls
 
the false positive rate (i.e. the rate at which truly null tests are called significant) at an alpha of < 
0.05 for 1.6 million independent markers in a European population (5,41). Second, we used a 
cutoff based on the false discovery rate (FDR), which is the rate at which tests called significant 
are truly null (43). To implement the latter method, for each p-value, we calculated a q-value 
(42,43), or an estimate of the proportion of false positives among all significant markers when 
the corresponding p-value is declared significant. We used a q-value threshold of 0.5 for 
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declaring significance (i.e. 50% of significant findings are false discoveries), since this threshold 
provides a good balance between controlling false positives and detecting true effects (268).  
AD: Replication and Meta-analysis. We pursued three different replication/meta-analytic 
approaches to maximize the potential of our data. We used both the IASPSAD and COGA as 
discovery samples and attempted to replicate SNPs with q < 0.5 in each discovery sample. 
Additionally, to detect signals in which both the IASPSAD and COGA samples yield low p-
values that may not have met the q < 0.5 threshold in either sample, we conducted a meta-
analysis of all overlapping SNPs in each sample that passed post-imputation filtering within the 
meta-analytic program, METAL (269,270). Combining summary statistics within a meta-
analytic framework is simpler than pooling data, especially when different analytic strategies, 
covariates, etc. are used within each sample and it is also just as efficient (271).  This software 
provides the option of either combining test statistics and standard errors or p-values with 
consideration of sample size and direction of effect. We chose the latter method because the 
former requires that variables from different studies be measured in exactly the same way (272) 
and MQLS does not generate standard errors.  
Quantitative Traits: Single Marker Analysis. We analyzed the quantitative traits ADsx 
and the externalizing component score in cases only using ProbABEL, which also utilizes a 
kinship matrix generated from genomic data to account for relatedness and allows for dosage 
data as input (266). ProbABEL uses a two-step mixed model-based score test in which the first 
step accounts for relatedness and the second step incorporates the effects of SNPs and covariates, 
which were age and sex.  
Principal Components Analysis. Because the IASPSAD and COGA samples used 
different measures for some phenotypes (e.g. drug dependence symptoms) that we wished to 
104 
 
include in our factor analysis, we wanted to ensure that the factor scores based on these items 
captured the same underlying construct. To test whether this was so, we compared for each 
sample factor scores derived from non-overlapping but complete phenotypic information (i.e. 
those we wished to use for analyses) with factor scores derived from a reduced set of items 
present in both samples. Ideally, we wished to include a measure of symptoms for AD, ASPD, 
CD, and DD as well as novelty seeking scores in our factor analyses. Of these, AD, ASPD, and 
CD were assessed identically in both samples. The quantitative drug phenotype in COGA 
consisted of DSM-III-R symptoms for 5 drug classes, whereas the quantitative drug phenotype in 
the Irish sample consisted of the number of positive DSM-IV drug dependence symptoms across 
7 drug classes. In the Irish sample, individuals had to endorse using drugs 11 times in the same 
month to qualify for the drug dependence questions, whereas in the COGA sample, subjects only 
needed to endorse use 11 times in a lifetime. Finally, COGA did not have enough individuals 
with NS scores to make inclusion of this trait in the analysis meaningful. Therefore, we entered 
phenotypes from each sample into the most complete factor analysis possible (i.e. making use of 
all externalizing phenotypes available, regardless of whether they were identical or not) as well 
as a more limited factor analysis based on the overlapping phenotypes assessed identically in 
both samples. The overlapping phenotypes included DSM-IV ADsx, DSM-III-R ASPDsx, and 
DSM-III-R CDsx as well as a drug phenotype consisting of the number of illicit substances tried. 
In all factor analyses, one factor could be retained by both eigenvalue and scree plot 
examination.  
Within each sample, we calculated the complete component scores and the more limited 
overlapping component scores, and then generated Pearson correlations between these values. 
The procedure used to generate externalizing component scores was described in the previous 
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Chapter, but briefly, all phenotypes were entered into a principal component analysis and 
loadings were used to calculate individual component scores. The correlations between the more 
complete and the more limited component scores were 0.96 and 0.95 in the Irish and COGA 
samples, respectively. Thus, we concluded that the more detailed, though not completely 
overlapping factors scores, could be used for this analysis. In the Irish sample, the complete 
factor had an eigenvalue of 2.23 and explained 44.6% of the variance. The component loadings 
were as follows: ADsx, 0.37; ASPDsx, 0.85; CDsx, 0.87, DDsx, 0.61, and novelty seeking 
scores, 0.48. In the COGA sample, the complete factor had an eigenvalue of 1.94 and explained 
48.7% of the variance. The component loadings for each phenotype were as follows: ADsx, 0.41; 
ASPDsx, 0.84; CDsx, 0.84; and DDsx, 0.70.  
 
Results 
 
AD: Single-Marker Analysis, Replication, and Meta-analysis 
Quantile-quantile (QQ) and Manhattan plots for AD are shown in Figure 5.2. In the QQ 
plot, the distribution of p-values closely follows the null distribution except at the tail, which is 
expected if there is no site difference or population stratification and there are real effects of 
modest size. The lambda is 1.05. The Manhattan plot shows 13 SNPs met criteria for genome-
wide significance (p < 3.06 x 10
-8
) with 12 falling in COL6A3 in chromosome 2 and 1 falling in 
an intergenic region of chromosome 3. While genome-wide significance is an important 
consideration, as previously mentioned, it may be better to approach GWAS results using an 
FDR method; therefore, our results are filtered according to this criterion. The tables of results 
are arranged by chromosome and base pair to demonstrate, by assessment of MAF, that multiple 
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signals in the same region often represent non-independent signals. This is further supported by 
the LD relationships between signals in each region illustrated in the regional association plots 
for selected regions in Figures 5.5, 5.6, and 5.7.  Table 5.1 shows the 180 SNPs with q < 0.1, 
while Table A.3 in the Appendix shows the 725 SNPs with q-value < 0.5. Of these SNPs, 657 
were present in the COGA sample and 31 showed evidence of replication at a nominal p-value; 
however, none showed evidence of replication by a q < 0.5 criterion.  
Figure 5.2. QQ and Manhattan plots of p-values for DSM-IV AD diagnosis. Analysis in 710 cases and 
1755 controls. QQ plot shows observed vs. expected –log p-values. λ=1.05. Red line in QQ plot 
represents distribution under the null hypothesis of no association. Red line in Manhattan plot indicates 
genome-wide significance threshold at p=3.06 x 10-8. 
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Table 5.1. Association results for IASPSAD AD GWAS and COGA replication with q-values < 0.1 
SNP CHR BP IASPSAD p IASPSAD q COGA p COGA q GENE LD ANNOTATION 
rs72833664 2 114506030 3.07E-07 0.1     NA   NA SLC35F5 - 
rs56310758 2 238240863 1.25E-08 0.1 0.04 0.6 COL6A3 - 
rs75561681 2 238241881 2.77E-08 0.1 0.01 0.6 COL6A3 - 
rs2270671 2 238243285 1.18E-08 0.1 0.06 0.6 COL6A3 - 
rs10929226 2 238244559 1.17E-08 0.1 0.06 0.6 COL6A3 - 
rs112523013 2 238247257 1.05E-08 0.1 0.07 0.6 COL6A3 - 
rs2646258 2 238253149 6.39E-09 0.1 0.05 0.6 COL6A3 - 
rs2256485 2 238253930 6.18E-09 0.1 0.03 0.6 COL6A3 - 
rs2646265 2 238257013 1.46E-08 0.1 0.07 0.6 COL6A3 - 
rs2646264 2 238257213 1.19E-08 0.1 0.10 0.6 COL6A3 - 
rs2646261 2 238259387 2.36E-08 0.1 0.08 0.6 COL6A3 - 
rs11901326 2 238261509 5.00E-07 0.1 0.33 0.8 COL6A3 - 
rs2646257 2 238261850 5.58E-07 0.1 0.33 0.8 COL6A3 - 
rs2645764 2 238262254 7.09E-09 0.1 0.18 0.6 COL6A3 - 
rs2645763 2 238263299 7.97E-09 0.1 0.17 0.6 COL6A3 - 
rs2645777 2 238266146 4.41E-08 0.1 0.13 0.6 COL6A3 - 
rs73149934 3 147209715 6.23E-07 0.1 0.53 0.9 intergenic ZIC4/ZIC1 
rs150268941 3 172575312 1.39E-08 0.1 0.20 0.6 intergenic - 
rs142645748 3 175451990 3.80E-07 0.1     NA   NA NAALADL2 - 
rs45619636 6 166823764 5.75E-07 0.1 0.66 1.0 RPS6KA2 - 
rs79048468 8 137895174 1.74E-07 0.1 0.53 0.9 intergenic - 
rs117687198 8 137907672 6.78E-08 0.1 0.40 0.8 intergenic - 
rs117695261 13 74325506 1.16E-07 0.1 0.82 1.0 KLF12 - 
rs117727648 14 77100157 3.36E-08 0.1 0.89 1.0 intergenic - 
rs192688395 14 77211718 2.70E-07 0.1 1.00 1.0 intergenic - 
rs113653607 14 77641605 3.61E-07 0.1 0.39 0.8 intergenic - 
rs142687658 14 77750946 1.47E-07 0.1     NA   NA POMT2 - 
rs150017190 14 77806492 3.47E-07 0.1     NA   NA intergenic - 
rs56198483 14 77828430 1.53E-07 0.1 0.08 0.6 TMED8 POMT2, GSTZ1 
rs4780153 15 33972420 1.69E-07 0.1 0.95 1.0 RYR3 - 
rs1353348 15 33984848 3.19E-07 0.1 0.76 1.0 RYR3 - 
rs939432 15 33986294 2.42E-07 0.1 0.81 1.0 RYR3 - 
rs72742523 15 79713106 3.77E-07 0.1 0.94 1.0 intergenic - 
rs7183304 15 92420700 4.52E-07 0.1 0.79 1.0 SLCO3A1 - 
rs185631468 22 42710609 6.56E-08 0.1     NA   NA intergenic - 
Notes: Genome-wide significant signals in bold. 
We show QQ plots for the p-values in the COGA discovery sample as well as the joint analysis 
meta-analysis in Figure 5.3. The lambdas for these analyses were 1.03 and 1.05, respectively. 
The COGA discovery component did not yield any q-values at the 0.5 level, so a table is not 
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presented. 196 SNPs with q-values < 0.5 in the joint meta-analysis are presented in Table A.4. 
SNPs in all tables were annotated using BioQ, which utilizes information from dbSNP build 137 
(273), while Table 5.1 has additional annotation information derived from consideration of LD in 
the program LocusZoom using hg19 European 1000 Genomes data (274). All neighboring genes 
that fell within an LD block defined by r
2
 > 0.2 of the index SNP were also used to annotate the 
SNP. 
 
AD: Gene-based analysis 
Genes with q < 0.5 in the VEGAS gene-based analysis are presented in the main text in 
Table 5.2. Some of the same genes present in Table A.3 also appear on the gene-based list, 
including COL6A3. One of the more promising findings from the SNP-based association 
Figure 5.3.  QQ plots of COGA and the joint meta-analysis p-values. Red lines represent 
distribution under the null hypothesis of no association. λ=1.03 and 1.05.  
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analysis, RYR3, is not on this list due to the fact that it is a very large gene (555 kb), and the 
signal is fairly focal. Therefore, VEGAS considered many non-significant SNPs in calculation of 
the gene-based statistic for this gene. Our list contains several clusters of genes in the same 
region that were likely generated from the same set of SNPs,  supported by the fact that the top 
SNP is the same for many of these genes. This is more prone to happen with small genes. 
Additionally, there are several additional genes that were not present in the single marker 
analysis of AD in the IASPSAD data.  
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Table 5.2. VEGAS gene-based results for IASPSAD AD with q-values < 0.5 
CHR GENE nSNPs START STOP GENE p GENE q BEST SNP 
1 MED8 58 43622174 43628070 8.48E-04 0.5 rs2842182 
1 C1orf84 64 43628142 43645152 7.09E-04 0.4 rs2782651 
1 KIAA0467 73 43661383 43690891 6.37E-04 0.4 rs2105029 
1 HYI 55 43689415 43692505 6.11E-04 0.4 rs2105029 
1 HSD3B1 118 119851348 119859204 6.95E-04 0.4 rs1047303 
1 LEFTY2 52 224190925 224195543 7.25E-04 0.4 rs2816330 
2 COL6A3 230 237897393 237987589 7.00E-06 0.3 rs2256485 
4 UGT2B15-1 8 69194909 69218969 2.89E-04 0.3 rs9999801 
5 LHFPL2 253 77816793 77980404 1.44E-04 0.3 rs9293756 
5 UBXD8 85 175807961 175869681 7.24E-04 0.4 rs2963296 
6 PRL 151 22395458 22405709 1.29E-04 0.3 rs707870 
6 REV3L 228 111726926 111911107 3.68E-04 0.3 rs455726 
6 TRAF3IP2 185 111986835 112034014 3.09E-04 0.3 rs10872068 
7 MICALL2 50 1440520 1465635 1.01E-04 0.3 rs10267348 
18 RAB27B 114 50646837 50708209 2.70E-04 0.3 rs12953492 
19 HKR1 67 42517419 42547197 3.03E-04 0.3 rs7258912 
19 ZNF527 74 42553898 42575806 3.16E-04 0.3 rs7258912 
19 ZNF569 87 42593899 42650179 2.40E-04 0.3 rs2161520 
19 ZNF570 58 42651821 42668082 2.47E-04 0.3 rs2161520 
19 ZNF793 84 42689680 42726079 1.17E-04 0.3 rs17245425 
19 ZNF540 101 42734147 42796836 2.12E-04 0.3 rs2927743 
19 ZNF571 82 42746994 42777513 3.02E-04 0.3 rs2927743 
19 ZFP30 68 42815228 42838153 4.09E-04 0.4 rs2927743 
19 ZNF781 68 42850489 42875056 5.09E-04 0.4 rs3095726 
19 ZNF607 59 42879115 42902531 7.71E-04 0.4 rs3095726 
19 ZNF573 81 42921040 42962040 6.06E-04 0.4 rs3095726 
19 CCDC61 86 51190178 51213714 1.77E-04 0.3 rs4803895 
19 PGLYRP1 85 51214280 51218163 7.10E-05 0.3 rs4803895 
19 IGFL4 89 51234845 51236114 6.10E-05 0.3 rs4803895 
 
 
ADsx and the Externalizing Component Score: Single Marker Analysis  
QQ plots for ADsx and the externalizing component score are shown in Figures 5.4. The 
genomic inflation factors are 0.92 and 1.04, respectively. ADsx has limited variation in our 
sample (over 80% endorsed > 6 symptoms), which may explain the deflated genomic inflation 
factor. While this trait has yielded interesting signals in the IASPSAD sample in previous work 
(23,275), it is clearly not ideal due the very limited variation in our severely affected clinical 
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sample. ADsx would be better assessed in a population sample or one that included controls, so 
that the full distribution of symptoms could be represented. There are several other quantitative 
traits that were measured in the IASPSAD, as discussed in Chapter 4, that may be more suited to 
gene discovery efforts that we plan to pursue. Nevertheless, one intergenic SNP did meet 
genome-wide significance for ADsx as well as one for the externalizing composite score. Table 
5.3 shows the 5 SNPs with q < 0.5 for ADsx and Table A.4 shows the 95 SNPs with q < 0.5 for 
the externalizing component score. 
 
 
 
 
 
 
 
 
Table 5.3: Association results for IASPSAD ADsx with q-values < 0.5 
SNP CHR BP  p q INFO GENE LD ANNOTATION 
rs62563410 9 94554802 4.13E-08 0.4 0.60 ROR2 - 
rs9557255 13 100213197 1.39E-07 0.4 0.94 TM9SF2 - 
rs149373539 13 110351186 2.43E-07 0.5 0.49 intergenic - 
rs74473255 18 52800791 1.29E-08 0.4 0.68 intergenic TCF4 
rs73927900 19 15104035 3.73E-08 0.4 0.78 SLC1A6 CCDC105 
Notes: Genome-wide significant SNPs in bold. 
 
Figure 5.4. QQ plots of p-values for DSM-IV ADsx and the externalizing component score. 
Analyses in cases only. λ=0.92 & 1.04. Red lines represent distribution under the null hypothesis 
of no association. 
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Discussion 
 
Our AD GWAS of a clinically and ethnically homogeneous Irish sample yielded several 
potentially interesting and novel candidates. There was no evidence for replication in the COGA 
sample by a FDR criterion of q < 0.5; however, some genes showed nominal replication p-values 
< 0.05. Furthermore, several genes present in Table A.3 in the Irish sample were also on the 
meta-analysis list (Table A.4), suggesting that the meta-analysis p-values were driven by the 
Irish data. However, there were also some new candidates, providing support for the utility of 
both a replication of top signals as well as a meta-analytic approach to the data. Many of these 
genes had low p-values (in the 10
-6
-10
-2
 range) in both samples, but neither p-value was low 
enough to be on the top gene list in either sample. 
Figure 5.5. Regional association plot of top SNP in COL6A3 and surrounding SNPs. 
Top SNP (rs2256485) is shown in purple and LD between that SNPs and other is 
indicated by colors shown in the legend. 
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There were 12 non-independent (as illustrated by LD relationships in the regional 
association plot in Figure 5.5) genome-wide significant signals in the novel candidate, COL6A3. 
This gene also harbors 4 SNPs with COGA replication p-values < 0.05. COL6A3 is one of six 
genes that encode α chains composing collagen VI, which is expressed in most connective 
tissues, including the extracellular matrices of the brain and liver. The most well-studied 
phenotypes associated with mutations in COL6A3 are a range of congenital muscular dystrophies 
(CMD), including the milder Bethlem myopathy and the more severe Ullrich CMD (276). While 
some CMD include CNS involvement, the type IV collagen disorders do not.  However, research 
suggests that collagen molecules function in neural cell migration, differentiation, and neurite 
outgrowth (277). Additionally, COL6A3 was located under a linkage peak for an alcohol 
withdrawal factor score in a study using this sample. While this gene has not been implicated in 
alcohol previously, SNPs contained within another collagen gene, COL8A1, were among the ten 
top that appeared in the case-control COGA GWAS and replicated in the family sample (64).  
In a gene expression study assessing mechanisms by which alcohol consumption 
enhances the progression of liver disease in patients with hepatic C virus, COL6A3 showed a 
significant change in gene expression in cirrhotic livers (278).  Considering our findings in light 
of this work, one might preliminarily hypothesize that there are polymorphism(s) in COL6A3 
that increase the risk of cirrhosis when the liver is exposed to high quantities of alcohol. To 
examine this more closely, we plan to pursue a follow-up association study in which we compare 
alcohol dependent cases who endorsed liver damage to those who did not. COL6A3 was also 
found to be upregulated in colorectal tumor tissue (279). There is strong evidence for a causal 
link between heavy alcohol consumption and the subsequent development of cancer, especially 
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cancers of the digestive tract and female breast (4). Thus, it is possible that COL6A3 may 
enhance risk for colorectal cancer development in individuals with heavy alcohol consumption.  
TNN (also known as TNW), which encodes tenascin N/W, was present on both our top 
IASPSAD discovery and meta-analytic lists. Figure 5.6 shows the non-independent associated 
SNPs in the IASPSAD discovery sample. This gene is also related to cancer in that it is highly 
expressed in colorectal and female breast tumors (280). Additionally, it is induced by BMP2 
(bone morphogenetic protein), which is a member of the BMP family and larger TGF-β family 
(281). There is some evidence that chronic alcohol exposure can affect BMP signaling in the 
liver of mice (282).  Also, the BMP signaling pathway is related to another pathway involved in 
CLIC signaling, which are intracellular chloride channels that have been implicated in acute 
Figure 5.6. Regional association plot of top SNP near TNN and surrounding 
SNPs. Top SNP (rs11590002) is shown in purple and LD between that SNPs and 
other is indicated by colors shown in the legend.  
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ethanol behaviors in model organisms (283).  Finally, in an analysis of combined case-control 
GWAS data from COGA and SAGE (the Study of Addiction: Genetics and Environment), Zuo 
et al. found that SNPs in the region of TNN and a neighboring gene, KIAA0040, were significant 
(284). No SNPs within KIAA0040 were significant in our analysis.  
RYR3 is another interesting candidate due to its relationship to genes in the ethanol-
related model organism literature. A regional association plot of associated SNPs (Figure 5.7) 
shows a focal signal toward the 5’ end of the gene. RYR3 encodes an intracellular calcium 
channel. Of the three ryanodine isoforms in humans, RyR3 is the most highly expressed in the 
brain (285). The ryanodine family of receptors has been shown to modulate BK channels (286), 
which were implicated in AD and alcohol-related traits in previous GWAS (64,68) as well as 
Figure 5.7. Regional association plot of top SNP in RYR3 and surrounding SNPs. Top 
SNP (rs4780153) is shown in purple and LD between that SNPs and other is indicated 
by colors shown in the legend. 
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model organism studies of ethanol behaviors (287). Furthermore, proteins in the ryanodine 
family have been found to interact with proteins in the CLIC family, intracellular chloride 
channels that have been implicated in acute ethanol behaviors in model organisms (283).   
Several genes in Table 5.1 have been implicated in developmental delay and intellectual 
disability, including the linked genes ZIC1 and ZIC4 (Zic family member 1 and 4), NAALADL2 
(N-acetylated alpha-linked acidic dipeptidase-like 2), POMT2 (protein O-mannosyltransferase 
2), and SMARCA2 (WI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2) (present in A.3). ZIC1 and ZIC4 encode highly related zinc finger 
transcription factors; heterozygous deletions in this region are responsible for a common 
cerebellar birth defect called Dandy Walker Syndrome (288). NAALADL2 is a candidate for 
Cornelia de Lange Syndrome, a disorder that involves neurological features, although no specific 
mutations were identified in a panel of patient DNA (289). Mutations in POMT2 are known to 
cause a type of CMD, Walker-Warburg syndrome, which can involve developmental delay and 
mental retardation (290). Finally, SMARCA2 is involved in regulation of gene transcription and 
heterozygous missense mutations have been shown to cause Nicolaides-Baraitser syndrome, 
which is characterized by facial and limb anomalies and intellectual disability (291).  There is a 
phenotypic association with cognitive ability and AD/related traits as well as modest genetic 
correlations, as discussed in Chapter 2 of this dissertation (104). While the mutations and 
deletions previously described in these genes lead to gross neurological deficits, it is reasonable 
to hypothesize that more subtle variation may lead to brain changes that predispose to alcohol 
dependence.  
Our gene-based analysis and joint meta-analysis for AD supported several interesting 
genes that were not implicated in our top results in either discovery sample. Of particular interest 
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in the gene-based analysis is PRL, which encodes the peptide hormone prolactin best known for 
its role in inducing lactation in mammals. However, this protein has a variety of other functions 
and was found to be elevated in alcohol dependent patients after alcohol intake (292) and while 
undergoing withdrawal (293).  Interestingly, Schukit et al. (294) found that elevation in prolactin 
levels after alcohol consumption was related to a positive family history of AD, suggesting a 
possible genetic mechanism. Prolactin expression/secretion is influenced by both dopamingeric 
(295) and glutamatergic activity (296). Both neurotransmitters have been implicated in mediating 
the effects of alcohol. Another interesting series of genes from the VEGAS analysis was the set 
of zinc finger transcription factors, as ZNF699 was previously associated in a candidate gene 
study of our sample (297). ZNF699 is not in LD with any zinc finger transcription factors in 
Table 5.1, suggesting that multiple ZNF genes may be involved in AD.  Genes to note from the 
joint analysis include CSMD1, which has been implicated in schizophrenia (298), and CDH12, 
which was a top hit in a GWAS of bipolar alcoholism (299).   
While the single marker analyses for ADsx and the externalizing factor score yielded 
fewer SNPs with q < 0.5, some interesting genes were on these lists. The intergenic genome-
wide significant hit for ADsx was in LD at the r
2
=0.4 level with SNPs in TCF4 (Transcription 
factor 4), which is involved in neurodevelopment and has been implicated in susceptibility to 
schizophrenia (300). This region is shown in Figure 5.8. A notable finding from the externalizing 
factor score results was in GRID2 (Glutamate receptor, ionotropic, delta 2), which actually does 
not bind glutamate but is involved in synaptogenesis and synaptic plasticity in cerebellar cells 
(301).   
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Our results must be considered in the context of several limitations. First, the most 
extreme signals in any GWAS are also the most likely to represent errors/bias. We cannot fully 
discount the possibility that some or all of our signals are spurious; however, the extensive QC 
procedure and the use of BC calling algorithm would suggest that some of these signals are not 
due solely to bias or error. Second, for financial reasons, we used a sample of lightly screened 
controls, even though AD is a high prevalence condition. However, we accounted for this by 
coding the controls as unknown and using a prevalence estimated based on quantity of 
consumption in non-remunerating blood donors (40). Third, we analyzed the binary diagnosis of 
AD because it is a standard measure with good reliability that has been used in several other 
genome-wide association studies, allowing for direct comparison with replication samples. 
However, as discussed in the Introduction to this dissertation, we know from twin studies that it 
Figure 5.8. Regional association plot of top SNP near TCF4 and surrounding 
SNPs. Top SNP (rs74473255) is shown in purple and LD between that SNPs 
and other is indicated by color. 
 
119 
 
is a genetically heterogeneous condition, which can reduce power to detect associated loci. For 
this reason, we also examined two quantitative traits, including ADsx and an externalizing 
component score.  
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CHAPTER 6: General Discussion 
 
Part I Summary, Future Directions, and Limitations 
The studies presented in this dissertation have attempted to expand our understanding of 
alcohol use disorders and related phenotypes with the use of two genetically informative study 
designs: twin (Part I) and association studies (Part II). In Chapter 2, we showed that education 
level is moderately genetically correlated with maximum drinks in 24 hours. Furthermore, we 
found that education significantly moderated the heritability of alcohol traits such that genetic 
influence was enhanced with increasing levels of education. These results may be useful in 
future work in two ways. First, the robust genetic correlation between education level and ARPs 
suggests that heritability estimates of these conditions are influenced by educational attainment. 
If twin modelers are interested in more “refined” phenotypes, they may consider using education 
level as a covariate in their twin analyses. For example, Agrawal et al. (302) found the 
heritability of regular cigarette smoking to be lower when they accounted for significant 
covariates in their twin model. Likewise, researchers conducting GWAS of ARPs could 
incorporate educational attainment into their analysis if they were interested in genes that 
influence a more refined alcohol phenotype. Also, the moderation findings could be used to 
inform forthcoming GWA studies in which education level is measured in the subjects. Some 
genes may not have main effects on risk of AD or ARPs and, therefore, will only be detectable at 
the extremes of the educational spectrum.  
We presented two main findings in Chapter 3. First, we showed that, compared to wine 
drinkers, beer and spirits preference drinkers are at greater risk of higher levels of consumption, 
AUD diagnoses, and particular AUD symptoms, as well as ASPD and illicit substance 
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abuse/dependence. Together with findings from the extant literature, these results suggest that 
spirit preference drinkers may be more likely to belong to a chronic/severe subtype of alcoholics 
consisting of early onset AD and a high risk for antisocial behavior and polysubstance use. Our 
findings also indicate, in contrast, that beer preference drinkers are more liable to be part of a 
subtype with class with high levels of drinking and legal consequences, but less probability of 
comorbidity. Characterizing alcohol dependent individuals into meaningful groups may be 
helpful in terms of treatment efforts and gene discovery. Second, we found that total AC 
measures index genetic liability to preference to a modest degree, indicating that association 
analyses for these total measures are not likely particular useful in identifying genetic influences 
on intake of particular beverages. Identifying the genes may be helpful in that they could also be 
influential in characterizing individuals into specific typologies by altering disease characteristics 
such as age of onset, severity, course of illness, and symptom profile (185). 
The findings from Part I of this dissertation must be interpreted with several limitations in 
mind. In Chapter 2, we were not able to use all of the same measures as in the Finnish study 
because RAPI scores were not assessed in the VATSPSUD; however, these scores were 
correlated at 0.55 with alcohol dependence symptoms in a subsample of the Finnish twins (73). 
Additionally, lifetime symptoms of ADsx and maximum consumption during the heaviest year 
were based on participants’ retrospective recall and it is possible that our results may have been 
influenced by recall errors.  In Chapter 3, we did not ask subjects directly about their alcoholic 
beverage preference, but rather assumed that their most frequently/heavily consumed beverage 
would reflect their preferences. Although alcoholic beverage choice may not always reflect 
preference, Straus and Bacon showed that the two traits are highly correlated (199). Also in 
Chapter 3, we did not have the data to assess additional alcoholic beverages beyond the three 
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main classes, including alcopops, cider, and caffeinated alcoholic beverages, which have been 
shown to have differential associations with particular traits as compared to wine, beer, and 
spirits (123,205).  Finally, for both epidemiological studies, it is unclear whether the samples of 
Virginia- and Finnish-born Caucasians generalizes to other populations. 
 
Part II Summary, Future Directions, and Limitations 
 In Chapter 4, we utilized a candidate gene design and found some evidence of 
involvement of particular DA genes in AD, ARPs, and externalizing behavior. The fact that we 
found a locus associated with general externalizing behavior in addition to individual phenotypes 
underscores the need for more association studies that consider the genetic overlap between 
phenotypes. In Chapter 5, we employed a genome-wide approach and identified several novel 
candidate genes for AD. 12 non-independent signals within COL6A3 were genome-wide 
significant. Other top findings by q < 0.1 fell within several categories, including those involved 
in neurodevelopmental disorders and cancer. Besides being false positives, there several other 
reasons why none of the other top markers showed evidence of replication. These include that 
our associated alleles are specific to an Irish or a severely affected population. Despite the lack 
of replication, several of our top signals are promising candidates based on prior model organism 
and molecular literature. Thus, follow-up studies should still be pursued. Results from Part II 
must be viewed within the context of several limitations. First, our strongest SNPs are also the 
most likely to represent errors/bias; however, we employed an extensive QC process to limit the 
effects of error. Second, for financial reasons, we used a sample of population controls in our 
GWAS, even though AD is a high prevalence condition. However, we accounted for this in the 
binary analysis by coding the controls as unknown and using a prevalence estimated based on 
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quantity of consumption in non-remunerating blood donors (40). Third, AD is not an ideal trait 
for gene discovery. For this reason, we also examined additional quantitative traits in both 
Chapters 4 and 5.   
Post-GWAS analysis. There are multiple ways to follow-up on these findings to gain 
more insight into their validity and functional relevance. One step will be to attempt replication 
in additional samples; however, even a real result may not replicate due to variety of factors, 
including lack of power in the replication sample, differences in the phenotypic presentations of 
the samples that have different underlying genetic causes, or ethnic differences between the 
samples. Even loci are replicated in other samples, it would not be clear whether the top SNPs 
are functionally relevant, or more likely, in LD with a functionally relevant SNP. At this point, 
bioinformatics tools or sequencing may be used to identify potentially causal SNPs to carry 
forward to molecular analyses. Because we imputed to the most recent 1000 Genomes reference 
panel, we will have a good handle on the common variants that are in high LD with the 
associated SNP. These SNPs may be evaluated for functional relevance by in silico examination 
of genomic location, influence on gene expression or protein function, and previous association 
with other phenotypes (303). Various molecular follow-up strategies could then be applied to 
prioritized SNPs based on predicted function. The most straightforward possibility is an exonic 
SNP that is predicted to affect protein function, although these are rarely associated with 
complex diseases (304). The only known SNPs of this kind for AD occur in the alcohol 
metabolizing genes and are generally protective. More common possibilities include SNPs 
located in known regulatory regions, such as enhancers, silencers, microRNA (short RNAs that 
cause gene silencing) binding sites, or non-coding regulatory RNA genes. In these cases, the 
effect of the SNP on regulation must be confirmed and then putative target genes must be 
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identified. One of the most common and challenging possibilities to interpret is a SNP in an 
intergenic regions or gene desert (304). One option in this case is to conduct targeted sequencing 
to detect SNPs within neighboring genes that may be driving the association. Both empirical and 
computational data provide evidence that a good proportion of trait-associated loci will contain 
variants, called expression quantitative trait loci (eQTLs), that influence the abundance of 
specific transcripts (305). We have access to postmortem brain samples from the New South 
Wales Tissue Resource Center that can be used to evaluate expression levels for genes 
potentially regulated by a top SNP. 
Model Organisms. To evaluate their functional relevance specifically in ethanol related 
behaviors, prioritized SNPs/genes may be tested in model organisms. Because both invertebrates 
and vertebrates encounter fermenting fruits in their natural environments, they have developed 
physiological processes for metabolizing ethanol. Many organisms show similar reactions to 
ethanol as humans, including intoxication, tolerance, and withdrawal (306) and utilize similar 
molecular and physiological pathways underlying ethanol-related behaviors (307). Not only are 
these organisms useful for following up on specific loci/genes, they are also helpful in evaluating 
the role of networks to which the genes belong in alcohol related phenotypes. Within the VCU 
ARC, we have a variety of model organisms to test our top findings, each with its own 
advantages. The majority of ethanol related behaviors assessed in these organisms are acute; that 
is, they measure reaction to alcohol on a temporary basis. This may be relevant to certain human 
phenotypes, such as initial sensitivity, but with the addition of the Rat core to our ARC, we will 
be able to assess more chronic phenotypes that are generally more in line with our human 
phenotypes.  
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 Rare Variation. Some have argued that despite the great deal of money and effort 
devoted to GWAS, much of the heritability for most complex traits remains to be explained and 
this missing heritability is likely due to rare variation (308,309). While it is true that the 
collective genetic variance explained by GWAS findings is still relatively small compared to the 
heritabilities estimated by twin studies, several lines of evidence suggest that the remaining 
heritability can mostly be explained by common variants of small effect and not rare variants of 
larger effect (310). Whole-genome analysis involving GWAS data of several psychiatric 
disorders, including schizophrenia and bipolar disorder, suggest that a good proportion of 
heritability estimated from twin studies can be explained by common variation (311). The 
variants that have surpassed genome wide significance for psychiatric disease thus far represent 
the largest effect sizes to be discovered. The others are obscured by the exceptionally high 
thresholds of significance. Other arguments for the so-called infinitesimal model include that the 
allele frequency distributions in GWAS are consistent with a limited number of rare variants, 
sibling recurrence rates are greater than would be expected for the postulated effect sizes of rare 
variants, and common variants are consistent across populations.  
Nevertheless, most in the field would agree that studies of rare variation should be 
pursued to explain some proportion of the missing heritability. There has been good success with 
finding both common and rare CNVs associated with certain psychiatric disorders, including 
autism, bipolar disorder, and schizophrenia (312). CNVs in addiction have started receiving 
attention more recently. To our knowledge, the first studies of CNVs in relation to AD and ARPs 
were published in late 2011 and 2012 and include three on AD and alcoholism (313-315), one on 
amount of consumption (316), and one on brain volume in AUDs (317). These studies have 
implicated regions that are both duplicated and deleted and contain genes involved in 
126 
 
neurological dysfunction (313), developmental processes, cell communication, and sensory 
perception (315) , and enzymatic activity (316). Sequencing studies have now been published for 
several psychiatric traits and disorders, including autism, schizophrenia, and bipolar disorder and 
lend support to the idea that the same genes may harbor both common and rare variation that 
contributes to disease (318). We plan to follow-up on top genes from our GWAS in the same 
sample by assessing rare variation using a high pass targeted sequencing approach. Furthermore, 
we plan to follow-up top loci using low pass sequencing in a community sample of college 
students, which will harbor greater variation in quantitative traits than our severely affected 
clinical sample.  
 
Lessons on Study Design 
 It is now commonplace in psychiatric genetics to combine samples that were collected 
and/or genotyped at different sites both in individual studies, as was the case in our GWAS, as 
well as through consortia. Even if genotyping occurs at the same site, batch effects can arise 
when investigators are not careful about randomizing cases and controls on different plates. 
While non-differential error between cases and controls results in reduced statistical power,  the 
more serious type is differential error, which can lead to false positives. Differential error or 
missingness may be caused by a variety of differences in laboratory conditions, including 
variable technical skill and hybridization temperature of DNA to chips as well as use of different 
lots of reagents/chips. Ideally, researchers would collect and genotype cases and controls at the 
same site in randomly distributed batches during the same time period. However, for practical 
and financial reasons, this is often impossible. Therefore, investigators with suspected site or 
batch effects must dedicate sufficient effort to dealing with these artifacts to avoid clouding the 
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literature with false positives, such as in the example of the manuscript on a GWAS of longevity 
that was withdrawn from Science (319). Even worse, there was a case in which a diagnostic 
assay for ovarian cancer was put on the market but it was later revealed that the biological 
variable of interest was highly correlated with processing day (320). There are several ways to 
confirm the existence of site or batch effects. We conducted multidimensional scaling of 
identity-by-descent estimates by site and found that each generated its own distinct cluster. We 
also ran an association analysis with site as the phenotype in controls only (from Affymetrix and 
Broad) and found severe elevation in the genomic inflation factor. If site differences are 
confirmed and are not completely confounded with the outcome of interest, several analytic 
techniques may be helpful. One common technique is to use known technical variables as 
covariates, such as site and processing date. However, this strategy may not account fully for 
unmeasured non-biological variables, such as laboratory conditions, reagent quality, and 
personnel changes.  Another strategy is called surrogate variable analysis (SVA), and was 
originally developed for gene expression microarrays, which are highly prone to be influenced 
by technical variables (321). In this method, unmeasured variables are estimated from the data 
and treated as standard covariates.  
Since the processing laboratories were completely correlated with affection status in our 
situation (e.g. cases genotyped entirely at one site and controls at two others), we needed to 
pursue other approaches. Here we outline the process we implemented as a guide to other 
researchers dealing with technical artifacts in GWAS. Although our initial process did not 
correct the issue, there was a significant reduction that may be sufficient for researchers dealing 
with a less severe site effect. A standard step prior to data analysis is normalization, which 
adjusts global properties of samples to compare them more appropriately. After experimenting 
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with different combinations of normalization and calling, we found that normalizing and calling 
all samples separately most reduced the site difference. We called the data using Birdseed v2 
(261), which uses prior information from HapMap3 as well as signal intensity data to cluster 
individuals into three groups according to their genotype. We then proceeded through a series of 
quality control steps in an effort to remove samples and SNPs that were responsible for the 
greatest amount of differential error between sites. We utilized all standard GWAS QC steps, 
such as removing arrays that were ancestry and heterozygosity outliers, but we also attempted 
several novel and under-used approaches. After an initial round of calling and QC, we recalled 
the samples because it has been shown that even a few poor quality samples can “profoundly” 
affect the allele calls of good quality samples (322).  
Figure  6.1 shows quantile-quantile (QQ) plots of p-values for an association analysis in 
controls only using site as the phenotype. The X-axis shows the expected distribution of p-values 
under that the null hypothesis of no association, while the Y-axis shows the distribution of p-
values for the analysis. The red line represents the distribution under the null in which the 
expected equals the observed (x=y), while the black points illustrates p-values generated in the 
analyses. In GWA studies with our sample size and expected effect size, the black points should 
follow the line until near the end, indicating mostly negative results with a handful of potentially 
true positive results at the tail. The first panel shows an analysis after Birdseed calling and QC. 
The line of points deviates early and sharply from the expected line, suggesting systematic 
differences between controls, such as population stratification or site effects. We knew there was 
not population stratification in our sample from previous tests, so the inflation represents a 
severe site effect. The genomic inflation factor (λ) quantifies the amount of deviation from the 
null. A λ of 1 would represent no deviation, but the first plot is highly inflated at 1.29. 
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At this point, we were fortunate to come across BEAGLECALL in the literature (262). 
This program was able to eliminate the site difference because calls are not only based on allele 
intensities, which were highly variable by site, but also LD information from neighboring SNPs. 
In the remaining panels of Figure 6.1, λ progressively declines with each iteration of 
BEAGLECALL until it reaches 1.06 in the last panel. As a field, it is imperative that we properly 
address the consequences of imperfect study design as we move forward with more advanced 
technologies, such as next generation sequencing (NGS). NGS has been subject to the same site 
and batch effects that plague other high throughput technologies, as seen in analyses of data from 
the 1000 Genomes project (320,323). Nevertheless, tools are being developed to deal with these 
artifacts, but researchers must be educated in their use (323). 
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Figure 6.1. QQ plots of a control-only analysis using site as a phenotype. The first panel shows a 
QQ plot of the association analysis using data called with Birdseed v2, while the remaining panels 
show QQ plots of the various iterations with BeagleCall.  
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A.1. Marker information and nominal p-values for AD and ARPs for DA SNPs 
GENE & 
CHR 
SNP BP LOCATION 
CALL 
RATE 
MAF 
AD 
(N=1028) 
ONSET 
(N=436) 
ISENS 
(N=428) 
TOLMX 
(N=427) 
MAX24 
(N=436) 
WDSFS 
(N=436) 
DRD1 rs686 174801306 3' UTR 99.5 0.401 0.41 0.45 0.68 0.014 0.015 0.46 
 (Chr 5) rs155417 174801446 exon 2 100.0 0.016 0.53 0.36 0.57 0.79 0.84 0.82 
  rs5326 174802802 exon 2 98.8 0.128 0.80 0.83 0.72 0.20 0.18 0.35 
  rs10078866 174804926 5' near gene 99.0 0.013 0.54 0.80 0.21 0.72 0.31 0.47 
DRD2 rs2242592 112784640 3' near gene 98.1 0.275 0.10 0.24 0.83 0.52 0.03 0.33 
(Chr 11) rs6279 112786283 exon 8 99.2 0.279 0.13 0.27 0.78 0.59 0.02 0.33 
  rs2587548 112797422 intron 1 99.4 0.389 0.30 0.24 0.15 0.98 0.10 0.64 
  rs1076563 112801119 intron 1 99.7 0.389 0.35 0.19 0.17 0.97 0.11 0.58 
  rs1079596 112801829 intron 1 99.5 0.162 0.36 0.82 0.37 0.97 0.83 0.39 
  rs1125394 112802395 intron 1 99.8 0.160 0.45 0.79 0.36 0.95 0.76 0.35 
  rs2471857 112803549 intron 1 100.0 0.162 0.29 0.84 0.32 0.94 0.98 0.41 
  rs4648318 112818599 intron 1 99.9 0.239 0.34 0.15 0.73 0.62 0.16 0.69 
  rs4274224 112824662 intron 1 99.3 0.482 0.11 0.47 0.33 0.57 0.84 0.89 
  rs4581480 112829684 intron 1 99.7 0.109 0.13 0.69 0.65 0.26 0.02 0.98 
  rs4648317 112836742 intron 1 99.9 0.149 0.79 0.80 0.92 0.25 0.46 0.39 
  rs4630328 112839419 intron 1 93.1 0.391 0.09 0.56 0.06 0.11 0.26 0.49 
  rs4350392 112840927 intron 1 98.9 0.161 0.31 0.65 0.87 0.22 0.32 0.39 
  rs1799978 112851561 5' near gene 99.8 0.041 0.33 0.79 0.22 0.64 0.70 0.79 
  rs12364283 112852165 5' near gene 99.9 0.079 0.64 0.86 0.33 0.29 0.71 0.68 
DRD3 rs2654754 115338486 intron 5 99.8 0.025 0.30 1.00 0.0021 0.07 0.18 0.09 
(Chr 3) rs2134655 115340891 intron 5 99.7 0.273 0.13 0.71 0.44 0.99 0.15 0.89 
  rs9288993 115341863 intron 4 99.9 0.023 0.37 0.78 0.00 0.07 0.18 0.07 
  rs963468 115345577 intron 4 99.1 0.388 0.60 0.10 0.17 0.39 0.77 0.65 
  rs3773678 115352768 intron 3 99.8 0.121 0.57 0.29 0.32 0.55 0.11 0.23 
  rs2630349 115356062 intron 3 98.6 0.057 0.96 0.15 0.83 0.84 0.70 0.81 
  rs167771 115358965 intron 3 99.8 0.156 0.18 0.14 0.55 0.28 0.56 0.09 
  rs167770 115362252 intron 2 99.5 0.287 0.01 0.59 0.32 0.27 0.06 0.57 
  rs324029 115364313 intron 2 99.4 0.288 0.01 0.75 0.22 0.24 0.04 0.61 
  rs10934256 115368342 intron 2 98.9 0.211 0.15 1.00 0.47 0.13 0.10 0.45 
  rs1486009 115371222 intron 2 99.9 0.050 0.09 0.43 0.52 0.08 0.85 0.33 
  rs6280 115373505 exon 2 99.8 0.340 0.03 0.40 0.25 0.34 0.08 0.65 
  rs9825563 115382910 5' near gene 99.0 0.317 0.35 0.57 0.22 0.14 0.07 0.68 
DRD4 rs12280580 616220 5' near gene 92.7 0.354 0.011 0.66 0.59 0.55 0.17 0.76 
(Chr 11) rs3758653 626399 5' near gene 100.0 0.168 0.77 0.89 0.49 0.54 0.54 0.71 
  rs916457 627014 5' near gene 100.0 0.044 0.22 0.74 0.56 0.81 0.49 0.78 
  rs11246226 631191 3' near gene 99.2 0.476 0.25 0.30 0.58 0.32 0.98 0.95 
DRD5 rs7655090 9374973 3' near gene 98.1 0.049 0.60 0.33 0.63 0.16 0.15 0.0017 
(Chr 4) rs11731100 9376278 3' near gene 96.7 0.376 0.97 0.71 1.00 0.14 0.27 0.22 
  rs10939507 9377921 3' near gene 97.9 0.330 0.85 0.43 0.75 0.048 0.23 0.81 
  rs2867383 9397033 3' near gene 99.7 0.332 0.89 0.62 0.75 0.06 0.24 0.72 
  rs12500086 9418957 3' near gene 97.4 0.193 0.50 0.55 0.11 0.05 0.23 0.53 
  rs10005226 9420903 3' near gene 98.3 0.193 0.73 0.50 0.34 0.73 0.41 0.85 
  rs1401438 9423554 3' near gene 96.0 0.166 0.77 0.71 0.05 0.012 0.19 0.26 
SLC18A2 rs363332 118992657 intron 2 100.0 0.259 0.72 0.09 0.72 0.59 0.31 0.12 
(Chr 10) rs363334 118994985 intron 3 99.4 0.256 0.89 0.09 0.74 0.61 0.32 0.13 
  rs363338 118999379 intron 3 99.9 0.334 0.64 0.09 0.64 0.97 0.63 0.45 
  rs3753127 118999902 intron 3 99.7 0.022 0.03 0.48 0.31 0.89 0.09 0.95 
  rs2283139 119008847 intron 10 100.0 0.012 0.87 0.70 0.63 0.14 0.32 0.94 
  rs4752045 119009680 intron 10 98.7 0.389 0.97 0.10 0.96 0.18 0.29 0.51 
  rs363256 119014215 intron 10 99.8 0.093 0.65 0.25 0.35 0.05 0.66 0.37 
  rs363271 119017401 intron 13 99.7 0.119 0.29 0.019 0.24 0.24 0.85 0.23 
  rs363230 119019505 intron 13 99.8 0.406 0.38 0.33 0.75 0.05 0.49 0.30 
  rs2244249 119022265 intron 15 99.6 0.141 0.51 0.00503 0.55 0.30 0.81 0.23 
  rs363276 119023799 intron 15 99.8 0.142 0.56 0.01 0.37 0.33 0.93 0.25 
SLC6A3 rs27072 1447522 intron 15 90.6 0.172 0.85 0.08 0.99 0.97 0.25 0.12 
(Chr 5) rs6869645 1457548 intron 12 100.0 0.044 0.55 0.98 0.89 0.44 0.04 0.77 
  rs6347 1464412 exon 9 98.6 0.281 0.14 0.96 0.22 0.19 0.03 0.72 
  rs27048 1465645 intron 8 97.1 0.451 0.042 0.68 0.24 0.61 0.79 0.24 
  rs37022 1468629 intron 7 99.9 0.201 0.94 0.55 0.56 0.14 0.20 0.68 
  rs11564758 1473588 intron 6  95.6 0.372 0.63 0.63 0.57 0.71 0.34 0.13 
  rs464049 1476905 intron 4 99.8 0.460 0.68 0.71 0.50 0.68 0.05 0.64 
  rs10052016 1481111 intron 4 93.9 0.412 0.00055 0.69 0.19 0.13 0.73 0.30 
  rs460000 1485825 intron 3 99.4 0.230 0.74 0.75 0.42 0.83 0.01 0.64 
  rs403636 1491354 intron 3 99.9 0.166 0.51 0.90 0.04 0.26 0.07 0.51 
  rs6350 1496199 exon 2 99.9 0.076 0.90 0.66 0.76 0.34 0.16 0.03 
  rs3756450 1501148 5' near gene 99.9 0.136 0.83 0.73 0.20 0.36 0.37 0.92 
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DDC rs4947510 50299629 3' near gene 99.2 0.486 0.62 0.46 0.13 0.64 0.51 0.58 
(Chr 7) rs11575542 50305196 exon 14 99.7 0.015 0.31 0.57 0.37 0.76 0.68 0.64 
  rs4947535 50305890 intron 13 99.5 0.360 0.30 0.86 0.07 0.92 0.34 0.34 
  rs11761683 50317088 intron 11 99.8 0.325 0.62 0.94 0.30 0.43 0.28 0.93 
  rs745043 50318164 intron 11 99.8 0.025 0.85 0.60 0.20 0.94 0.21 0.56 
  rs732215 50318272 intron 11 97.6 0.285 0.64 0.83 0.24 0.56 0.68 0.66 
  rs4490786 50318523 intron 11 93.0 0.358 0.23 0.69 0.97 0.44 0.64 0.13 
  rs2122822 50326361 intron 9 95.5 0.199 0.29 0.82 0.22 0.86 0.55 0.82 
  rs1037351 50339613 intron 8 99.7 0.433 0.50 0.65 0.71 0.36 0.92 0.39 
  rs880028 50344345 intron 7 99.2 0.238 0.32 0.80 0.84 0.48 0.66 0.17 
  rs11238178 50365599 intron 6  100.0 0.437 0.13 0.70 0.08 0.89 0.04 0.68 
  rs11575343 50370556 intron 5 95.2 0.342 0.48 0.86 0.46 0.66 0.90 0.84 
  rs10244632 50372912 intron 4 99.5 0.240 0.16 0.77 0.20 0.83 0.07 0.76 
  rs1466163 50381415 intron 3 98.2 0.269 0.59 0.58 0.67 0.53 0.11 0.67 
  rs7786398 50387115 intron 1 100.0 0.022 0.40 0.50 0.55 0.85 0.94 0.69 
  rs10499695 50392813 intron 1 98.8 0.293 0.12 0.34 0.89 0.96 0.30 0.66 
  rs2329341 50394484 intron 1 99.3 0.109 0.45 0.55 0.37 0.98 0.92 0.20 
  rs10499696 50395797 intron 1 94.6 0.482 0.33 0.95 0.69 0.66 0.14 0.49 
  rs921451 50397494 intron 1 94.2 0.478 0.51 0.61 0.50 0.73 0.87 0.26 
  rs6969081 50398714 intron 1 99.7 0.358 0.18 0.75 0.24 0.77 0.16 0.52 
  rs3829897 50403973 intron 1 99.7 0.116 0.06 0.35 0.83 0.42 0.54 0.26 
  rs7804365 50411357 5' near gene 99.7 0.353 0.04 0.27 0.94 0.66 0.21 0.11 
TH rs2070762 2142911 intron 13 91.9 0.403 0.22 0.93 0.50 0.67 0.88 0.91 
(Chr 11) rs11564717 2143465 intron 12 99.9 0.408 0.31 0.70 0.20 0.91 0.05 0.0094 
  rs6356 2147527 exon 3 98.9 0.479 0.14 0.53 0.32 0.75 0.98 0.56 
COMT rs737866 18304663 intron 1 99.7 0.286 0.29 0.73 0.33 0.04 0.37 0.68 
(Chr 22) rs933271 18305961 intron 1 99.6 0.282 0.02 0.96 0.06 0.04 0.65 0.44 
  rs5993883 18312192 intron 1 99.8 0.499 0.06 0.93 0.40 0.24 0.40 0.52 
  rs740603 18319731 intron 1 99.6 0.487 0.17 0.92 0.42 0.36 0.25 0.63 
  rs2239393 18324982 intron 3 99.2 0.407 0.61 1.00 0.88 0.99 0.28 0.77 
  rs4680 18325825 exon 4 99.4 0.498 0.66 0.38 0.84 0.98 0.51 0.26 
  rs4646316 18326686 intron 5 98.6 0.260 0.45 0.46 0.98 0.58 0.85 0.11 
  rs174696 18327730 intron 5 100.0 0.219 0.86 0.14 0.80 0.23 0.02 0.48 
  rs174697 18328386 intron 5 99.1 0.061 0.42 0.90 0.88 0.66 0.29 0.61 
  rs9332377 18330246 intron 5 99.8 0.150 0.29 0.72 0.87 0.97 0.38 0.22 
Notes: AD, alcohol dependence; ONSET, age-at-onset of AD; ISENS, initial sensitivity; TOLMX, tolerance/maximum drinking; MAX24, 
maximum drinks in 24 hours; WDSFS, withdrawal severity factor score. Nominal p-values significant after permutation are in bold. 
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A.2. Marker information and nominal p-values for disinhibitory symptom counts and factor score for DA SNPs 
GENE & 
CHR 
SNP BP LOCATION 
CALL 
RATE 
MAF 
ADsx 
(N=436) 
ADHDsx 
(N=426) 
ASPDsx 
(N=436) 
CDsx 
(N=436) 
DDsx 
(N=432) 
NS 
(N=429) 
Factor 
Score 
(N=426) 
DRD1 rs686 174801306 3' UTR 99.5 0.401 0.24 0.36 0.83 0.77 0.58 0.74 0.37 
 (Chr 5) rs155417 174801446 exon 2 100.0 0.016 0.20 0.03 0.43 0.59 0.86 0.54 0.26 
  rs5326 174802802 exon 2 98.8 0.128 0.31 0.20 0.19 0.07 0.07 0.95 0.05 
  rs10078866 174804926 5' near gene 99.0 0.013 0.59 0.38 0.021 0.023 0.75 0.46 0.02 
DRD2 rs2242592 112784640 3' near gene 98.1 0.275 0.60 0.72 0.60 0.73 0.22 0.42 0.43 
(Chr 11) rs6279 112786283 exon 8 99.2 0.279 0.74 0.58 0.53 0.64 0.26 0.43 0.35 
  rs2587548 112797422 intron 1 99.4 0.389 0.80 0.34 0.85 0.71 0.52 0.047 0.35 
  rs1076563 112801119 intron 1 99.7 0.389 0.83 0.45 0.91 0.76 0.49 0.05 0.40 
  rs1079596 112801829 intron 1 99.5 0.162 0.83 0.28 0.43 0.59 0.32 0.29 0.84 
  rs1125394 112802395 intron 1 99.8 0.160 0.68 0.31 0.46 0.59 0.30 0.31 0.81 
  rs2471857 112803549 intron 1 100.0 0.162 0.77 0.24 0.50 0.71 0.37 0.26 0.94 
  rs4648318 112818599 intron 1 99.9 0.239 0.69 0.40 0.82 0.87 0.30 0.08 0.62 
  rs4274224 112824662 intron 1 99.3 0.482 0.87 0.93 0.19 0.72 0.43 0.028 0.71 
  rs4581480 112829684 intron 1 99.7 0.109 0.89 0.42 0.66 0.46 0.39 0.07 0.21 
  rs4648317 112836742 intron 1 99.9 0.149 0.58 0.39 0.82 0.17 0.21 0.82 0.09 
  rs4630328 112839419 intron 1 93.1 0.391 0.91 0.50 0.12 0.84 0.47 0.00049 1.00 
  rs4350392 112840927 intron 1 98.9 0.161 0.44 0.24 0.81 0.14 0.21 0.73 0.07 
  rs1799978 112851561 5' near gene 99.8 0.041 0.85 0.29 0.73 0.62 0.51 0.54 0.47 
  rs12364283 112852165 5' near gene 99.9 0.079 0.17 0.64 0.09 0.78 0.91 0.42 0.84 
DRD3 rs2654754 115338486 intron 5 99.8 0.025 0.05 0.55 0.25 0.23 0.84 0.84 0.29 
(Chr 3) rs2134655 115340891 intron 5 99.7 0.273 0.84 0.81 0.63 0.85 0.57 0.58 0.56 
  rs9288993 115341863 intron 4 99.9 0.023 0.07 0.55 0.18 0.25 0.91 0.79 0.28 
  rs963468 115345577 intron 4 99.1 0.388 0.70 0.37 0.29 0.88 0.51 0.74 0.66 
  rs3773678 115352768 intron 3 99.8 0.121 0.97 0.65 0.79 0.85 0.06 0.73 0.78 
  rs2630349 115356062 intron 3 98.6 0.057 0.97 0.73 0.59 0.50 0.14 0.77 0.50 
  rs167771 115358965 intron 3 99.8 0.156 0.99 0.12 0.70 0.87 0.05 0.83 1.00 
  rs167770 115362252 intron 2 99.5 0.287 0.43 0.78 0.32 0.92 0.67 0.49 0.95 
  rs324029 115364313 intron 2 99.4 0.288 0.39 0.58 0.25 0.68 0.65 0.54 0.77 
  rs10934256 115368342 intron 2 98.9 0.211 0.11 0.46 0.52 0.90 0.89 0.79 0.80 
  rs1486009 115371222 intron 2 99.9 0.050 0.85 0.06 0.60 0.97 0.35 0.38 0.89 
  rs6280 115373505 exon 2 99.8 0.340 0.43 0.72 0.87 0.52 0.38 0.38 0.60 
  rs9825563 115382910 5' near gene 99.0 0.317 0.44 0.68 0.63 0.80 0.51 0.99 0.98 
DRD4 rs12280580 616220 5' near gene 92.7 0.354 0.81 0.93 0.52 0.92 0.56 0.47 0.86 
(Chr 11) rs3758653 626399 5' near gene 100.0 0.168 0.90 0.92 0.87 0.79 0.46 0.80 0.87 
  rs916457 627014 5' near gene 100.0 0.044 0.32 0.21 0.03 0.10 0.90 0.68 0.22 
  rs11246226 631191 3' near gene 99.2 0.476 0.65 0.45 0.92 0.81 0.42 0.45 0.89 
DRD5 rs7655090 9374973 3' near gene 98.1 0.049 0.15 0.08 0.17 0.029 0.07 0.38 0.0094 
(Chr 4) rs11731100 9376278 3' near gene 96.7 0.376 0.10 0.90 0.08 0.0063 0.48 0.78 0.09 
  rs10939507 9377921 3' near gene 97.9 0.330 0.58 0.34 0.21 0.06 0.71 0.79 0.55 
  rs2867383 9397033 3' near gene 99.7 0.332 0.50 0.53 0.05 0.016 0.79 0.82 0.28 
  rs12500086 9418957 3' near gene 97.4 0.193 0.48 0.77 0.15 0.21 0.88 0.50 0.60 
  rs10005226 9420903 3' near gene 98.3 0.193 0.18 0.04 0.94 0.59 0.67 0.14 0.40 
  rs1401438 9423554 3' near gene 96.0 0.166 0.16 0.84 0.18 0.17 0.81 0.75 0.79 
SLC18A2 rs363332 118992657 intron 2 100.0 0.259 0.016 0.13 0.21 0.71 0.67 0.19 0.18 
(Chr 10) rs363334 118994985 intron 3 99.4 0.256 0.02 0.13 0.22 0.73 0.67 0.18 0.19 
  rs363338 118999379 intron 3 99.9 0.334 0.13 0.30 0.24 0.47 0.36 0.23 0.32 
  rs3753127 118999902 intron 3 99.7 0.022 0.92 0.94 0.62 0.99 0.27 0.57 0.84 
  rs2283139 119008847 intron 10 100.0 0.012 0.20 0.79 0.04 0.24 0.51 0.29 0.19 
  rs4752045 119009680 intron 10 98.7 0.389 0.33 0.25 0.72 0.48 0.80 0.35 0.86 
  rs363256 119014215 intron 10 99.8 0.093 0.69 0.76 0.08 0.27 0.40 0.07 0.15 
  rs363271 119017401 intron 13 99.7 0.119 0.98 0.62 0.09 0.20 0.48 0.35 0.32 
  rs363230 119019505 intron 13 99.8 0.406 0.77 0.69 0.55 0.84 0.29 0.41 0.51 
  rs2244249 119022265 intron 15 99.6 0.141 0.60 0.68 0.08 0.27 0.49 0.34 0.54 
  rs363276 119023799 intron 15 99.8 0.142 0.64 0.65 0.09 0.31 0.55 0.36 0.55 
SLC6A3 rs27072 1447522 intron 15 90.6 0.172 0.84 0.29 0.89 0.90 0.45 1.00 0.96 
(Chr 5) rs6869645 1457548 intron 12 100.0 0.044 0.19 0.86 0.97 0.56 0.84 0.76 0.80 
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A.2. Marker information and nominal p-values for disinhibitory symptom counts and factor score for DA SNPs 
GENE & 
CHR 
SNP BP LOCATION 
CALL 
RATE 
MAF 
ADsx 
(N=436) 
ADHDsx 
(N=426) 
ASPDsx 
(N=436) 
CDsx 
(N=436) 
DDsx 
(N=432) 
NS 
(N=429) 
Factor 
Score 
(N=426) 
  rs6347 1464412 exon 9 98.6 0.281 0.57 0.70 0.18 0.21 0.61 0.67 0.31 
  rs27048 1465645 intron 8 97.1 0.451 0.74 0.90 0.35 0.45 0.64 0.43 0.94 
  rs37022 1468629 intron 7 99.9 0.201 0.32 0.38 0.60 0.89 0.76 0.96 0.72 
  rs11564758 1473588 intron 6  95.6 0.372 0.92 0.38 0.15 0.98 0.56 0.93 1.00 
  rs464049 1476905 intron 4 99.8 0.460 0.93 0.96 0.75 0.71 0.73 0.70 0.88 
  rs10052016 1481111 intron 4 93.9 0.412 0.81 0.44 0.37 0.06 0.57 0.25 0.60 
  rs460000 1485825 intron 3 99.4 0.230 0.39 0.17 0.56 0.63 0.83 0.70 0.96 
  rs403636 1491354 intron 3 99.9 0.166 0.83 0.37 0.46 0.85 0.86 0.85 0.99 
  rs6350 1496199 exon 2 99.9 0.076 0.0021 0.94 0.52 0.80 0.89 0.31 0.89 
  rs3756450 1501148 5' near gene 99.9 0.136 0.51 0.08 0.69 0.85 0.03 0.58 0.82 
DDC rs4947510 50299629 3' near gene 99.2 0.486 0.99 0.12 0.44 0.83 0.16 0.27 0.52 
(Chr 7) rs11575542 50305196 exon 14 99.7 0.015 0.22 0.48 0.54 0.63 0.0028 0.86 0.52 
  rs4947535 50305890 intron 13 99.5 0.360 0.55 0.44 0.60 0.54 0.65 0.64 0.56 
  rs11761683 50317088 intron 11 99.8 0.325 0.41 0.86 0.28 0.50 0.24 0.69 0.90 
  rs745043 50318164 intron 11 99.8 0.025 1.00 0.79 0.97 0.58 0.88 0.32 1.00 
  rs732215 50318272 intron 11 97.6 0.285 0.97 0.28 0.98 0.55 0.40 0.33 0.55 
  rs4490786 50318523 intron 11 93.0 0.358 0.40 0.16 0.21 0.87 0.17 0.08 0.17 
  rs2122822 50326361 intron 9 95.5 0.199 0.30 0.19 0.66 0.76 0.95 0.24 0.55 
  rs1037351 50339613 intron 8 99.7 0.433 0.46 0.72 0.73 0.61 0.79 0.78 0.70 
  rs880028 50344345 intron 7 99.2 0.238 0.37 0.19 0.23 0.88 0.23 0.10 0.19 
  rs11238178 50365599 intron 6  100.0 0.437 0.50 0.43 0.28 0.31 0.93 0.87 0.17 
  rs11575343 50370556 intron 5 95.2 0.342 0.34 0.97 0.39 0.90 0.01 0.63 0.29 
  rs10244632 50372912 intron 4 99.5 0.240 0.38 0.50 0.26 0.45 0.44 0.86 0.12 
  rs1466163 50381415 intron 3 98.2 0.269 0.32 0.84 0.46 0.80 0.73 0.66 0.81 
  rs7786398 50387115 intron 1 100.0 0.022 0.23 0.44 0.06 0.86 0.95 0.21 0.08 
  rs10499695 50392813 intron 1 98.8 0.293 0.49 0.88 0.21 0.73 0.27 0.28 0.97 
  rs2329341 50394484 intron 1 99.3 0.109 0.41 0.45 0.61 0.82 0.43 0.85 0.60 
  rs10499696 50395797 intron 1 94.6 0.482 0.44 0.76 0.76 0.80 0.82 0.43 0.98 
  rs921451 50397494 intron 1 94.2 0.478 0.53 0.31 0.53 0.75 0.48 0.83 0.46 
  rs6969081 50398714 intron 1 99.7 0.358 0.79 0.82 0.51 0.41 0.55 0.83 0.98 
  rs3829897 50403973 intron 1 99.7 0.116 0.70 0.38 0.08 0.27 0.32 0.93 0.12 
  rs7804365 50411357 5' near gene 99.7 0.353 0.95 0.83 0.22 0.35 0.41 0.41 0.23 
TH rs2070762 2142911 intron 13 91.9 0.403 0.68 0.43 0.50 0.98 0.51 0.56 0.96 
(Chr 11) rs11564717 2143465 intron 12 99.9 0.408 0.16 0.014a 0.46 0.27 0.19 0.17 0.13 
  rs6356 2147527 exon 3 98.9 0.479 0.80 0.98 0.85 0.83 0.50 0.52 0.63 
COMT rs737866 18304663 intron 1 99.7 0.286 0.97 0.03 0.52 0.90 0.08 0.54 0.39 
(Chr 22) rs933271 18305961 intron 1 99.6 0.282 0.78 0.13 0.44 0.64 0.53 0.69 0.91 
  rs5993883 18312192 intron 1 99.8 0.499 0.85 0.57 0.53 0.74 0.02 0.62 0.32 
  rs740603 18319731 intron 1 99.6 0.487 0.95 0.92 0.81 0.79 0.05 0.89 0.60 
  rs2239393 18324982 intron 3 99.2 0.407 0.14 0.42 0.99 0.63 0.52 0.33 0.97 
  rs4680 18325825 exon 4 99.4 0.498 0.54 0.79 0.49 0.12 0.55 0.26 0.35 
  rs4646316 18326686 intron 5 98.6 0.260 0.55 0.44 0.44 0.59 0.76 0.14 0.69 
  rs174696 18327730 intron 5 100.0 0.219 0.49 0.72 0.11 0.18 0.74 0.75 0.22 
  rs174697 18328386 intron 5 99.1 0.061 0.99 0.13 0.71 0.88 0.46 0.58 0.48 
  rs9332377 18330246 intron 5 99.8 0.150 0.11 0.83 0.79 0.51 0.88 0.13 0.88 
             
Notes: ADsx, alcohol dependence symptoms; APSDsx, antisocial personality disorder symptoms; ADHDsx, attention 
deficit/hyperactivity symptoms; CDsx, conduct disorder symptoms; DDsx, drug dependence symptoms; NS, novelty seeking score. 
Nominal p-values significant after permutation are in bold.  
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs2154358 1 20143206 0.92 1.09E-05 0.3 0.92 1.0 intergenic 
rs111575277 1 47789513 0.73 1.10E-05 0.3 0.44 0.9 intergenic 
rs2182241 1 62805139 1.00 4.11E-06 0.2 0.68 1.0 intergenic 
rs76132455 1 64839483 0.56 1.82E-05 0.4 0.63 1.0 intergenic 
rs59409703 1 65535046 0.72 3.11E-06 0.2 0.49 0.9 intergenic 
rs3762312 1 65535986 0.72 2.42E-06 0.2 0.49 0.9 intergenic 
rs114102876 1 65560909 0.72 9.60E-06 0.3 0.28 0.7 intergenic 
rs61798772 1 89641171 0.88 1.52E-05 0.3 0.77 1.0 GBP7 
rs139254361 1 89732527 0.91 7.32E-07 0.2 0.64 1.0 GBP5 
rs58778527 1 100407807 0.99 3.14E-05 0.5 0.93 1.0 intergenic 
rs1541044 1 100411287 0.99 3.90E-05 0.5 0.93 1.0 intergenic 
rs1530683 1 104990673 0.95 2.06E-05 0.4 0.15 0.6 intergenic 
rs7417007 1 105002929 0.99 2.20E-05 0.4 0.16 0.6 intergenic 
rs9662391 1 105014143 0.99 6.11E-06 0.2 0.22 0.7 intergenic 
rs72987611 1 105020384 0.99 5.75E-06 0.2 0.14 0.6 intergenic 
rs74105009 1 105029400 0.98 3.66E-06 0.2 0.11 0.6 intergenic 
rs9662087 1 105047970 0.99 3.52E-06 0.2 0.21 0.7 intergenic 
rs6583098 1 105050992 0.99 4.31E-06 0.2 0.22 0.7 intergenic 
rs75382510 1 105054941 0.98 2.13E-06 0.2 0.21 0.7 intergenic 
rs75182375 1 105055795 0.99 4.39E-06 0.2 0.23 0.7 intergenic 
rs74634766 1 105056575 0.99 4.39E-06 0.2 0.24 0.7 intergenic 
rs2218672 1 105060691 0.98 4.45E-06 0.2 0.25 0.7 intergenic 
rs76565683 1 105061521 0.98 4.48E-06 0.2 0.25 0.7 intergenic 
rs1448393 1 105115585 0.99 4.15E-05 0.5 0.28 0.7 intergenic 
rs11589124 1 105116823 0.99 4.15E-05 0.5 0.28 0.7 intergenic 
rs74557654 1 105119188 0.96 4.06E-05 0.5 0.30 0.7 intergenic 
rs11589477 1 105142710 0.93 3.97E-05 0.5 0.12 0.6 intergenic 
rs6662838 1 156403701 0.63 2.31E-05 0.4 0.78 1.0 intergenic 
rs11590002 1 175032518 1.00 2.17E-06 0.2 0.30 0.7 intergenic 
rs11582546 1 175049009 0.91 2.58E-06 0.2 0.03 0.6 TNN 
rs61827435 1 175066967 0.90 2.44E-06 0.2 0.02 0.6 TNN 
rs59698324 1 201965855 0.99 3.51E-05 0.5 0.90 1.0 RNPEP 
rs61821542 1 201967669 1.00 2.81E-05 0.4 0.98 1.0 RNPEP 
rs13375435 1 201971862 1.00 3.02E-05 0.5 0.99 1.0 RNPEP 
rs4630172 1 201972889 1.00 3.03E-05 0.5 0.99 1.0 RNPEP 
rs3820439 1 201973565 1.00 3.03E-05 0.5 0.97 1.0 RNPEP 
rs7516412 1 201976201 0.99 3.57E-05 0.5 0.95 1.0 LOC1002894
88 rs36073842 1 204694428 0.51 4.35E-05 0.5 0.15 0.6 intergenic 
rs114901102 1 210901331 0.89 9.06E-06 0.3 0.13 0.6 KCNH1 
rs16845712 1 226536337 0.75 8.25E-07 0.2 0.46 0.9 intergenic 
rs6701940 1 226649170 0.72 1.66E-05 0.4 0.05 0.6 intergenic 
rs185448 1 238471801 0.99 2.33E-05 0.4 0.82 1.0 intergenic 
rs259578 1 238471842 0.99 2.36E-05 0.4 0.82 1.0 intergenic 
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs259577 1 238471915 0.99 2.42E-05 0.4 0.87 1.0 intergenic 
rs259602 1 238481474 1.00 2.73E-05 0.4 0.89 1.0 intergenic 
rs259601 1 238483478 1.00 2.72E-05 0.4 0.88 1.0 intergenic 
rs259580 1 238492061 1.00 1.67E-05 0.4 0.82 1.0 intergenic 
rs7539749 1 238492486 0.99 1.72E-05 0.4 0.70 1.0 intergenic 
rs1414538 1 238498167 0.99 9.01E-06 0.3 0.87 1.0 intergenic 
rs1027189 1 238500210 1.00 1.57E-05 0.4 0.83 1.0 intergenic 
rs1964602 1 238501171 0.97 2.90E-05 0.5 0.74 1.0 intergenic 
rs1361655 1 238504548 1.00 1.22E-05 0.3 0.91 1.0 intergenic 
rs7538546 1 238512343 1.00 1.22E-05 0.3 0.92 1.0 intergenic 
rs7550834 1 238516057 1.00 1.21E-05 0.3 0.86 1.0 intergenic 
rs4659522 1 238518836 0.99 1.08E-05 0.3 0.94 1.0 intergenic 
rs10737824 1 238519408 0.99 4.00E-05 0.5 1.00 1.0 intergenic 
rs6702470 1 238520218 0.99 3.91E-05 0.5 1.00 1.0 intergenic 
rs7550792 1 238522218 0.99 8.15E-06 0.3 1.00 1.0 intergenic 
rs10158750 1 238525963 0.95 4.18E-06 0.2 0.96 1.0 intergenic 
rs12129735 1 238528907 0.85 2.59E-05 0.4 0.79 1.0 intergenic 
rs72768910 2 15940724 0.94 2.95E-05 0.5 0.09 0.6 intergenic 
rs77224371 2 16948876 0.84 1.76E-05 0.4 0.39 0.8 intergenic 
rs10203610 2 27572265 0.74 1.71E-05 0.4 0.05 0.6 GTF3C2 
rs74467769 2 35410184 0.66 3.00E-05 0.5 NA NA intergenic 
rs10496077 2 57943044 0.96 3.39E-05 0.5 0.87 1.0 intergenic 
rs55950043 2 57943869 0.82 1.30E-05 0.3 0.73 1.0 intergenic 
rs72804544 2 57970078 0.83 2.66E-05 0.4 0.82 1.0 intergenic 
rs72804548 2 57974646 0.88 1.12E-05 0.3 0.67 1.0 intergenic 
rs72804553 2 57982530 0.82 4.04E-06 0.2 0.78 1.0 intergenic 
rs67973994 2 57987808 0.99 3.97E-05 0.5 0.59 1.0 intergenic 
rs72804580 2 58048234 0.84 1.61E-05 0.4 0.83 1.0 intergenic 
rs72840080 2 85596043 0.79 2.59E-05 0.4 0.38 0.8 ELMOD3 
rs112480835 2 104070773 0.56 3.09E-05 0.5 0.39 0.8 intergenic 
rs72833664 2 114506030 0.97 3.07E-07 0.1 NA NA SLC35F5 
rs113069166 2 115918943 0.90 9.60E-07 0.2 0.73 1.0 DPP10 
rs112287044 2 116086394 1.00 4.40E-05 0.5 0.73 1.0 DPP10 
rs17823041 2 116101097 1.00 4.12E-05 0.5 0.44 0.9 DPP10 
rs66827093 2 116160527 0.89 5.36E-06 0.2 0.98 1.0 DPP10 
rs150113144 2 122393805 0.83 2.52E-05 0.4 0.46 0.9 CLASP1 
rs17753709 2 145986219 0.50 1.59E-05 0.4 0.62 1.0 intergenic 
rs142227413 2 154351630 0.85 2.17E-05 0.4 0.50 0.9 intergenic 
rs72920194 2 199362905 0.72 6.62E-06 0.2 0.74 1.0 intergenic 
rs191005325 2 199392149 0.99 1.52E-06 0.2 NA NA intergenic 
rs137943609 2 199462960 0.97 1.35E-06 0.2 NA NA intergenic 
rs17229679 2 199560757 0.64 9.26E-06 0.3 0.91 1.0 intergenic 
rs116203419 2 200649995 0.77 1.39E-05 0.3 0.19 0.6 FONG 
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs193137425 2 206245058 0.57 3.21E-05 0.5 0.65 1.0 PARD3B 
rs79260980 2 215012873 0.72 2.93E-05 0.5 0.65 1.0 SPAG16 
rs77454352 2 222078482 0.91 2.71E-05 0.4 0.14 0.6 intergenic 
rs28439910 2 238209899 0.91 1.68E-05 0.4 0.09 0.6 intergenic 
rs28432742 2 238210290 0.97 1.37E-05 0.3 0.10 0.6 intergenic 
rs28620087 2 238210323 0.97 1.37E-05 0.3 0.10 0.6 intergenic 
rs28666656 2 238210395 0.98 1.37E-05 0.3 0.10 0.6 intergenic 
rs28497536 2 238210416 0.98 1.38E-05 0.3 0.10 0.6 intergenic 
rs11897292 2 238210640 1.00 1.30E-05 0.3 0.11 0.6 intergenic 
rs11897373 2 238210881 1.00 1.29E-05 0.3 0.09 0.6 intergenic 
rs13404258 2 238214571 1.00 1.38E-05 0.3 0.10 0.6 intergenic 
rs6729500 2 238215479 1.00 1.74E-05 0.4 0.07 0.6 intergenic 
rs7598750 2 238217274 1.00 1.54E-05 0.4 0.07 0.6 intergenic 
rs10184009 2 238219581 1.00 1.88E-05 0.4 0.06 0.6 intergenic 
rs61035261 2 238221360 1.00 2.07E-05 0.4 0.06 0.6 intergenic 
rs10929224 2 238225610 1.00 2.29E-05 0.4 0.04 0.6 intergenic 
rs10204947 2 238226513 0.99 2.26E-05 0.4 0.05 0.6 intergenic 
rs924209 2 238227536 0.99 2.10E-05 0.4 0.05 0.6 intergenic 
rs56310758 2 238240863 1.00 1.25E-08 0.1 0.04 0.6 COL6A3 
rs75561681 2 238241881 0.97 2.77E-08 0.1 0.01 0.6 COL6A3 
rs2270671 2 238243285 1.00 1.18E-08 0.1 0.06 0.6 COL6A3 
rs10929226 2 238244559 0.99 1.17E-08 0.1 0.06 0.6 COL6A3 
rs112523013 2 238247257 0.99 1.05E-08 0.1 0.07 0.6 COL6A3 
rs2646258 2 238253149 0.99 6.39E-09 0.1 0.05 0.6 COL6A3 
rs2256485 2 238253930 0.99 6.18E-09 0.1 0.03 0.6 COL6A3 
rs2270656 2 238255120 0.99 9.12E-07 0.2 0.13 0.6 COL6A3 
rs2645767 2 238256171 1.00 1.60E-06 0.2 0.24 0.7 COL6A3 
rs2646265 2 238257013 1.00 1.46E-08 0.1 0.07 0.6 COL6A3 
rs3790990 2 238257127 1.00 2.45E-05 0.4 0.30 0.7 COL6A3 
rs2646264 2 238257213 1.00 1.19E-08 0.1 0.10 0.6 COL6A3 
rs2646263 2 238257353 0.99 1.56E-06 0.2 0.19 0.6 COL6A3 
rs2645766 2 238257896 0.99 2.38E-05 0.4 0.31 0.8 COL6A3 
rs2646261 2 238259387 1.00 2.36E-08 0.1 0.08 0.6 COL6A3 
rs3790999 2 238260701 1.00 1.83E-06 0.2 0.38 0.8 COL6A3 
rs3828135 2 238260829 0.99 1.03E-05 0.3 0.69 1.0 COL6A3 
rs11901326 2 238261509 0.99 5.00E-07 0.1 0.33 0.8 COL6A3 
rs7605340 2 238261744 0.99 1.12E-05 0.3 0.42 0.9 COL6A3 
rs7605341 2 238261746 0.99 9.53E-06 0.3 0.39 0.8 COL6A3 
rs2646257 2 238261850 0.99 5.58E-07 0.1 0.33 0.8 COL6A3 
rs2645764 2 238262254 1.00 7.09E-09 0.1 0.18 0.6 COL6A3 
rs2645763 2 238263299 1.00 7.97E-09 0.1 0.17 0.6 COL6A3 
rs10929228 2 238265684 0.96 1.62E-05 0.4 0.40 0.8 COL6A3 
rs2645777 2 238266146 0.96 4.41E-08 0.1 0.13 0.6 COL6A3 
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs2646254 2 238267717 0.88 3.98E-05 0.5 0.32 0.8 COL6A3 
rs2645769 2 238269871 0.96 5.11E-06 0.2 0.23 0.7 COL6A3 
rs7597795 2 238270726 0.98 1.36E-05 0.3 0.24 0.7 COL6A3 
rs10202497 2 238270894 0.96 1.43E-06 0.2 0.16 0.6 COL6A3 
rs7598394 2 238271229 1.00 1.73E-05 0.4 0.31 0.8 COL6A3 
rs10167850 2 238271284 0.97 2.35E-06 0.2 0.17 0.6 COL6A3 
rs11915389 3 6960199 0.99 2.47E-05 0.4 0.20 0.6 GRM7 
rs115937108 3 6992572 0.99 2.30E-05 0.4 0.23 0.7 GRM7 
rs73808494 3 7002079 0.99 2.98E-05 0.5 0.27 0.7 GRM7 
rs149456087 3 55912341 0.73 1.66E-05 0.4 0.46 0.9 ERC2 
rs75104355 3 67223691 1.00 3.20E-05 0.5 0.44 0.9 intergenic 
rs9870011 3 67232976 0.99 2.98E-05 0.5 0.39 0.8 intergenic 
rs12635253 3 67237603 1.00 2.98E-05 0.5 0.29 0.7 intergenic 
rs9844493 3 67261017 1.00 2.23E-05 0.4 0.29 0.7 intergenic 
rs13067571 3 67263927 0.99 1.35E-05 0.3 0.35 0.8 intergenic 
rs4857009 3 67267448 1.00 2.39E-05 0.4 0.39 0.8 intergenic 
rs138167890 3 79572545 0.71 1.30E-05 0.3 NA NA ROBO1 
rs111317410 3 79596496 0.71 1.67E-05 0.4 NA NA ROBO1 
rs113065987 3 79616504 0.71 1.72E-05 0.4 NA NA ROBO1 
rs112777194 3 79861124 0.71 1.82E-05 0.4 NA NA intergenic 
rs113597039 3 79873473 0.70 1.51E-05 0.3 NA NA intergenic 
rs139966448 3 79938342 0.70 1.45E-05 0.3 NA NA intergenic 
rs185680021 3 80011168 0.56 1.67E-05 0.4 NA NA intergenic 
rs188263218 3 80031296 0.63 3.96E-05 0.5 NA NA intergenic 
rs149144768 3 80065406 0.70 1.14E-05 0.3 NA NA intergenic 
rs190250423 3 96339264 0.48 1.75E-05 0.4 0.50 0.9 intergenic 
rs74686325 3 107151825 0.86 2.76E-05 0.4 0.26 0.7 intergenic 
rs8177279 3 133485366 0.83 4.45E-05 0.5 NA NA TF 
rs147453475 3 141554677 0.83 2.08E-05 0.4 NA NA intergenic 
rs73149932 3 147209249 0.83 8.39E-07 0.2 0.39 0.8 intergenic 
rs73149934 3 147209715 0.82 6.23E-07 0.1 0.53 0.9 intergenic 
rs183486479 3 148499451 0.52 5.44E-06 0.2 0.63 1.0 intergenic 
rs78046234 3 149328575 0.69 3.74E-05 0.5 0.31 0.8 WWTR1 
rs186341850 3 153682165 0.65 3.95E-05 0.5 0.58 1.0 intergenic 
rs150268941 3 172575312 0.91 1.39E-08 0.1 0.20 0.6 intergenic 
rs150327282 3 175334707 0.88 2.29E-06 0.2 NA NA NAALADL2 
rs143156290 3 175367776 0.92 2.01E-06 0.2 NA NA NAALADL2 
rs190711641 3 175376010 0.93 1.82E-06 0.2 NA NA NAALADL2 
rs114114549 3 175392668 0.91 1.70E-06 0.2 0.77 1.0 NAALADL2 
rs16826149 3 175402695 0.97 2.50E-05 0.4 0.96 1.0 NAALADL2 
rs142645748 3 175451990 0.93 3.80E-07 0.1 NA NA NAALADL2 
rs6776133 3 175458526 0.99 1.90E-06 0.2 0.96 1.0 NAALADL2 
rs74201644 3 175459872 0.99 2.69E-06 0.2 1.00 1.0 NAALADL2 
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rs9857587 3 175463441 0.99 2.64E-06 0.2 0.98 1.0 NAALADL2 
rs7609843 3 175485960 0.98 2.38E-06 0.2 0.98 1.0 NAALADL2 
rs139426341 3 175503655 0.55 1.24E-05 0.3 0.39 0.8 NAALADL2 
rs183579266 3 178477833 0.55 9.41E-07 0.2 0.29 0.7 KCNMB2 
rs73185354 3 178673972 0.89 2.25E-05 0.4 0.87 1.0 intergenic 
rs114261362 3 178676706 0.89 2.23E-05 0.4 0.87 1.0 intergenic 
rs73185398 3 178722033 0.89 3.41E-05 0.5 0.80 1.0 intergenic 
rs73185401 3 178723562 0.89 3.35E-05 0.5 0.80 1.0 intergenic 
rs2268844 3 185920603 1.00 1.24E-05 0.3 0.48 0.9 DGKG 
rs189732250 3 192855932 0.73 2.18E-05 0.4 NA NA intergenic 
rs4689549 4 6776649 1.00 1.50E-05 0.3 0.64 1.0 intergenic 
rs2324647 4 25040739 1.00 3.70E-05 0.5 0.82 1.0 intergenic 
rs2324648 4 25041054 1.00 4.14E-05 0.5 0.82 1.0 intergenic 
rs113600173 4 58649957 0.85 8.47E-06 0.3 0.05 0.6 intergenic 
rs186460260 4 61621339 0.93 3.31E-05 0.5 NA NA intergenic 
rs151098570 4 61660503 0.94 4.11E-05 0.5 NA NA intergenic 
rs190727238 4 61701164 0.94 4.55E-06 0.2 NA NA intergenic 
rs140667745 4 88451921 0.81 2.99E-05 0.5 0.63 1.0 intergenic 
rs7657524 4 88742562 0.89 3.61E-05 0.5 0.55 0.9 intergenic 
rs265070 4 96401647 1.00 4.53E-05 0.5 0.14 0.6 UNC5C 
rs116306628 4 114327260 0.82 3.90E-05 0.5 0.97 1.0 intergenic 
rs145313326 4 136556300 0.83 2.05E-05 0.4 NA NA intergenic 
rs72687317 4 158224381 0.80 7.49E-06 0.3 0.63 1.0 GRIA2 
rs72689009 4 158427649 0.90 5.49E-06 0.2 0.45 0.9 intergenic 
rs114397078 4 176431598 0.70 3.92E-05 0.5 0.27 0.7 intergenic 
rs116122755 4 183267177 0.81 9.60E-06 0.3 0.84 1.0 ODZ3 
rs6823293 4 188314906 0.92 2.10E-05 0.4 0.03 0.6 LOC339975 
rs78616487 4 188322087 0.96 1.84E-05 0.4 0.05 0.6 LOC339975 
rs11943588 4 188322659 0.94 1.20E-05 0.3 0.06 0.6 LOC339975 
rs116134219 4 188326029 0.96 1.03E-05 0.3 0.05 0.6 LOC339975 
rs113165089 4 188327733 0.95 1.13E-05 0.3 0.06 0.6 LOC339975 
rs112232951 4 188329318 0.96 1.09E-05 0.3 0.05 0.6 LOC339975 
rs76911486 4 188333134 0.96 2.34E-05 0.4 0.07 0.6 LOC339975 
rs75828282 4 188333577 0.96 2.40E-05 0.4 0.07 0.6 LOC339975 
rs78465996 4 188338304 0.96 1.40E-05 0.3 0.07 0.6 LOC339975 
rs113266307 4 188338566 0.96 1.39E-05 0.3 0.07 0.6 LOC339975 
rs11933754 4 188339771 0.96 1.38E-05 0.3 0.08 0.6 LOC339975 
rs11935240 4 188341193 0.96 1.42E-05 0.3 0.07 0.6 LOC339975 
rs144115853 4 188341998 0.96 1.31E-05 0.3 0.08 0.6 LOC339975 
rs77414185 4 188344450 0.97 1.29E-05 0.3 0.07 0.6 LOC339975 
rs77097179 4 188344799 0.97 1.39E-05 0.3 0.06 0.6 LOC339975 
rs75536828 4 188357518 1.00 8.23E-06 0.3 0.14 0.6 LOC339975 
rs57438669 4 188360032 0.99 4.02E-06 0.2 0.08 0.6 LOC339975 
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rs76655731 4 188360163 1.00 8.30E-06 0.3 0.09 0.6 LOC339975 
rs74464601 4 188360229 1.00 6.02E-06 0.2 0.09 0.6 LOC339975 
rs11931480 4 188362893 1.00 6.15E-06 0.2 0.09 0.6 LOC339975 
rs77547664 4 188371961 0.99 4.61E-06 0.2 0.07 0.6 LOC339975 
rs76656386 4 188375913 0.99 6.19E-06 0.2 0.07 0.6 LOC339975 
rs76446531 4 188379086 0.99 6.20E-06 0.2 0.07 0.6 LOC339975 
rs75496321 4 188381891 0.99 4.82E-06 0.2 0.07 0.6 LOC339975 
rs112168621 4 188383350 0.99 6.62E-06 0.2 0.06 0.6 LOC339975 
rs77667574 4 188391705 1.00 5.40E-06 0.2 0.08 0.6 LOC339975 
rs4862808 4 188398633 1.00 8.28E-06 0.3 0.08 0.6 LOC339975 
rs4862809 4 188398663 1.00 1.14E-05 0.3 0.10 0.6 LOC339975 
rs76307063 4 188398832 1.00 4.77E-06 0.2 0.08 0.6 LOC339975 
rs79440070 4 188399004 1.00 4.75E-06 0.2 0.08 0.6 LOC339975 
rs13133236 4 188399321 1.00 8.13E-06 0.3 0.08 0.6 LOC339975 
rs13133469 4 188399430 1.00 8.11E-06 0.3 0.08 0.6 LOC339975 
rs4862812 4 188400337 1.00 7.96E-06 0.3 0.08 0.6 LOC339975 
rs4862813 4 188400742 1.00 8.00E-06 0.3 0.08 0.6 LOC339975 
rs79071854 4 188403196 1.00 3.89E-06 0.2 0.09 0.6 LOC339975 
rs112858899 4 188408330 1.00 3.24E-06 0.2 0.09 0.6 LOC339975 
rs143715208 4 188409336 1.00 3.23E-06 0.2 0.09 0.6 LOC339975 
rs147704297 4 188409464 1.00 3.23E-06 0.2 0.09 0.6 LOC339975 
rs113574664 4 188411134 1.00 3.20E-06 0.2 0.09 0.6 LOC339975 
rs113237987 4 188411190 1.00 3.20E-06 0.2 0.09 0.6 LOC339975 
rs111557585 4 188411234 1.00 3.21E-06 0.2 0.07 0.6 LOC339975 
rs116733741 4 188411375 1.00 3.20E-06 0.2 0.07 0.6 LOC339975 
rs75061382 4 188412397 1.00 3.19E-06 0.2 0.07 0.6 LOC339975 
rs76107485 4 188414534 1.00 3.17E-06 0.2 0.07 0.6 LOC339975 
rs77477912 4 188416674 1.00 3.16E-06 0.2 0.09 0.6 LOC339975 
rs77867835 4 188417458 1.00 3.16E-06 0.2 0.09 0.6 LOC339975 
rs111755541 4 188419930 1.00 3.16E-06 0.2 0.09 0.6 LOC339975 
rs1367555 4 188420909 1.00 5.54E-06 0.2 0.07 0.6 LOC339975 
rs77692574 4 188421215 1.00 3.16E-06 0.2 0.09 0.6 LOC339975 
rs10001779 4 188423355 1.00 5.54E-06 0.2 0.07 0.6 LOC339975 
rs9996952 4 188424578 1.00 7.97E-06 0.3 0.06 0.6 LOC339975 
rs112048494 4 188425380 1.00 3.50E-06 0.2 0.08 0.6 LOC339975 
rs11726136 4 188426585 0.96 1.05E-06 0.2 0.09 0.6 LOC339975 
rs6841040 4 188426755 0.94 3.17E-06 0.2 0.07 0.6 LOC339975 
rs61300960 4 188428337 0.99 5.99E-06 0.2 0.06 0.6 intergenic 
rs75525298 4 188428338 0.99 4.00E-06 0.2 0.09 0.6 intergenic 
rs10026638 4 188429196 0.97 2.50E-06 0.2 0.13 0.6 intergenic 
rs11736878 4 188431095 0.97 1.21E-06 0.2 0.14 0.6 intergenic 
rs10032833 4 188431411 0.97 1.73E-06 0.2 0.11 0.6 intergenic 
rs11929993 4 188432233 0.96 3.36E-05 0.5 0.22 0.7 intergenic 
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rs11930080 4 188432452 0.99 8.22E-06 0.3 0.07 0.6 intergenic 
rs9996885 4 188433623 0.99 5.88E-06 0.2 0.07 0.6 intergenic 
rs28475332 4 188434677 0.96 1.91E-06 0.2 0.10 0.6 intergenic 
rs28579034 4 188434935 0.96 2.80E-06 0.2 0.12 0.6 intergenic 
rs77598188 4 188435868 0.98 4.34E-06 0.2 0.09 0.6 intergenic 
rs145889915 4 188442359 0.97 4.80E-06 0.2 0.09 0.6 intergenic 
rs28876409 4 188443338 0.96 8.20E-06 0.3 0.07 0.6 intergenic 
rs112567828 4 188443982 0.96 6.18E-06 0.2 0.07 0.6 intergenic 
rs145753563 4 188445993 0.94 8.52E-06 0.3 0.07 0.6 intergenic 
rs140865211 5 1486075 0.72 2.41E-05 0.4 0.25 0.7 LPCAT1 
rs186220053 5 65346295 0.68 1.21E-05 0.3 0.55 0.9 ERBB2IP 
rs1561398 5 71486785 1.00 2.81E-05 0.4 0.51 0.9 MAP1B 
rs10077261 5 77880332 0.91 2.85E-05 0.5 0.85 1.0 LHFPL2 
rs10474560 5 77880436 0.91 2.84E-05 0.5 0.86 1.0 LHFPL2 
rs9293756 5 77918136 1.00 2.31E-05 0.4 0.37 0.8 LHFPL2 
rs6868848 5 77928880 0.90 1.88E-05 0.4 0.12 0.6 LHFPL2 
rs6868849 5 77928881 0.90 1.74E-05 0.4 0.11 0.6 LHFPL2 
rs61757417 5 142816370 0.90 1.92E-05 0.4 0.64 1.0 NR3C1 
rs2546694 5 168960626 0.58 6.42E-06 0.2 0.15 0.6 intergenic 
rs150080552 5 175673833 0.86 2.31E-05 0.4 0.63 1.0 C5orf25 
rs140024910 5 175677335 0.87 1.80E-05 0.4 0.68 1.0 C5orf25 
rs75753052 5 175680389 0.87 1.18E-05 0.3 0.69 1.0 C5orf25 
rs6863942 5 175682713 0.88 1.52E-05 0.3 0.70 1.0 C5orf25 
rs56145408 5 175684714 0.88 1.47E-05 0.3 0.76 1.0 C5orf25 
rs148614682 5 175687581 0.89 2.20E-05 0.4 0.78 1.0 C5orf25 
rs189483775 5 175688102 0.89 1.49E-05 0.3 0.87 1.0 C5orf25 
rs7736390 5 175691922 0.89 1.49E-05 0.3 0.86 1.0 C5orf25 
rs113708040 5 175699526 0.91 2.37E-05 0.4 0.96 1.0 C5orf25 
rs150930492 5 175704361 0.80 3.11E-05 0.5 0.21 0.7 C5orf25 
rs71599477 5 175704389 0.80 7.62E-07 0.2 0.63 1.0 C5orf25 
rs140753856 5 175704589 0.90 1.60E-05 0.4 0.93 1.0 C5orf25 
rs140351658 5 175706000 0.90 1.24E-05 0.3 0.89 1.0 C5orf25 
rs149533417 5 175706083 0.90 1.60E-05 0.4 0.89 1.0 C5orf25 
rs141966194 5 175707578 0.89 2.42E-05 0.4 0.84 1.0 C5orf25 
rs142491407 5 175715202 0.91 2.08E-05 0.4 0.83 1.0 C5orf25 
rs56164224 5 175719092 0.94 3.76E-05 0.5 0.96 1.0 C5orf25 
rs6860403 5 175734589 0.99 4.44E-05 0.5 0.91 1.0 C5orf25 
rs66505320 5 175737851 0.99 4.44E-05 0.5 0.91 1.0 C5orf25 
rs66532964 5 175793171 0.98 4.48E-05 0.5 0.87 1.0 ARL10 
rs67175907 5 175795653 0.96 4.30E-05 0.5 0.83 1.0 ARL10 
rs78999839 6 1531294 0.88 3.94E-06 0.2 NA NA intergenic 
rs114403119 6 1532809 0.89 5.95E-06 0.2 NA NA intergenic 
rs141397728 6 1533251 0.88 3.90E-06 0.2 NA NA intergenic 
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rs77034495 6 1548032 0.88 1.17E-05 0.3 NA NA intergenic 
rs76107504 6 14252112 0.62 8.54E-06 0.3 0.36 0.8 intergenic 
rs145978565 6 14324540 0.60 3.88E-05 0.5 NA NA intergenic 
rs62398911 6 20506272 0.80 3.11E-05 0.5 0.42 0.9 intergenic 
rs1737236 6 22350806 1.00 3.06E-05 0.5 0.16 0.6 intergenic 
rs1737235 6 22351177 1.00 3.06E-05 0.5 0.16 0.6 intergenic 
rs1772075 6 22351325 1.00 2.93E-05 0.5 0.16 0.6 intergenic 
rs1737232 6 22351919 1.00 3.46E-05 0.5 0.16 0.6 intergenic 
rs1737231 6 22352142 1.00 3.84E-05 0.5 0.16 0.6 intergenic 
rs1737230 6 22352366 1.00 3.62E-05 0.5 0.16 0.6 intergenic 
rs1737229 6 22352455 1.00 3.62E-05 0.5 0.16 0.6 intergenic 
rs1737225 6 22353202 1.00 3.62E-05 0.5 0.16 0.6 intergenic 
rs1629125 6 22353431 1.00 3.62E-05 0.5 0.16 0.6 intergenic 
rs1772077 6 22353749 1.00 3.62E-05 0.5 0.16 0.6 intergenic 
rs1772078 6 22353844 1.00 3.64E-05 0.5 0.16 0.6 intergenic 
rs1772079 6 22354105 1.00 3.63E-05 0.5 0.16 0.6 intergenic 
rs1772080 6 22354220 1.00 3.64E-05 0.5 0.16 0.6 intergenic 
rs1772081 6 22354351 1.00 3.64E-05 0.5 0.16 0.6 intergenic 
rs1772082 6 22354566 1.00 3.64E-05 0.5 0.16 0.6 intergenic 
rs1737224 6 22355309 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1772083 6 22355537 1.00 2.51E-06 0.2 0.20 0.6 intergenic 
rs1772084 6 22355624 0.99 4.31E-06 0.2 0.17 0.6 intergenic 
rs1772085 6 22355889 0.97 3.07E-05 0.5 0.28 0.7 intergenic 
rs1737223 6 22355948 0.98 8.23E-06 0.3 0.23 0.7 intergenic 
rs9366446 6 22356438 0.98 2.23E-06 0.2 0.15 0.6 intergenic 
rs9379384 6 22356478 0.97 8.44E-07 0.2 0.19 0.6 intergenic 
rs66815324 6 22356528 0.97 2.24E-06 0.2 0.37 0.8 intergenic 
rs113931720 6 22356614 0.99 2.73E-06 0.2 0.26 0.7 intergenic 
rs111776589 6 22356621 0.96 1.67E-05 0.4 0.35 0.8 intergenic 
rs113397700 6 22356664 0.98 1.61E-06 0.2 0.22 0.7 intergenic 
rs111410562 6 22356677 0.97 7.41E-06 0.3 0.12 0.6 intergenic 
rs78526335 6 22356703 0.93 2.40E-05 0.4 0.69 1.0 intergenic 
rs73393321 6 22356753 0.97 3.41E-06 0.2 0.46 0.9 intergenic 
rs1205944 6 22356823 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1205943 6 22356914 1.00 2.50E-06 0.2 0.21 0.7 intergenic 
rs34183148 6 22356970 0.95 1.67E-05 0.4 0.36 0.8 intergenic 
rs35363281 6 22356972 0.94 1.14E-05 0.3 0.29 0.7 intergenic 
rs35097027 6 22356983 0.94 7.34E-06 0.3 0.40 0.8 intergenic 
rs35519411 6 22356987 0.95 1.06E-05 0.3 0.36 0.8 intergenic 
rs1205942 6 22357011 0.95 1.06E-05 0.3 0.36 0.8 intergenic 
rs1205941 6 22357033 0.95 4.06E-05 0.5 0.33 0.8 intergenic 
rs1205940 6 22357113 0.98 1.06E-05 0.3 0.26 0.7 intergenic 
rs1205939 6 22357130 0.99 2.03E-06 0.2 0.18 0.6 intergenic 
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rs1205938 6 22357296 1.00 2.47E-06 0.2 0.19 0.6 intergenic 
rs1318602 6 22357342 1.00 2.42E-06 0.2 0.21 0.6 intergenic 
rs1318601 6 22357345 1.00 2.47E-06 0.2 0.19 0.6 intergenic 
rs1205937 6 22357993 1.00 2.88E-06 0.2 0.16 0.6 intergenic 
rs1205936 6 22358116 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1205935 6 22358129 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1205934 6 22358196 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1205933 6 22358361 1.00 2.48E-06 0.2 0.19 0.6 intergenic 
rs1205932 6 22358391 1.00 2.48E-06 0.2 0.18 0.6 intergenic 
rs1205931 6 22358551 1.00 2.43E-06 0.2 0.21 0.6 intergenic 
rs1205930 6 22359007 1.00 2.88E-06 0.2 0.16 0.6 intergenic 
rs1205929 6 22359126 1.00 2.64E-06 0.2 0.19 0.6 intergenic 
rs1205928 6 22359465 1.00 3.00E-06 0.2 0.16 0.6 intergenic 
rs1205927 6 22359577 1.00 2.43E-06 0.2 0.19 0.6 intergenic 
rs1205926 6 22359759 1.00 2.43E-06 0.2 0.19 0.6 intergenic 
rs714589 6 22359969 1.00 1.82E-06 0.2 0.20 0.6 intergenic 
rs714590 6 22360029 1.00 2.43E-06 0.2 0.19 0.6 intergenic 
rs714591 6 22360046 1.00 2.43E-06 0.2 0.19 0.6 intergenic 
rs1008200 6 22360741 1.00 2.35E-06 0.2 0.18 0.6 intergenic 
rs1205925 6 22361476 1.00 2.85E-06 0.2 0.21 0.7 intergenic 
rs1205924 6 22361929 1.00 2.83E-06 0.2 0.16 0.6 intergenic 
rs1205923 6 22362760 1.00 2.43E-06 0.2 0.15 0.6 intergenic 
rs1205921 6 22364446 1.00 1.92E-06 0.2 0.20 0.6 intergenic 
rs1205919 6 22365242 1.00 1.44E-06 0.2 0.15 0.6 intergenic 
rs1205916 6 22367062 1.00 1.34E-06 0.2 0.16 0.6 intergenic 
rs1205913 6 22371494 0.99 2.35E-06 0.2 0.13 0.6 intergenic 
rs1100578 6 22371990 0.99 1.20E-06 0.2 0.18 0.6 intergenic 
rs1100576 6 22373216 0.98 2.04E-06 0.2 0.11 0.6 intergenic 
rs1100575 6 22373710 0.97 2.41E-06 0.2 0.11 0.6 intergenic 
rs1100583 6 22375081 0.97 2.20E-06 0.2 0.11 0.6 intergenic 
rs138132573 6 32978261 1.00 3.58E-06 0.2 NA NA HLA-DOA 
rs146683088 6 32984983 1.00 3.57E-06 0.2 NA NA intergenic 
rs150406963 6 32989951 0.99 3.57E-06 0.2 NA NA intergenic 
rs114104288 6 32997592 0.99 4.11E-06 0.2 NA NA intergenic 
rs181275409 6 32999504 0.99 3.74E-06 0.2 NA NA intergenic 
rs181330926 6 33004097 1.00 3.58E-06 0.2 NA NA intergenic 
rs115338659 6 33004745 0.98 8.99E-06 0.3 NA NA intergenic 
rs150480104 6 33005434 1.00 3.73E-06 0.2 NA NA intergenic 
rs188001307 6 33008064 1.00 3.58E-06 0.2 NA NA intergenic 
rs116519378 6 33017238 0.99 1.83E-06 0.2 NA NA intergenic 
rs116832467 6 33017950 1.00 2.20E-06 0.2 NA NA intergenic 
rs143148648 6 49908506 0.85 2.25E-05 0.4 0.85 1.0 intergenic 
rs239777 6 54830038 0.78 3.73E-05 0.5 0.05 0.6 intergenic 
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rs12209224 6 77030438 0.81 4.47E-05 0.5 0.31 0.8 intergenic 
rs2485801 6 93585436 1.00 3.89E-05 0.5 0.51 0.9 intergenic 
rs2138340 6 93586078 1.00 3.76E-05 0.5 0.51 0.9 intergenic 
rs2506909 6 93597512 1.00 3.55E-05 0.5 0.51 0.9 intergenic 
rs1572632 6 93598512 1.00 3.54E-05 0.5 0.51 0.9 intergenic 
rs16870432 6 93638655 0.90 2.46E-05 0.4 0.96 1.0 intergenic 
rs188106941 6 104905706 0.94 1.44E-05 0.3 0.90 1.0 intergenic 
rs111329411 6 114611601 0.70 3.68E-05 0.5 0.44 0.9 intergenic 
rs2356078 6 118567605 1.00 3.12E-05 0.5 0.95 1.0 SLC35F1 
rs281871 6 118571414 1.00 3.12E-05 0.5 0.95 1.0 SLC35F1 
rs1387918 6 129663271 1.00 3.96E-05 0.5 0.90 1.0 LAMA2 
rs7766742 6 129666380 1.00 1.67E-05 0.4 0.95 1.0 LAMA2 
rs9398900 6 129669931 1.00 1.56E-05 0.4 0.99 1.0 LAMA2 
rs13193413 6 129677895 0.95 4.21E-05 0.5 0.99 1.0 LAMA2 
rs9372926 6 129684622 0.99 2.29E-05 0.4 0.88 1.0 LAMA2 
rs63196263 6 129687026 0.99 2.47E-05 0.4 0.95 1.0 LAMA2 
rs13194587 6 129694064 0.98 2.01E-05 0.4 0.84 1.0 LAMA2 
rs4298368 6 129694961 0.97 2.25E-05 0.4 0.92 1.0 LAMA2 
rs9388700 6 129697797 0.98 2.82E-05 0.4 0.83 1.0 LAMA2 
rs79898774 6 137477313 0.57 3.72E-06 0.2 0.92 1.0 IL22RA2 
rs6923972 6 138909661 0.99 3.95E-05 0.5 0.65 1.0 intergenic 
rs75350744 6 143647820 0.94 3.21E-05 0.5 0.63 1.0 AIG1 
rs77919378 6 143655982 0.94 2.22E-05 0.4 0.67 1.0 AIG1 
rs78754824 6 143657178 0.94 2.23E-05 0.4 0.67 1.0 AIG1 
rs76184032 6 143662887 0.89 4.14E-05 0.5 0.77 1.0 intergenic 
rs6930238 6 145228890 0.99 4.21E-05 0.5 0.43 0.9 intergenic 
rs75556273 6 147688190 1.00 4.21E-05 0.5 0.47 0.9 STXBP5 
rs73787171 6 147689457 1.00 4.18E-05 0.5 0.42 0.9 STXBP5 
rs117826317 6 147691033 1.00 4.21E-05 0.5 0.47 0.9 STXBP5 
rs117646839 6 147694579 1.00 4.21E-05 0.5 0.47 0.9 STXBP5 
rs79806067 6 147695718 0.94 1.59E-05 0.4 0.55 0.9 STXBP5 
rs78647861 6 147695746 1.00 4.21E-05 0.5 0.47 0.9 STXBP5 
rs9497762 6 147696197 1.00 4.18E-05 0.5 0.43 0.9 STXBP5 
rs1034245 6 147706791 1.00 4.19E-05 0.5 0.43 0.9 STXBP5 
rs12194637 6 151263284 0.94 2.62E-05 0.4 0.06 0.6 MTHFD1L 
rs803448 6 151264132 0.98 4.48E-05 0.5 0.05 0.6 MTHFD1L 
rs45619636 6 166823764 0.62 5.75E-07 0.1 0.66 1.0 RPS6KA2 
rs145686314 7 1386960 0.60 3.39E-05 0.5 0.49 0.9 intergenic 
rs113147352 7 1637024 0.57 3.19E-06 0.2 0.53 0.9 intergenic 
rs143614258 7 1696933 0.60 2.23E-05 0.4 NA NA intergenic 
rs118120700 7 5721117 0.68 7.42E-06 0.3 0.79 1.0 RNF216 
rs116997033 7 5837618 0.62 3.60E-05 0.5 0.91 1.0 intergenic 
rs145944844 7 9386123 0.78 1.94E-05 0.4 0.91 1.0 intergenic 
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rs9769459 7 47786445 1.00 1.09E-05 0.3 0.93 1.0 intergenic 
rs62457904 7 55580097 0.93 1.56E-05 0.4 NA NA VOPP1 
rs149460737 7 113494910 0.94 2.26E-05 0.4 0.58 0.9 intergenic 
rs138373005 7 113607020 0.99 3.72E-05 0.5 0.93 1.0 intergenic 
rs144790732 7 118685098 0.39 1.22E-05 0.3 0.58 1.0 intergenic 
rs2170478 8 3464175 0.99 1.07E-05 0.3 0.06 0.6 CSMD1 
rs2469338 8 3466917 1.00 1.84E-05 0.4 0.03 0.6 CSMD1 
rs2469334 8 3467396 0.82 1.04E-05 0.3 0.14 0.6 CSMD1 
rs2469331 8 3467762 0.99 1.67E-05 0.4 0.03 0.6 CSMD1 
rs2469329 8 3468180 1.00 2.68E-05 0.4 0.04 0.6 CSMD1 
rs1121619 8 3469700 0.99 2.67E-05 0.4 0.04 0.6 CSMD1 
rs72639918 8 36200105 0.88 3.64E-05 0.5 0.08 0.6 intergenic 
rs143420877 8 51696312 0.85 3.02E-05 0.5 0.76 1.0 SNTG1 
rs72645876 8 51720873 0.88 4.04E-05 0.5 0.84 1.0 intergenic 
rs149203983 8 51727143 0.88 4.15E-05 0.5 0.85 1.0 intergenic 
rs10087464 8 51763094 0.99 4.18E-05 0.5 0.69 1.0 intergenic 
rs7846269 8 51831461 0.96 3.39E-05 0.5 0.80 1.0 intergenic 
rs117535834 8 76073376 0.60 4.27E-05 0.5 0.57 0.9 intergenic 
rs557807 8 90615624 0.99 2.76E-05 0.4 0.63 1.0 intergenic 
rs79048468 8 137895174 0.89 1.74E-07 0.1 0.53 0.9 intergenic 
rs117687198 8 137907672 0.90 6.78E-08 0.1 0.40 0.8 intergenic 
rs148161159 8 137910630 0.89 1.27E-05 0.3 0.09 0.6 intergenic 
rs75683128 8 142506570 0.37 1.70E-05 0.4 0.53 0.9 FLJ43860 
rs149489509 8 144360947 0.53 2.17E-05 0.4 0.06 0.6 intergenic 
rs3750416 9 2054380 0.96 5.72E-06 0.2 0.78 1.0 SMARCA2 
rs79825622 9 2058984 0.97 4.16E-06 0.2 0.76 1.0 SMARCA2 
rs113524072 9 2069929 0.99 1.05E-05 0.3 NA NA SMARCA2 
rs78301395 9 2071686 0.99 1.12E-05 0.3 NA NA SMARCA2 
rs12342240 9 2074021 0.98 7.42E-06 0.3 0.53 0.9 SMARCA2 
rs17471283 9 2271886 0.81 3.72E-05 0.5 0.76 1.0 intergenic 
rs2589305 9 23558910 0.80 1.43E-06 0.2 0.30 0.7 intergenic 
rs12380156 9 28007018 1.00 1.18E-05 0.3 0.58 0.9 LINGO2 
rs10968272 9 28007239 1.00 1.18E-05 0.3 0.57 0.9 LINGO2 
rs10968273 9 28007813 1.00 1.18E-05 0.3 0.58 0.9 LINGO2 
rs79144456 9 28008378 1.00 1.18E-05 0.3 0.58 1.0 LINGO2 
rs117562410 9 28008569 1.00 1.18E-05 0.3 0.58 1.0 LINGO2 
rs182385046 9 70993692 0.43 1.09E-05 0.3 0.27 0.7 PGM5 
rs138328727 9 75953590 0.76 1.84E-05 0.4 0.43 0.9 intergenic 
rs142071081 9 76024441 0.75 3.58E-05 0.5 0.75 1.0 intergenic 
rs182666170 9 98325920 0.65 1.64E-05 0.4 NA NA intergenic 
rs138160086 9 118602789 0.96 4.44E-05 0.5 0.76 1.0 intergenic 
rs139178463 9 121440368 0.93 1.47E-05 0.3 0.61 1.0 intergenic 
rs140651197 9 121440507 0.92 1.56E-05 0.4 0.88 1.0 intergenic 
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rs1335261 9 121453610 1.00 3.51E-05 0.5 0.83 1.0 intergenic 
rs7045014 9 136658734 0.77 3.24E-05 0.5 0.50 0.9 VAV2 
rs73553919 9 136659327 0.86 4.12E-05 0.5 0.50 0.9 VAV2 
rs59232037 9 136664901 0.90 4.12E-05 0.5 0.62 1.0 VAV2 
rs59158070 9 136665094 0.90 4.11E-05 0.5 0.62 1.0 VAV2 
rs73663847 9 136666574 0.90 3.94E-05 0.5 0.62 1.0 VAV2 
rs1548380 9 136668393 0.91 3.80E-05 0.5 0.62 1.0 VAV2 
rs56035119 9 136671469 0.94 2.77E-05 0.4 0.49 0.9 VAV2 
rs55940550 9 136672358 0.92 3.46E-05 0.5 0.70 1.0 VAV2 
rs28578536 9 136673248 0.94 2.61E-05 0.4 0.50 0.9 VAV2 
rs7042276 9 136675739 0.95 2.58E-05 0.4 0.51 0.9 VAV2 
rs2077392 9 136679457 0.96 2.84E-05 0.5 0.55 0.9 VAV2 
rs7047672 9 136679921 1.00 2.54E-05 0.4 0.56 0.9 VAV2 
rs78132252 10 70984526 0.72 1.48E-05 0.3 0.03 0.6 HKDC1 
rs189208264 10 76878339 0.55 1.96E-05 0.4 0.71 1.0 SAMD8 
rs2670223 10 80127055 0.96 4.12E-05 0.5 0.26 0.7 intergenic 
rs150976965 10 81525997 0.56 2.12E-05 0.4 0.85 1.0 intergenic 
rs191720898 10 100860117 0.80 1.40E-05 0.3 NA NA HPSE2 
rs12784542 10 102769710 0.95 3.13E-05 0.5 0.06 0.6 PDZD7 
rs10509835 10 109205283 0.98 4.51E-05 0.5 0.28 0.7 intergenic 
rs147541483 10 109628602 0.44 2.03E-05 0.4 0.24 0.7 intergenic 
rs2420781 10 122370247 0.92 4.08E-05 0.5 0.63 1.0 intergenic 
rs150067672 10 123915941 0.71 1.51E-05 0.3 0.83 1.0 TACC2 
rs76537500 10 130053296 0.78 2.52E-05 0.4 0.81 1.0 intergenic 
rs11597322 10 131492126 0.99 2.59E-05 0.4 0.74 1.0 MGMT 
rs4751111 10 131502995 1.00 9.56E-06 0.3 0.55 0.9 MGMT 
rs11815846 10 131504196 1.00 8.34E-06 0.3 0.90 1.0 MGMT 
rs11016884 10 131504495 1.00 4.92E-06 0.2 0.78 1.0 MGMT 
rs78037285 10 134367856 0.86 3.72E-05 0.5 0.78 1.0 INPP5A 
rs141710236 10 134400013 0.85 3.81E-05 0.5 0.90 1.0 INPP5A 
rs149345061 10 134447849 0.82 1.42E-05 0.3 0.89 1.0 INPP5A 
rs150499775 10 134495006 0.70 4.25E-05 0.5 0.79 1.0 INPP5A 
rs117644802 10 134498721 0.69 3.56E-05 0.5 0.79 1.0 INPP5A 
rs114202853 10 134517256 0.75 1.28E-05 0.3 0.46 0.9 INPP5A 
rs61873115 11 2318964 0.75 4.28E-05 0.5 0.36 0.8 C11orf21 
rs4929975 11 2319303 0.75 4.29E-05 0.5 0.37 0.8 C11orf21 
rs71488794 11 21841125 0.59 3.35E-05 0.5 NA NA intergenic 
rs188553612 11 22050642 0.56 3.99E-05 0.5 0.63 1.0 intergenic 
rs117023318 11 22240250 0.60 3.93E-05 0.5 0.90 1.0 ANO5 
rs72882668 11 31062562 0.64 2.25E-06 0.2 NA NA LOC1005087
36 rs72888131 11 31286032 0.89 5.52E-06 0.2 NA NA DCDC1 
rs149522059 11 36980477 0.61 1.37E-05 0.3 0.78 1.0 intergenic 
rs117496632 11 36983355 0.62 1.79E-05 0.4 0.47 0.9 intergenic 
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rs145100044 11 67569004 0.59 3.34E-05 0.5 0.59 1.0 FAM86C2P 
rs76380214 11 68149280 0.70 3.97E-06 0.2 0.95 1.0 LRP5 
rs141570922 11 68244370 0.89 3.86E-06 0.2 0.56 0.9 PPP6R3 
rs181741343 11 68245257 0.91 6.11E-06 0.2 0.59 1.0 PPP6R3 
rs185193806 11 68404877 0.66 7.61E-06 0.3 0.93 1.0 intergenic 
rs191238062 11 109396279 0.54 3.55E-05 0.5 0.70 1.0 intergenic 
rs11218131 11 120928722 1.00 4.42E-05 0.5 0.73 1.0 TBCEL 
rs78610152 11 129354006 0.89 1.24E-05 0.3 0.84 1.0 intergenic 
rs3019806 11 129374559 0.97 2.88E-05 0.5 0.71 1.0 intergenic 
rs7942352 11 129380953 0.94 1.35E-05 0.3 0.77 1.0 intergenic 
rs7941324 11 129384263 0.93 2.63E-05 0.4 0.62 1.0 intergenic 
rs113240933 11 132910459 0.63 3.93E-05 0.5 0.96 1.0 OPCML 
rs11047037 12 23825407 0.74 4.08E-05 0.5 0.98 1.0 SOX5 
rs17176610 12 65114763 1.00 6.13E-06 0.2 0.48 0.9 GNS 
rs79073680 12 65156596 0.96 1.03E-05 0.3 0.71 1.0 intergenic 
rs17764405 12 65202269 0.89 2.81E-05 0.4 0.50 0.9 intergenic 
rs17176841 12 65204874 0.95 3.48E-05 0.5 0.89 1.0 intergenic 
rs79280005 12 84181090 0.62 3.10E-05 0.5 0.89 1.0 intergenic 
rs73207068 12 88446859 0.73 9.23E-06 0.3 NA NA CEP290 
rs182110748 13 34484961 0.83 2.18E-05 0.4 NA NA RFC3 
rs75689743 13 34487594 0.83 2.20E-05 0.4 NA NA RFC3 
rs146733701 13 39814716 0.82 2.46E-05 0.4 NA NA intergenic 
rs111596958 13 69770858 0.99 3.92E-05 0.5 0.96 1.0 intergenic 
rs77304322 13 69772371 0.99 3.84E-05 0.5 0.96 1.0 intergenic 
rs117695261 13 74325506 0.57 1.16E-07 0.1 0.82 1.0 KLF12 
rs17377290 13 85167241 0.76 4.31E-05 0.5 0.06 0.6 intergenic 
rs146736842 13 85187435 0.81 3.84E-05 0.5 0.05 0.6 intergenic 
rs189306812 13 87150672 0.67 4.45E-05 0.5 0.25 0.7 intergenic 
rs76003828 13 88044777 0.85 8.30E-06 0.3 0.61 1.0 intergenic 
rs9513263 13 88051360 0.84 7.25E-06 0.3 0.84 1.0 intergenic 
rs149154304 13 92479378 0.79 6.59E-06 0.2 0.94 1.0 GPC5 
rs7982492 13 93543743 0.96 3.19E-05 0.5 0.15 0.6 intergenic 
rs113211811 13 106903793 0.88 3.03E-05 0.5 0.31 0.8 intergenic 
rs142025631 14 28311095 0.79 3.41E-05 0.5 NA NA intergenic 
rs72712459 14 65734600 0.97 2.08E-05 0.4 0.19 0.6 intergenic 
rs117727648 14 77100157 0.54 3.36E-08 0.1 0.89 1.0 intergenic 
rs192688395 14 77211718 0.55 2.70E-07 0.1 1.00 1.0 intergenic 
rs113653607 14 77641605 0.80 3.61E-07 0.1 0.39 0.8 intergenic 
rs142687658 14 77750946 0.94 1.47E-07 0.1 NA NA POMT2 
rs150915059 14 77755799 0.93 6.61E-07 0.2 NA NA POMT2 
rs150017190 14 77806492 0.94 3.47E-07 0.1 NA NA intergenic 
rs56198483 14 77828430 0.85 1.53E-07 0.1 0.08 0.6 TMED8 
rs115653266 14 77843222 0.78 3.91E-06 0.2 NA NA TMED8 
174 
 
A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs145730217 14 77940220 0.92 1.41E-06 0.2 NA NA intergenic 
rs142877874 14 77975928 0.88 2.62E-06 0.2 NA NA SPTLC2 
rs141530129 14 77994346 0.81 1.61E-05 0.4 NA NA SPTLC2 
rs139545749 14 78078188 0.91 2.99E-06 0.2 NA NA SPTLC2 
rs6574877 14 86695129 1.00 2.61E-05 0.4 0.01 0.6 intergenic 
rs1505173 14 86695795 1.00 2.67E-05 0.4 0.01 0.6 intergenic 
rs150334896 14 86696062 0.99 2.80E-05 0.4 0.01 0.55 intergenic 
rs187136545 14 86775771 0.64 7.63E-07 0.2 NA NA intergenic 
rs74919671 14 87140828 0.81 4.89E-06 0.2 0.15 0.6 intergenic 
rs17128291 14 92882826 1.00 1.17E-05 0.3 0.15 0.6 SLC24A4 
rs7158887 14 94241933 0.79 2.10E-05 0.4 1.00 1.0 PRIMA1 
rs35980137 14 94245799 0.86 9.77E-07 0.2 0.73 1.0 PRIMA1 
rs75051938 14 103459051 0.90 4.39E-05 0.5 0.56 0.9 CDC42BPB 
rs2269326 14 103476438 0.83 9.01E-06 0.3 0.50 0.9 CDC42BPB 
rs2285017 14 103484440 0.82 7.53E-06 0.3 0.52 0.9 CDC42BPB 
rs35485315 14 103503352 0.81 2.06E-05 0.4 0.42 0.9 CDC42BPB 
rs62010548 15 33946424 0.87 6.50E-06 0.2 0.18 0.6 RYR3 
rs7163100 15 33951138 0.98 2.33E-05 0.4 0.44 0.9 RYR3 
rs7178736 15 33951141 0.98 2.16E-05 0.4 0.38 0.8 RYR3 
rs28735770 15 33959197 0.96 1.83E-05 0.4 0.67 1.0 RYR3 
rs78828848 15 33968766 0.85 2.15E-06 0.2 0.03 0.6 RYR3 
rs4780153 15 33972420 1.00 1.69E-07 0.1 0.95 1.0 RYR3 
rs12907278 15 33973177 1.00 2.31E-06 0.2 0.65 1.0 RYR3 
rs2172855 15 33977340 0.98 1.58E-06 0.2 0.62 1.0 RYR3 
rs141657190 15 33977672 0.99 2.09E-06 0.2 0.65 1.0 RYR3 
rs11631255 15 33978895 0.99 5.02E-06 0.2 0.60 1.0 RYR3 
rs62012577 15 33979644 0.86 9.65E-06 0.3 0.21 0.7 RYR3 
rs28602988 15 33982726 0.99 3.53E-05 0.5 0.51 0.9 RYR3 
rs7169195 15 33983296 0.99 3.58E-05 0.5 0.51 0.9 RYR3 
rs2088143 15 33983545 0.99 4.14E-05 0.5 0.44 0.9 RYR3 
rs7174044 15 33983566 0.99 4.23E-05 0.5 0.46 0.9 RYR3 
rs1353348 15 33984848 1.00 3.19E-07 0.1 0.76 1.0 RYR3 
rs11632363 15 33984987 1.00 3.95E-06 0.2 0.63 1.0 RYR3 
rs12592542 15 33985818 1.00 3.89E-06 0.2 0.63 1.0 RYR3 
rs939432 15 33986294 0.99 2.42E-07 0.1 0.81 1.0 RYR3 
rs2076954 15 33987341 1.00 2.84E-06 0.2 0.85 1.0 RYR3 
rs2339298 15 33987505 0.99 3.50E-05 0.5 0.30 0.7 RYR3 
rs6495216 15 33994836 1.00 1.60E-05 0.4 0.67 1.0 RYR3 
rs11072621 15 33995495 1.00 2.37E-05 0.4 0.77 1.0 RYR3 
rs8040310 15 34005613 1.00 4.50E-05 0.5 0.93 1.0 RYR3 
rs118013228 15 50274508 0.89 3.43E-05 0.5 0.35 0.8 ATP8B4 
rs111511606 15 50346721 0.96 4.89E-06 0.2 0.37 0.8 ATP8B4 
rs113002981 15 50349114 0.99 8.01E-06 0.3 0.81 1.0 ATP8B4 
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rs72742523 15 79713106 0.60 3.77E-07 0.1 0.94 1.0 intergenic 
rs182003445 15 82246207 0.80 2.98E-05 0.5 0.25 0.7 intergenic 
rs113550094 15 84248208 0.83 4.44E-06 0.2 0.67 1.0 SH3GL3 
rs7183304 15 92420700 0.83 4.52E-07 0.1 0.79 1.0 SLCO3A1 
rs62029493 15 94313625 0.65 2.98E-05 0.5 0.48 0.9 intergenic 
rs547673 16 1113621 0.51 1.52E-05 0.3 0.27 0.7 intergenic 
rs562647 16 1117662 0.54 1.63E-05 0.4 0.13 0.6 LOC146336 
rs669264 16 1120645 0.54 4.38E-05 0.5 0.14 0.6 LOC146336 
rs77730974 16 11800685 0.82 3.50E-05 0.5 NA NA TXNDC11 
rs76512865 16 11924051 0.97 4.10E-05 0.5 0.76 1.0 intergenic 
rs7184515 16 12001447 1.00 4.53E-05 0.5 0.73 1.0 GSPT1 
rs13335494 16 12001772 0.98 2.84E-05 0.5 0.68 1.0 GSPT1 
rs4781162 16 12003035 1.00 4.52E-05 0.5 0.73 1.0 GSPT1 
rs28880613 16 12018374 0.96 4.20E-05 0.5 0.65 1.0 intergenic 
rs117060081 16 50245502 0.79 1.71E-05 0.4 0.91 1.0 PAPD5 
rs116988464 16 50355115 0.79 6.55E-06 0.2 0.58 1.0 BRD7 
rs8058581 16 66361269 0.86 2.41E-05 0.4 0.45 0.9 intergenic 
rs12599734 16 73451181 0.95 1.13E-05 0.3 0.21 0.7 LOC1005061
72 rs35614540 16 73458459 0.97 3.24E-06 0.2 0.25 0.7 intergenic 
rs35236088 16 73458610 0.97 3.15E-06 0.2 0.22 0.7 intergenic 
rs6564189 16 73460072 0.96 3.77E-05 0.5 0.22 0.7 intergenic 
rs141652736 16 82538255 0.82 5.67E-06 0.2 0.96 1.0 intergenic 
rs16954993 17 5616349 0.98 3.95E-05 0.5 0.02 0.6 intergenic 
rs11867305 17 5622186 0.98 3.74E-05 0.5 0.02 0.6 intergenic 
rs77142476 17 7032762 0.53 4.53E-05 0.5 0.93 1.0 intergenic 
rs141874876 17 36949890 0.70 4.30E-06 0.2 NA NA PIP4K2B 
rs111885856 17 50788068 0.68 1.62E-05 0.4 0.79 1.0 intergenic 
rs147319530 18 30888675 0.55 1.24E-05 0.3 NA NA C18orf34 
rs73470849 18 40174449 0.99 4.47E-05 0.5 0.67 1.0 LOC284260 
rs73470851 18 40174503 0.99 4.41E-05 0.5 0.67 1.0 LOC284260 
rs55868360 18 40174704 0.99 4.46E-05 0.5 0.67 1.0 LOC284260 
rs56300458 18 40174748 0.99 4.17E-05 0.5 0.67 1.0 LOC284260 
rs1594434 18 40174924 0.99 3.99E-05 0.5 0.67 1.0 LOC284260 
rs8088979 18 40176118 1.00 6.57E-06 0.2 0.82 1.0 LOC284260 
rs10048404 18 54578482 1.00 1.89E-05 0.4 0.68 1.0 WDR7 
rs117779952 18 56698860 0.91 3.51E-05 0.5 0.79 1.0 intergenic 
rs77201620 18 63158485 0.71 4.07E-05 0.5 0.60 1.0 intergenic 
rs60388875 19 3339134 0.60 5.49E-06 0.2 0.60 1.0 intergenic 
rs773916 19 16856864 1.00 1.59E-05 0.4 0.78 1.0 NWD1 
rs186607440 19 29649259 0.56 2.99E-06 0.2 0.95 1.0 intergenic 
rs71356041 19 37703129 0.93 4.29E-05 0.5 0.25 0.7 intergenic 
rs2161520 19 37945039 0.98 8.15E-06 0.3 0.08 0.6 ZNF569 
rs77379396 19 38169881 1.00 4.23E-05 0.5 0.85 1.0 ZNF781 
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs112555037 19 38171107 1.00 4.23E-05 0.5 0.85 1.0 ZNF781 
rs74774310 19 38173433 1.00 4.23E-05 0.5 0.85 1.0 ZNF781 
rs3095726 19 38229824 0.92 4.42E-05 0.5 0.09 0.6 ZNF573 
rs144953949 19 40726691 0.77 4.45E-05 0.5 0.88 1.0 intergenic 
rs3730053 19 40743739 0.92 4.63E-06 0.2 0.91 1.0 AKT2 
rs76137255 19 40783832 0.92 4.27E-06 0.2 0.94 1.0 AKT2 
rs190665219 19 40889198 0.74 3.54E-05 0.5 0.26 0.7 HIPK4 
rs1861792 19 46558503 0.97 8.22E-06 0.3 0.97 1.0 intergenic 
rs2160735 19 46558752 0.97 5.07E-06 0.2 0.48 0.9 intergenic 
rs4802285 19 46559146 0.98 2.80E-05 0.4 0.83 1.0 intergenic 
rs8111075 19 46560510 0.99 7.99E-06 0.3 0.93 1.0 intergenic 
rs2009468 19 46560881 0.99 3.20E-05 0.5 0.75 1.0 intergenic 
rs2216348 19 46561785 1.00 2.89E-05 0.5 0.75 1.0 intergenic 
rs4802287 19 46561988 1.00 2.82E-05 0.4 0.76 1.0 intergenic 
rs11669138 19 46562524 0.99 6.71E-06 0.2 0.89 1.0 intergenic 
rs8101164 19 46563471 1.00 2.49E-05 0.4 0.76 1.0 LOC400706 
rs8101445 19 46563653 1.00 2.36E-05 0.4 0.76 1.0 LOC400706 
rs7250943 19 46564525 1.00 2.10E-05 0.4 0.80 1.0 LOC400706 
rs2880179 19 46564972 1.00 2.05E-05 0.4 0.80 1.0 LOC400706 
rs4803895 19 46565481 0.99 3.03E-06 0.2 0.49 0.9 LOC400706 
rs1035254 19 46566661 1.00 2.04E-05 0.4 0.80 1.0 LOC400706 
rs16980258 19 46566808 1.00 1.98E-05 0.4 0.80 1.0 LOC400706 
rs35237775 19 46566881 1.00 2.05E-05 0.4 0.81 1.0 LOC400706 
rs11083798 19 46568638 1.00 1.74E-05 0.4 0.73 1.0 LOC400706 
rs713409 19 46569619 1.00 2.17E-05 0.4 0.75 1.0 LOC400706 
rs713411 19 46569630 1.00 2.17E-05 0.4 0.74 1.0 LOC400706 
rs713412 19 46569831 0.99 2.21E-05 0.4 0.73 1.0 LOC400706 
rs7251500 19 46571411 0.97 7.44E-06 0.3 0.76 1.0 LOC400706 
rs7250786 19 46571668 0.97 1.20E-05 0.3 0.79 1.0 LOC400706 
rs4802288 19 46590131 0.90 1.24E-05 0.3 0.54 0.9 intergenic 
rs2341902 19 46601339 0.90 1.22E-05 0.3 0.56 0.9 intergenic 
rs8102694 19 46602690 0.90 1.21E-05 0.3 0.56 0.9 intergenic 
rs2080618 19 46608823 0.87 1.93E-05 0.4 0.48 0.9 intergenic 
rs10418330 19 46611282 0.82 2.47E-05 0.4 0.25 0.7 intergenic 
rs145409557 20 2849618 0.86 3.82E-05 0.5 NA NA PTPRA 
rs59330923 20 8198472 1.00 3.45E-05 0.5 0.53 0.9 PLCB1 
rs2876128 20 8205124 1.00 2.06E-05 0.4 0.50 0.9 PLCB1 
rs6055677 20 8210961 1.00 4.49E-05 0.5 0.51 0.9 PLCB1 
rs6055678 20 8211200 1.00 4.12E-05 0.5 0.52 0.9 PLCB1 
rs6108126 20 8211226 1.00 4.36E-05 0.5 0.50 0.9 PLCB1 
rs6055679 20 8211285 1.00 4.36E-05 0.5 0.47 0.9 PLCB1 
rs6055680 20 8211559 1.00 4.36E-05 0.5 0.50 0.9 PLCB1 
rs181084932 20 53517832 0.42 3.80E-05 0.5 0.07 0.6 intergenic 
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A.3. Association results for AD in the IASPSAD with q-values < 0.5 and COGA replication  
SNP CHR BP INFO IASPSAD p IASPSAD q COGA p COGA q GENE 
rs2268260 21 35941233 0.84 1.04E-05 0.3 0.82 1.0 RCAN1 
rs140130045 21 38017102 0.91 1.67E-05 0.4 0.07 0.6 intergenic 
rs112814695 21 38022514 0.92 4.40E-05 0.5 0.06 0.6 intergenic 
rs113277403 21 38029653 0.95 3.81E-05 0.5 0.18 0.6 intergenic 
rs113916689 21 38037118 0.80 2.92E-05 0.5 0.02 0.6 intergenic 
rs4819991 22 17750681 0.68 9.90E-06 0.3 0.92 1.0 intergenic 
rs62236482 22 17751803 0.64 1.41E-05 0.3 0.89 1.0 intergenic 
rs80270647 22 17752392 0.63 1.36E-05 0.3 0.89 1.0 intergenic 
rs75748085 22 17759713 0.57 2.94E-05 0.5 0.50 0.9 intergenic 
rs5749005 22 17759885 0.57 2.99E-05 0.5 0.50 0.9 intergenic 
rs9613388 22 21305473 0.68 2.18E-05 0.4 0.26 0.7 CRKL 
rs118082458 22 35222253 0.93 4.38E-05 0.5 0.42 0.9 intergenic 
rs62243094 22 35380612 0.97 4.25E-05 0.5 0.29 0.7 intergenic 
rs9610187 22 35381350 0.97 4.22E-05 0.5 0.29 0.7 intergenic 
rs62243095 22 35381546 0.97 4.22E-05 0.5 0.29 0.7 intergenic 
rs9610188 22 35382016 0.98 4.23E-05 0.5 0.28 0.7 intergenic 
rs62243096 22 35387936 0.99 2.98E-05 0.5 0.36 0.8 intergenic 
rs713985 22 35388018 0.99 2.98E-05 0.5 0.36 0.8 intergenic 
rs9607217 22 35388905 1.00 3.83E-05 0.5 0.36 0.8 intergenic 
rs9610190 22 35388938 1.00 3.63E-05 0.5 0.36 0.8 intergenic 
rs9607218 22 35389220 1.00 3.63E-05 0.5 0.36 0.8 intergenic 
rs7284941 22 35389727 1.00 3.63E-05 0.5 0.36 0.8 intergenic 
rs7286439 22 35390051 1.00 3.63E-05 0.5 0.36 0.8 intergenic 
rs7285304 22 35390101 1.00 3.61E-05 0.5 0.36 0.8 intergenic 
rs62243111 22 35390127 1.00 3.61E-05 0.5 0.37 0.8 intergenic 
rs9610191 22 35390306 1.00 3.61E-05 0.5 0.36 0.8 intergenic 
rs9607219 22 35390327 1.00 3.64E-05 0.5 0.36 0.8 intergenic 
rs9610192 22 35390669 1.00 3.80E-05 0.5 0.36 0.8 intergenic 
rs6518917 22 35390846 1.00 3.89E-05 0.5 0.36 0.8 intergenic 
rs6518918 22 35391073 1.00 4.05E-05 0.5 0.36 0.8 intergenic 
rs6518920 22 35391265 1.00 4.19E-05 0.5 0.36 0.8 intergenic 
rs142314105 22 41667156 0.88 1.53E-05 0.4 0.68 1.0 RANGAP1 
rs116434743 22 41783206 0.91 3.33E-05 0.5 0.91 1.0 TEF 
rs117530017 22 41785067 0.91 3.30E-05 0.5 0.99 1.0 TEF 
rs138772877 22 41822725 0.93 2.63E-05 0.4 0.80 1.0 intergenic 
rs185631468 22 42710609 0.85 6.56E-08 0.1 NA NA intergenic 
rs59649586 22 48652075 0.40 7.67E-06 0.3 0.66 1.0 intergenic 
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A.4. Association results for the joint meta-analysis of AD in the IASPSAD and COGA 
SNP CHR BP Z META p DIR META q COGA p IASPSAD p GENE 
rs114720027 1 1226690 4.68 2.82E-06 ++ 0.3 3.27E-03 2.64E-04 SCNN1D 
rs11590002 1 175032518 -4.41 1.04E-05 -- 0.5 2.98E-01 2.17E-06 intergenic 
rs11582546 1 175049009 5.06 4.23E-07 ++ 0.3 3.04E-02 2.58E-06 TNN 
rs61827435 1 175066967 5.13 2.87E-07 ++ 0.3 2.31E-02 2.44E-06 TNN 
rs114901102 1 210901331 -4.45 8.75E-06 -- 0.4 1.34E-01 9.06E-06 KCNH1 
rs1002159 2 23538632 4.48 7.43E-06 ++ 0.4 3.28E-02 6.27E-05 intergenic 
rs10203610 2 27572265 4.59 4.35E-06 ++ 0.3 5.40E-02 1.71E-05 GTF3C2 
rs13011459 2 166012871 -4.53 5.91E-06 -- 0.3 8.02E-03 2.39E-04 SCN3A 
rs73011180 3 3256506 4.63 3.75E-06 ++ 0.3 2.47E-03 4.47E-04 intergenic 
rs143582116 3 3300915 4.54 5.56E-06 ++ 0.3 1.91E-03 8.13E-04 intergenic 
rs73149932 3 147209249 -4.45 8.71E-06 -- 0.4 3.94E-01 8.39E-07 intergenic 
rs150268941 3 172575312 5.30 1.16E-07 ++ 0.3 2.02E-01 1.39E-08 intergenic 
rs9870004 3 192625680 4.37 1.25E-05 ++ 0.5 2.25E-06 5.65E-02 MB21D2 
rs11719444 3 192626348 4.40 1.09E-05 ++ 0.5 2.07E-06 5.33E-02 MB21D2 
rs9853424 3 192629549 -4.53 5.90E-06 -- 0.3 1.59E-06 3.98E-02 MB21D2 
rs114613162 4 58610828 -4.64 3.51E-06 -- 0.3 2.93E-03 3.62E-04 intergenic 
rs113600173 4 58649957 4.72 2.42E-06 ++ 0.3 5.42E-02 8.47E-06 intergenic 
rs1911588 4 148021144 -4.42 9.79E-06 -- 0.4 9.72E-04 2.28E-03 intergenic 
rs6823293 4 188314906 -4.74 2.19E-06 -- 0.3 2.63E-02 2.10E-05 LOC339975 
rs78616487 4 188322087 -4.60 4.29E-06 -- 0.3 5.07E-02 1.84E-05 LOC339975 
rs11943588 4 188322659 4.62 3.84E-06 ++ 0.3 6.20E-02 1.20E-05 LOC339975 
rs116134219 4 188326029 -4.69 2.78E-06 -- 0.3 5.32E-02 1.03E-05 LOC339975 
rs113165089 4 188327733 -4.64 3.43E-06 -- 0.3 5.91E-02 1.13E-05 LOC339975 
rs112232951 4 188329318 4.68 2.94E-06 ++ 0.3 5.34E-02 1.09E-05 LOC339975 
rs76911486 4 188333134 4.46 8.04E-06 ++ 0.4 7.11E-02 2.34E-05 LOC339975 
rs75828282 4 188333577 -4.46 8.23E-06 -- 0.4 7.13E-02 2.40E-05 LOC339975 
rs78465996 4 188338304 -4.55 5.31E-06 -- 0.3 7.20E-02 1.40E-05 LOC339975 
rs113266307 4 188338566 -4.55 5.30E-06 -- 0.3 7.21E-02 1.39E-05 LOC339975 
rs11933754 4 188339771 4.53 5.84E-06 ++ 0.3 7.82E-02 1.38E-05 LOC339975 
rs11935240 4 188341193 4.54 5.53E-06 ++ 0.3 7.34E-02 1.42E-05 LOC339975 
rs144115853 4 188341998 -4.54 5.71E-06 -- 0.3 7.93E-02 1.31E-05 LOC339975 
rs77414185 4 188344450 -4.56 5.18E-06 -- 0.3 7.44E-02 1.29E-05 LOC339975 
rs77097179 4 188344799 4.59 4.42E-06 ++ 0.3 6.27E-02 1.39E-05 LOC339975 
rs75536828 4 188357518 4.46 8.17E-06 ++ 0.4 1.35E-01 8.23E-06 LOC339975 
rs57438669 4 188360032 4.72 2.35E-06 ++ 0.3 8.44E-02 4.02E-06 LOC339975 
rs76655731 4 188360163 -4.59 4.50E-06 -- 0.3 8.79E-02 8.30E-06 LOC339975 
rs74464601 4 188360229 4.64 3.46E-06 ++ 0.3 8.79E-02 6.02E-06 LOC339975 
rs11931480 4 188362893 4.63 3.64E-06 ++ 0.3 9.00E-02 6.15E-06 LOC339975 
rs77547664 4 188371961 4.74 2.12E-06 ++ 0.3 7.21E-02 4.61E-06 LOC339975 
rs76656386 4 188375913 -4.70 2.65E-06 -- 0.3 7.11E-02 6.19E-06 LOC339975 
rs76446531 4 188379086 4.69 2.68E-06 ++ 0.3 7.15E-02 6.20E-06 LOC339975 
rs75496321 4 188381891 4.75 2.03E-06 ++ 0.3 6.78E-02 4.82E-06 LOC339975 
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A.4. Association results for the joint meta-analysis of AD in the IASPSAD and COGA 
SNP CHR BP Z META p DIR META q COGA p IASPSAD p GENE 
rs112168621 4 188383350 -4.72 2.34E-06 -- 0.3 6.19E-02 6.62E-06 LOC339975 
rs77667574 4 188391705 4.68 2.86E-06 ++ 0.3 8.17E-02 5.40E-06 LOC339975 
rs4862808 4 188398633 -4.61 3.98E-06 -- 0.3 8.04E-02 8.28E-06 LOC339975 
rs4862809 4 188398663 -4.51 6.61E-06 -- 0.4 9.66E-02 1.14E-05 LOC339975 
rs76307063 4 188398832 -4.71 2.44E-06 -- 0.3 7.83E-02 4.77E-06 LOC339975 
rs79440070 4 188399004 4.71 2.43E-06 ++ 0.3 7.83E-02 4.75E-06 LOC339975 
rs13133236 4 188399321 -4.62 3.91E-06 -- 0.3 8.03E-02 8.13E-06 LOC339975 
rs13133469 4 188399430 -4.62 3.91E-06 -- 0.3 8.03E-02 8.11E-06 LOC339975 
rs4862812 4 188400337 4.63 3.64E-06 ++ 0.3 7.71E-02 7.96E-06 LOC339975 
rs4862813 4 188400742 -4.63 3.58E-06 -- 0.3 7.59E-02 8.00E-06 LOC339975 
rs79071854 4 188403196 4.71 2.50E-06 ++ 0.3 9.00E-02 3.89E-06 LOC339975 
rs112858899 4 188408330 4.75 2.09E-06 ++ 0.3 8.80E-02 3.24E-06 LOC339975 
rs143715208 4 188409336 -4.75 2.08E-06 -- 0.3 8.80E-02 3.23E-06 LOC339975 
rs147704297 4 188409464 -4.75 2.08E-06 -- 0.3 8.80E-02 3.23E-06 LOC339975 
rs113574664 4 188411134 4.75 2.07E-06 ++ 0.3 8.80E-02 3.20E-06 LOC339975 
rs113237987 4 188411190 4.75 2.07E-06 ++ 0.3 8.80E-02 3.20E-06 LOC339975 
rs111557585 4 188411234 4.79 1.64E-06 ++ 0.3 7.43E-02 3.21E-06 LOC339975 
rs116733741 4 188411375 -4.79 1.64E-06 -- 0.3 7.43E-02 3.20E-06 LOC339975 
rs75061382 4 188412397 4.79 1.63E-06 ++ 0.3 7.43E-02 3.19E-06 LOC339975 
rs76107485 4 188414534 4.80 1.62E-06 ++ 0.3 7.43E-02 3.17E-06 LOC339975 
rs77477912 4 188416674 4.75 2.05E-06 ++ 0.3 8.80E-02 3.16E-06 LOC339975 
rs77867835 4 188417458 -4.75 2.05E-06 -- 0.3 8.80E-02 3.16E-06 LOC339975 
rs111755541 4 188419930 4.75 2.05E-06 ++ 0.3 8.80E-02 3.16E-06 LOC339975 
rs1367555 4 188420909 4.71 2.51E-06 ++ 0.3 7.30E-02 5.54E-06 LOC339975 
rs77692574 4 188421215 -4.75 2.05E-06 -- 0.3 8.79E-02 3.16E-06 LOC339975 
rs10001779 4 188423355 4.71 2.54E-06 ++ 0.3 7.38E-02 5.54E-06 LOC339975 
rs9996952 4 188424578 -4.72 2.40E-06 -- 0.3 5.60E-02 7.97E-06 LOC339975 
rs112048494 4 188425380 4.75 2.01E-06 ++ 0.3 8.17E-02 3.50E-06 LOC339975 
rs11726136 4 188426585 -4.92 8.66E-07 -- 0.3 9.00E-02 1.05E-06 LOC339975 
rs6841040 4 188426755 4.80 1.60E-06 ++ 0.3 7.36E-02 3.17E-06 LOC339975 
rs61300960 4 188428337 -4.74 2.09E-06 -- 0.3 6.07E-02 5.99E-06 intergenic 
rs75525298 4 188428338 -4.71 2.45E-06 -- 0.3 8.72E-02 4.00E-06 intergenic 
rs10026638 4 188429196 4.68 2.94E-06 ++ 0.3 1.29E-01 2.50E-06 intergenic 
rs11736878 4 188431095 4.77 1.81E-06 ++ 0.3 1.36E-01 1.21E-06 intergenic 
rs10032833 4 188431411 4.78 1.74E-06 ++ 0.3 1.10E-01 1.73E-06 intergenic 
rs11930080 4 188432452 4.64 3.42E-06 ++ 0.3 7.21E-02 8.22E-06 intergenic 
rs9996885 4 188433623 4.71 2.53E-06 ++ 0.3 7.09E-02 5.88E-06 intergenic 
rs28475332 4 188434677 -4.78 1.73E-06 -- 0.3 1.04E-01 1.91E-06 intergenic 
rs28579034 4 188434935 -4.67 3.07E-06 -- 0.3 1.25E-01 2.80E-06 intergenic 
rs77598188 4 188435868 4.68 2.91E-06 ++ 0.3 9.41E-02 4.34E-06 intergenic 
rs145889915 4 188442359 4.67 2.99E-06 ++ 0.3 9.04E-02 4.80E-06 intergenic 
rs28876409 4 188443338 4.67 2.98E-06 ++ 0.3 6.51E-02 8.20E-06 intergenic 
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A.4. Association results for the joint meta-analysis of AD in the IASPSAD and COGA 
SNP CHR BP Z META p DIR META q COGA p IASPSAD p GENE 
rs112567828 4 188443982 4.69 2.72E-06 ++ 0.3 7.25E-02 6.18E-06 intergenic 
rs145753563 4 188445993 4.66 3.20E-06 ++ 0.3 6.70E-02 8.52E-06 intergenic 
rs74973212 5 22730877 4.61 4.01E-06 ++ 0.3 7.91E-03 1.62E-04 CDH12 
rs77454938 5 22892433 -4.57 4.90E-06 -- 0.3 3.19E-04 2.62E-03 intergenic 
rs189681803 5 22900277 -4.59 4.42E-06 -- 0.3 3.57E-04 2.23E-03 intergenic 
rs9716627 5 22933007 4.37 1.23E-05 ++ 0.5 9.12E-04 2.92E-03 intergenic 
rs79708954 5 22964609 4.89 9.93E-07 ++ 0.3 1.76E-04 9.68E-04 intergenic 
rs7728036 5 22970127 4.93 8.33E-07 ++ 0.3 1.59E-04 8.89E-04 intergenic 
rs189537064 5 23187921 4.45 8.78E-06 ++ 0.4 3.17E-02 7.91E-05 intergenic 
rs143975413 5 23187926 -4.45 8.78E-06 -- 0.4 3.17E-02 7.91E-05 intergenic 
rs111997333 5 148298840 -4.41 1.03E-05 -- 0.5 2.80E-02 1.10E-04 intergenic 
rs13232384 7 22186176 4.42 1.01E-05 ++ 0.5 9.97E-03 3.35E-04 RAPGEF5 
rs12592 7 22202117 4.81 1.48E-06 ++ 0.3 9.50E-03 4.63E-05 RAPGEF5 
rs1981601 7 22202485 -4.58 4.72E-06 -- 0.3 1.38E-02 1.07E-04 RAPGEF5 
rs2170478 8 3464175 -4.67 3.04E-06 -- 0.3 5.54E-02 1.07E-05 CSMD1 
rs2469338 8 3466917 -4.76 1.96E-06 -- 0.3 2.64E-02 1.84E-05 CSMD1 
rs2469334 8 3467396 4.41 1.04E-05 ++ 0.5 1.41E-01 1.04E-05 CSMD1 
rs2469331 8 3467762 4.78 1.72E-06 ++ 0.3 2.53E-02 1.67E-05 CSMD1 
rs2469329 8 3468180 4.62 3.78E-06 ++ 0.3 3.50E-02 2.68E-05 CSMD1 
rs1121619 8 3469700 4.60 4.26E-06 ++ 0.3 3.87E-02 2.67E-05 CSMD1 
rs144690006 8 107766355 -4.68 2.89E-06 -- 0.3 1.38E-04 2.83E-03 intergenic 
rs79048468 8 137895174 -4.56 5.22E-06 -- 0.3 5.25E-01 1.74E-07 intergenic 
rs117687198 8 137907672 4.81 1.49E-06 ++ 0.3 4.05E-01 6.78E-08 intergenic 
rs148161159 8 137910630 4.51 6.51E-06 ++ 0.4 8.93E-02 1.27E-05 intergenic 
rs149489509 8 144360947 4.54 5.65E-06 ++ 0.3 5.65E-02 2.17E-05 intergenic 
rs78132252 10 70984526 -4.80 1.58E-06 -- 0.3 2.59E-02 1.48E-05 HKDC1 
rs12784542 10 102769710 -4.44 9.02E-06 -- 0.4 6.41E-02 3.13E-05 PDZD7 
rs78145908 11 131034265 4.40 1.07E-05 ++ 0.5 8.11E-04 2.79E-03 intergenic 
rs142465076 12 70447861 -4.53 5.96E-06 -- 0.3 1.08E-03 1.34E-03 intergenic 
rs73188186 12 107846289 4.38 1.19E-05 ++ 0.5 2.01E-02 1.90E-04 BTBD11 
rs138166981 12 107846404 4.38 1.17E-05 ++ 0.5 1.98E-02 1.90E-04 BTBD11 
rs149633740 12 107846410 -4.38 1.17E-05 -- 0.5 1.98E-02 1.89E-04 BTBD11 
rs11113334 12 107847283 4.41 1.03E-05 ++ 0.5 1.74E-02 1.92E-04 BTBD11 
rs189083626 12 121693090 -4.43 9.49E-06 -- 0.4 3.13E-03 9.05E-04 CAMKK2 
rs12306064 12 127603048 4.48 7.65E-06 ++ 0.4 1.75E-05 1.79E-02 intergenic 
rs1039792 12 127606132 4.47 7.98E-06 ++ 0.4 1.93E-05 1.77E-02 intergenic 
rs11058993 12 127606502 -4.47 7.96E-06 -- 0.4 1.92E-05 1.77E-02 intergenic 
rs61543828 12 127607255 -4.47 7.93E-06 -- 0.4 1.92E-05 1.77E-02 intergenic 
rs11613288 12 127611661 -4.56 5.18E-06 -- 0.3 1.99E-05 1.27E-02 intergenic 
rs34224343 12 127612167 4.64 3.52E-06 ++ 0.3 1.75E-05 1.01E-02 intergenic 
rs34404953 12 127612361 4.64 3.50E-06 ++ 0.3 1.74E-05 1.01E-02 intergenic 
rs78518547 12 127613578 -4.65 3.40E-06 -- 0.3 1.73E-05 9.93E-03 intergenic 
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rs191968104 12 127614398 4.48 7.59E-06 ++ 0.4 1.32E-05 2.02E-02 intergenic 
rs181655177 12 127614399 4.48 7.58E-06 ++ 0.4 1.32E-05 2.02E-02 intergenic 
rs74981202 12 127615159 -4.65 3.28E-06 -- 0.3 1.73E-05 9.66E-03 intergenic 
rs11058997 12 127615824 -4.66 3.23E-06 -- 0.3 1.73E-05 9.55E-03 intergenic 
rs79805024 12 127617105 -4.66 3.14E-06 -- 0.3 1.72E-05 9.37E-03 intergenic 
rs56780684 12 127618799 4.67 3.04E-06 ++ 0.3 1.72E-05 9.14E-03 intergenic 
rs58333498 12 127618854 4.67 3.03E-06 ++ 0.3 1.72E-05 9.13E-03 intergenic 
rs11058998 12 127620311 -4.67 2.96E-06 -- 0.3 1.72E-05 8.97E-03 intergenic 
rs11058999 12 127620476 -4.67 2.96E-06 -- 0.3 1.72E-05 8.97E-03 intergenic 
rs11503010 12 127622486 4.67 3.02E-06 ++ 0.3 1.73E-05 9.08E-03 intergenic 
rs117348945 12 127623739 4.67 3.09E-06 ++ 0.3 1.75E-05 9.20E-03 intergenic 
rs12302509 12 127625419 4.60 4.18E-06 ++ 0.3 1.40E-05 1.28E-02 intergenic 
rs12312674 12 127627973 -4.68 2.94E-06 -- 0.3 1.43E-05 9.76E-03 intergenic 
rs10847280 12 127628993 -4.55 5.47E-06 -- 0.3 4.74E-05 8.61E-03 intergenic 
rs10847281 12 127629300 -4.68 2.82E-06 -- 0.3 1.21E-05 1.03E-02 intergenic 
rs11612470 12 127629492 4.69 2.80E-06 ++ 0.3 1.19E-05 1.03E-02 intergenic 
rs10847282 12 127629984 -4.60 4.16E-06 -- 0.3 1.20E-05 1.37E-02 intergenic 
rs117695004 12 127630545 -4.53 6.01E-06 -- 0.3 1.69E-05 1.53E-02 intergenic 
rs117558206 12 127631620 -4.70 2.64E-06 -- 0.3 1.13E-05 1.01E-02 intergenic 
rs78954849 12 127632323 -4.70 2.57E-06 -- 0.3 1.05E-05 1.02E-02 intergenic 
rs76027692 12 127632352 -4.70 2.56E-06 -- 0.3 1.05E-05 1.02E-02 intergenic 
rs74596781 12 127634115 4.70 2.55E-06 ++ 0.3 1.02E-05 1.03E-02 intergenic 
rs11059001 12 127634847 4.70 2.55E-06 ++ 0.3 1.01E-05 1.04E-02 intergenic 
rs74398605 12 127635455 4.69 2.73E-06 ++ 0.3 1.00E-05 1.09E-02 intergenic 
rs80334165 12 127635520 -4.69 2.76E-06 -- 0.3 1.00E-05 1.10E-02 intergenic 
rs10847286 12 127636509 -4.74 2.12E-06 -- 0.3 4.27E-06 1.34E-02 intergenic 
rs12313900 12 127637474 4.74 2.09E-06 ++ 0.3 4.21E-06 1.34E-02 intergenic 
rs11059002 12 127637964 -4.70 2.61E-06 -- 0.3 6.01E-06 1.33E-02 intergenic 
rs9538694 13 61001708 4.60 4.14E-06 ++ 0.3 4.22E-05 7.38E-03 TDRD3 
rs9528178 13 61220743 -4.86 1.18E-06 -- 0.3 3.62E-04 6.79E-04 intergenic 
rs17377290 13 85167241 -4.38 1.17E-05 -- 0.5 6.35E-02 4.31E-05 intergenic 
rs146736842 13 85187435 4.44 8.84E-06 ++ 0.4 5.49E-02 3.84E-05 intergenic 
rs79862295 13 85204822 -4.39 1.16E-05 -- 0.5 5.31E-02 5.52E-05 intergenic 
rs117455152 13 85205057 -4.38 1.16E-05 -- 0.5 5.31E-02 5.53E-05 intergenic 
rs9520259 13 107633055 -4.57 4.89E-06 -- 0.3 8.40E-03 1.87E-04 intergenic 
rs147277902 14 61720703 4.75 2.08E-06 ++ 0.3 1.12E-02 5.55E-05 intergenic 
rs117727648 14 77100157 4.49 7.05E-06 ++ 0.4 8.91E-01 3.36E-08 intergenic 
rs56198483 14 77828430 5.24 1.63E-07 ++ 0.3 8.25E-02 1.53E-07 TMED8 
rs74919671 14 87140828 -4.52 6.27E-06 -- 0.4 1.49E-01 4.89E-06 intergenic 
rs62010548 15 33946424 4.40 1.07E-05 ++ 0.5 1.83E-01 6.50E-06 RYR3 
rs78828848 15 33968766 -5.07 3.98E-07 -- 0.3 3.27E-02 2.15E-06 RYR3 
rs2899683 15 62938169 -4.42 9.75E-06 -- 0.4 6.00E-03 5.26E-04 intergenic 
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rs938979 15 62939440 4.63 3.59E-06 ++ 0.3 2.12E-03 4.89E-04 intergenic 
rs8041641 15 62941808 4.38 1.17E-05 ++ 0.5 1.70E-02 2.25E-04 TLN2 
rs6494336 15 62941810 -4.55 5.33E-06 -- 0.3 7.73E-03 2.22E-04 TLN2 
rs12903725 15 62942792 4.44 9.07E-06 ++ 0.4 9.46E-03 3.16E-04 TLN2 
rs12438306 15 62942835 4.43 9.56E-06 ++ 0.4 1.12E-02 2.81E-04 TLN2 
rs8039436 15 62944576 4.52 6.17E-06 ++ 0.4 4.58E-03 4.26E-04 TLN2 
rs12916083 15 62945250 4.49 7.00E-06 ++ 0.4 7.35E-03 3.10E-04 TLN2 
rs56376861 15 62947019 4.50 6.72E-06 ++ 0.4 7.19E-03 3.04E-04 TLN2 
rs12591037 15 62948909 4.79 1.64E-06 ++ 0.3 2.77E-03 1.79E-04 TLN2 
rs12593694 15 62951029 4.44 9.21E-06 ++ 0.4 2.69E-03 9.96E-04 TLN2 
rs7167388 15 62959101 4.82 1.47E-06 ++ 0.3 1.24E-03 3.23E-04 TLN2 
rs1574119 15 62962294 4.46 8.30E-06 ++ 0.4 3.93E-03 6.54E-04 TLN2 
rs72742462 15 77371206 4.37 1.23E-05 ++ 0.5 1.36E-03 2.20E-03 intergenic 
rs45455291 16 16232976 4.40 1.11E-05 ++ 0.5 4.47E-03 7.76E-04 ABCC1 
rs113328089 16 16235366 4.39 1.13E-05 ++ 0.5 4.50E-03 7.90E-04 ABCC1 
rs4781906 16 18013160 -4.42 9.76E-06 -- 0.4 3.17E-03 9.21E-04 intergenic 
rs6498759 16 18020295 4.46 8.32E-06 ++ 0.4 1.79E-03 1.25E-03 intergenic 
rs2923133 16 57732437 -4.91 9.01E-07 -- 0.3 5.79E-06 6.25E-03 CCDC135 
rs28868312 16 73314930 4.37 1.22E-05 ++ 0.5 7.16E-04 3.42E-03 intergenic 
rs28825739 16 73314935 4.77 1.88E-06 ++ 0.3 8.75E-04 5.41E-04 intergenic 
rs149157093 18 7864399 -4.38 1.22E-05 -- 0.5 1.23E-02 3.27E-04 PTPRM 
rs6042781 20 14510635 -4.50 6.72E-06 -- 0.4 1.22E-05 1.92E-02 MACROD2 
rs58677849 20 48429508 4.50 6.71E-06 ++ 0.4 3.08E-05 1.25E-02 SLC9A8 
rs140130045 21 38017102 4.52 6.15E-06 ++ 0.4 7.19E-02 1.67E-05 intergenic 
rs112814695 21 38022514 4.40 1.10E-05 ++ 0.5 5.97E-02 4.40E-05 intergenic 
rs78624947 21 38023820 4.37 1.24E-05 ++ 0.5 5.64E-02 5.46E-05 intergenic 
rs75877632 21 38033949 4.37 1.22E-05 ++ 0.5 5.03E-02 6.28E-05 intergenic 
rs113916689 21 38037118 4.69 2.75E-06 ++ 0.3 2.48E-02 2.92E-05 intergenic 
Notes: DIR refers to the direction of effect. “++” and “--" indicate that the same allele increases and decreases risk, 
respectively.  
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rs34100349 1 166465517 0.83 2.50E-06 0.4 intergenic 
rs11579746 1 166486813 0.85 4.27E-06 0.4 intergenic 
rs12070599 1 166499803 0.71 3.75E-07 0.2 intergenic 
rs10918508 1 166503560 0.72 1.18E-07 0.2 intergenic 
rs12028217 1 238584540 0.75 4.14E-06 0.4 intergenic 
rs75651477 2 5704362 0.53 2.12E-06 0.4 intergenic 
rs149985535 2 29735999 0.73 4.59E-06 0.4 ALK 
rs62170104 2 114532234 0.99 9.08E-07 0.3 intergenic 
rs72946678 2 114532605 0.98 4.80E-07 0.2 intergenic 
rs62170106 2 114536469 1.00 5.26E-07 0.2 intergenic 
rs59123894 2 114536834 1.00 5.26E-07 0.2 intergenic 
rs56884727 2 114536952 1.00 2.19E-07 0.2 intergenic 
rs60221109 2 114537300 1.00 2.25E-07 0.2 intergenic 
rs58511785 2 114538464 1.00 5.26E-07 0.2 intergenic 
rs11685086 2 114540117 1.00 5.45E-07 0.2 intergenic 
rs11692142 2 114540218 1.00 5.12E-07 0.2 intergenic 
rs4849276 2 114542568 1.00 5.58E-07 0.2 intergenic 
rs3870303 2 114548110 1.00 6.07E-07 0.2 intergenic 
rs3982388 2 114548860 1.00 1.14E-06 0.3 intergenic 
rs57489086 2 114550308 0.99 9.53E-07 0.3 intergenic 
rs7567042 2 114555675 0.99 3.37E-07 0.2 intergenic 
rs62170136 2 114556912 0.99 2.49E-07 0.2 intergenic 
rs7587985 2 114559118 0.98 9.29E-08 0.2 intergenic 
rs2900745 2 114563960 0.97 1.34E-07 0.2 intergenic 
rs7588108 2 114566404 0.97 2.29E-07 0.2 intergenic 
rs4292100 2 114571647 0.97 3.08E-07 0.2 intergenic 
rs72835407 2 114572589 0.98 1.02E-06 0.3 intergenic 
rs62170141 2 114572676 0.98 1.02E-06 0.3 intergenic 
rs62170142 2 114572796 0.98 8.35E-07 0.3 intergenic 
rs62170143 2 114572913 0.98 9.96E-07 0.3 intergenic 
rs62170145 2 114576025 0.98 1.79E-06 0.4 intergenic 
rs4450608 2 114576118 0.98 1.80E-06 0.4 intergenic 
rs7589706 2 114576819 0.99 1.84E-06 0.4 intergenic 
rs4389338 2 114577383 0.98 1.74E-06 0.4 intergenic 
rs11903680 2 114577551 0.97 2.55E-06 0.4 intergenic 
rs62170148 2 114577728 0.99 1.75E-06 0.4 intergenic 
rs6715643 2 114578252 0.97 2.04E-06 0.4 intergenic 
rs146366850 2 114579180 0.88 7.71E-07 0.3 intergenic 
rs4848353 2 114580423 1.00 3.22E-06 0.4 intergenic 
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rs10172576 2 114581008 1.00 3.92E-06 0.4 intergenic 
rs62170155 2 114582948 1.00 3.31E-06 0.4 intergenic 
rs57106417 2 114583321 1.00 3.33E-06 0.4 intergenic 
rs61050591 2 114583915 1.00 3.68E-06 0.4 intergenic 
rs72948684 2 114584490 1.00 3.37E-06 0.4 intergenic 
rs4411702 2 114584909 1.00 3.37E-06 0.4 intergenic 
rs11676646 2 114585305 1.00 3.38E-06 0.4 intergenic 
rs10185135 2 114586483 1.00 3.38E-06 0.4 intergenic 
rs10209659 2 114586805 1.00 3.38E-06 0.4 intergenic 
rs4849285 2 114587432 1.00 3.14E-06 0.4 intergenic 
rs4849286 2 114587447 1.00 3.14E-06 0.4 intergenic 
rs4849287 2 114587481 1.00 3.14E-06 0.4 intergenic 
rs11685296 2 114588257 0.96 4.51E-07 0.2 intergenic 
rs11675908 2 114588784 1.00 3.37E-06 0.4 LOC100506762 
rs4849288 2 114589155 1.00 3.37E-06 0.4 LOC100506762 
rs62170159 2 114589534 0.93 3.50E-06 0.4 LOC100506762 
rs9646927 2 114590106 0.98 2.98E-06 0.4 LOC100506762 
rs79238088 2 114590284 0.99 2.63E-06 0.4 LOC100506762 
rs4849289 2 114591178 1.00 3.40E-06 0.4 LOC100506762 
rs4849290 2 114591194 1.00 3.40E-06 0.4 LOC100506762 
rs11691664 2 114592257 1.00 3.38E-06 0.4 LOC100506762 
rs4849291 2 114594099 1.00 3.38E-06 0.4 LOC100506762 
rs62171760 2 114594883 1.00 3.16E-06 0.4 LOC100506762 
rs62171761 2 114595287 1.00 3.06E-06 0.4 LOC100506762 
rs4571059 2 114599209 0.99 2.37E-06 0.4 LOC100506762 
rs1028245 2 114601335 0.99 2.13E-06 0.4 LOC100506762 
rs4241126 2 114603003 0.99 3.38E-06 0.4 LOC100506762 
rs149679967 3 193096170 0.88 4.38E-06 0.4 ATP13A5 
rs17356266 4 94527621 0.74 4.30E-06 0.4 GRID2 
rs2973135 5 152555110 0.94 1.24E-06 0.3 intergenic 
rs3849719 5 173248856 1.00 4.30E-06 0.4 intergenic 
rs75850170 8 117417368 0.68 4.88E-06 0.4 intergenic 
rs1410200 9 120981143 0.85 4.70E-06 0.4 intergenic 
rs4836713 9 120998947 0.92 4.69E-06 0.4 intergenic 
rs11185686 9 137134266 0.65 1.74E-06 0.4 intergenic 
rs12235472 9 137134549 0.65 1.75E-06 0.4 intergenic 
rs12237177 9 137134557 0.66 1.86E-06 0.4 intergenic 
rs56168824 9 137135968 0.78 2.83E-06 0.4 intergenic 
rs2399972 10 13557945 1.00 3.99E-06 0.4 intergenic 
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rs10752308 10 13558641 1.00 4.00E-06 0.4 intergenic 
rs11258443 10 13583831 0.96 3.34E-06 0.4 intergenic 
rs140886841 12 11652416 0.55 3.56E-06 0.4 intergenic 
rs12184900 13 101522004 0.62 1.32E-07 0.2 intergenic 
rs77419548 13 101525115 0.69 2.59E-06 0.4 intergenic 
rs148336229 15 54594443 0.97 3.31E-06 0.4 UNC13C 
rs75469002 15 54597980 0.99 2.64E-06 0.4 UNC13C 
rs71474867 15 54598259 0.99 2.63E-06 0.4 UNC13C 
rs71474868 15 54598286 0.99 2.63E-06 0.4 UNC13C 
rs12915790 15 54599640 0.99 2.58E-06 0.4 UNC13C 
rs12898437 15 54600325 0.99 2.78E-06 0.4 UNC13C 
rs34432386 15 54600639 0.99 2.77E-06 0.4 UNC13C 
rs8025641 15 54601303 0.99 2.77E-06 0.4 UNC13C 
rs35926155 15 54604477 0.99 2.60E-06 0.4 UNC13C 
rs12916554 15 54607255 1.00 2.50E-06 0.4 UNC13C 
rs4404011 15 54997983 0.93 5.37E-06 0.5 intergenic 
rs4889357 16 81688626 0.88 4.95E-07 0.2 CMIP 
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